<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults - Hristovska, AM - 2017 | Cochrane Library</title> <meta content="Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults - Hristovska, AM - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012763/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults - Hristovska, AM - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012763/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012763" name="dc.identifier" scheme="DOI"/> <meta content="Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults" name="citation_title"/> <meta content="Ana‐Marija Hristovska" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="anamarijahristovska@gmail.com" name="citation_author_email"/> <meta content="Patricia Duch" name="citation_author"/> <meta content="Copenhagen University Hospital Hvidovre" name="citation_author_institution"/> <meta content="Mikkel Allingstrup" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Arash Afshari" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012763" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012763/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012763/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012763/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Neuromuscular Blockade; Androstanols [antagonists &amp; inhibitors]; Atracurium [analogs &amp; derivatives, antagonists &amp; inhibitors]; Cholinesterase Inhibitors [administration &amp; dosage, adverse effects, *pharmacology]; Neostigmine [administration &amp; dosage, adverse effects, *pharmacology]; Neuromuscular Nondepolarizing Agents [*antagonists &amp; inhibitors]; Randomized Controlled Trials as Topic; Rocuronium; Sugammadex; Time Factors; Vecuronium Bromide [antagonists &amp; inhibitors]; gamma‐Cyclodextrins [administration &amp; dosage, adverse effects, *pharmacology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012763&amp;doi=10.1002/14651858.CD012763&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="UDgTyLGV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012763\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012763\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012763\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012763",title:"Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults",firstPublishedDate:"Aug 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Anaesthesia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012763&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012763';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012763/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012763/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012763%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012763/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012763/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012763/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012763/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012763" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012763/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012763" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012763/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012763/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16375 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012763" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-sec-0131"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-sec-0031"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-sec-0032"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-sec-0125"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012763/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/appendices#CD012763-sec-0136"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/table_n/CD012763StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/table_n/CD012763StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012763/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012763/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012763/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012763/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012763/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012763/information#CD012763-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ana‐Marija Hristovska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012763/information#CD012763-cr-0003">Patricia Duch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012763/information#CD012763-cr-0004">Mikkel Allingstrup</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012763/information#CD012763-cr-0005">Arash Afshari</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012763/information/en#CD012763-sec-0153">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012763/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012763">https://doi.org/10.1002/14651858.CD012763</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012763-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012763-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012763-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012763-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012763-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012763-abs-0001" lang="en"> <section id="CD012763-sec-0001"> <h3 class="title" id="CD012763-sec-0001">Background</h3> <p>Acetylcholinesterase inhibitors, such as neostigmine, have traditionally been used for reversal of non‐depolarizing neuromuscular blocking agents. However, these drugs have significant limitations, such as indirect mechanisms of reversal, limited and unpredictable efficacy, and undesirable autonomic responses. Sugammadex is a selective relaxant‐binding agent specifically developed for rapid reversal of non‐depolarizing neuromuscular blockade induced by rocuronium. Its potential clinical benefits include fast and predictable reversal of any degree of block, increased patient safety, reduced incidence of residual block on recovery, and more efficient use of healthcare resources. </p> </section> <section id="CD012763-sec-0002"> <h3 class="title" id="CD012763-sec-0002">Objectives</h3> <p>The main objective of this review was to compare the efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade caused by non‐depolarizing neuromuscular agents in adults. </p> </section> <section id="CD012763-sec-0003"> <h3 class="title" id="CD012763-sec-0003">Search methods</h3> <p>We searched the following databases on 2 May 2016: Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (WebSPIRS Ovid SP), Embase (WebSPIRS Ovid SP), and the clinical trials registries <a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>, <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>, and <a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a>. We re‐ran the search on 10 May 2017. </p> </section> <section id="CD012763-sec-0004"> <h3 class="title" id="CD012763-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published, or language. We included adults, classified as American Society of Anesthesiologists (ASA) I to IV, who received non‐depolarizing neuromuscular blocking agents for an elective in‐patient or day‐case surgical procedure. We included all trials comparing sugammadex versus neostigmine that reported recovery times or adverse events. We included any dose of sugammadex and neostigmine and any time point of study drug administration. </p> </section> <section id="CD012763-sec-0005"> <h3 class="title" id="CD012763-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened titles and abstracts to identify trials for eligibility, examined articles for eligibility, abstracted data, assessed the articles, and excluded obviously irrelevant reports. We resolved disagreements by discussion between review authors and further disagreements through consultation with the last review author. We assessed risk of bias in 10 methodological domains using the Cochrane risk of bias tool and examined risk of random error through trial sequential analysis. We used the principles of the GRADE approach to prepare an overall assessment of the quality of evidence. For our primary outcomes (recovery times to train‐of‐four ratio (TOFR) &gt; 0.9), we presented data as mean differences (MDs) with 95 % confidence intervals (CIs), and for our secondary outcomes (risk of adverse events and risk of serious adverse events), we calculated risk ratios (RRs) with CIs. </p> </section> <section id="CD012763-sec-0006"> <h3 class="title" id="CD012763-sec-0006">Main results</h3> <p>We included 41 studies (4206 participants) in this updated review, 38 of which were new studies. Twelve trials were eligible for meta‐analysis of primary outcomes (n = 949), 28 trials were eligible for meta‐analysis of secondary outcomes (n = 2298), and 10 trials (n = 1647) were ineligible for meta‐analysis. </p> <p>We compared sugammadex 2 mg/kg and neostigmine 0.05 mg/kg for reversal of rocuronium‐induced moderate neuromuscular blockade (NMB). Sugammadex 2 mg/kg was 10.22 minutes (6.6 times) faster then neostigmine 0.05 mg/kg (1.96 vs 12.87 minutes) in reversing NMB from the second twitch (T2) to TOFR &gt; 0.9 (MD 10.22 minutes, 95% CI 8.48 to 11.96; I<sup>2</sup> = 84%; 10 studies, n = 835; GRADE: moderate quality). </p> <p>We compared sugammadex 4 mg/kg and neostigmine 0.07 mg/kg for reversal of rocuronium‐induced deep NMB. Sugammadex 4 mg/kg was 45.78 minutes (16.8 times) faster then neostigmine 0.07 mg/kg (2.9 vs 48.8 minutes) in reversing NMB from post‐tetanic count (PTC) 1 to 5 to TOFR &gt; 0.9 (MD 45.78 minutes, 95% CI 39.41 to 52.15; I<sup>2</sup> = 0%; two studies, n = 114; GRADE: low quality). </p> <p>For our secondary outcomes, we compared sugammadex, any dose, and neostigmine, any dose, looking at risk of adverse and serious adverse events. We found significantly fewer composite adverse events in the sugammadex group compared with the neostigmine group (RR 0.60, 95% CI 0.49 to 0.74; I<sup>2</sup> = 40%; 28 studies, n = 2298; GRADE: moderate quality). Risk of adverse events was 28% in the neostigmine group and 16% in the sugammadex group, resulting in a number needed to treat for an additional beneficial outcome (NNTB) of 8. When looking at specific adverse events, we noted significantly less risk of bradycardia (RR 0.16, 95% CI 0.07 to 0.34; I<sup>2</sup>= 0%; 11 studies, n = 1218; NNTB 14; GRADE: moderate quality), postoperative nausea and vomiting (PONV) (RR 0.52, 95% CI 0.28 to 0.97; I<sup>2</sup> = 0%; six studies, n = 389; NNTB 16; GRADE: low quality) and overall signs of postoperative residual paralysis (RR 0.40, 95% CI 0.28 to 0.57; I<sup>2</sup> = 0%; 15 studies, n = 1474; NNTB 13; GRADE: moderate quality) in the sugammadex group when compared with the neostigmine group. Finally, we found no significant differences between sugammadex and neostigmine regarding risk of serious adverse events (RR 0.54, 95% CI 0.13 to 2.25; I<sup>2</sup>= 0%; 10 studies, n = 959; GRADE: low quality). </p> <p>Application of trial sequential analysis (TSA) indicates superiority of sugammadex for outcomes such as recovery time from T2 to TOFR &gt; 0.9, adverse events, and overall signs of postoperative residual paralysis. </p> </section> <section id="CD012763-sec-0007"> <h3 class="title" id="CD012763-sec-0007">Authors' conclusions</h3> <p>Review results suggest that in comparison with neostigmine, sugammadex can more rapidly reverse rocuronium‐induced neuromuscular block regardless of the depth of the block. Sugammadex 2 mg/kg is 10.22 minutes (˜ 6.6 times) faster in reversing moderate neuromuscular blockade (T2) than neostigmine 0.05 mg/kg (GRADE: moderate quality), and sugammadex 4 mg/kg is 45.78 minutes (˜ 16.8 times) faster in reversing deep neuromuscular blockade (PTC 1 to 5) than neostigmine 0.07 mg/kg (GRADE: low quality). With an NNTB of 8 to avoid an adverse event, sugammadex appears to have a better safety profile than neostigmine. Patients receiving sugammadex had 40% fewer adverse events compared with those given neostigmine. Specifically, risks of bradycardia (RR 0.16, NNTB 14; GRADE: moderate quality), PONV (RR 0.52, NNTB 16; GRADE: low quality), and overall signs of postoperative residual paralysis (RR 0.40, NNTB 13; GRADE: moderate quality) were reduced. Both sugammadex and neostigmine were associated with serious adverse events in less than 1% of patients, and data showed no differences in risk of serious adverse events between groups (RR 0.54; GRADE: low quality). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012763-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012763-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012763-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012763-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012763-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012763-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012763-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012763-abs-0003" lang="en"> <h3>Benefits and harms of sugammadex versus neostigmine in reversing induced paralysis</h3> <p><b>Background</b> </p> <p>Different levels of induced paralysis are sometimes necessary when patients are put to sleep or are prepared for operations. When the operation is finished, paralysis should be reversed in a fast, reliable, and safe way. Neostigmine is a medication that is traditionally used to reverse induced paralysis. However, its use can be associated with incomplete or slow reversal as well as changes in lung function, heart function, and vomiting and nausea. Sugammadex is a relatively new medication specifically designed to reverse rocuronium‐induced paralysis in a faster, more reliable, and safer way when compared with neostigmine. </p> <p><b>Objective</b> </p> <p>This review systematically sets out to compare the benefits and harms of sugammadex and neostigmine. The evidence is current up to May 2017. </p> <p><b>Study characteristics</b> </p> <p>We identified 41 randomized controlled trials comparing sugammadex with neostigmine that provided suitable data on efficacy and safety. All of these trials included adults undergoing surgery and involved a total of 4206 participants. </p> <p><b>Key results</b> </p> <p>Data indicate that sugammadex was 10.22 minutes (6.6 times) faster than neostigmine (1.96 vs 12.87 minutes) in reversing moderate induced paralysis. Sugammadex was 45.78 minutes (16.8 times) faster than neostigmine (2.9 vs 48.8 minutes) in reversing deep induced paralysis. Participants receiving sugammadex appeared to have a 40% reduced risk of experiencing harmful events than those given neostigmine. Statistically, eight persons can be treated with sugammadex as opposed to neostigmine to avoid one person experiencing a single random harmful event. The occurrence of serious harmful events was nearly non‐existent and data show no differences between compared groups. </p> <p><b>Conclusion</b> </p> <p>Sugammadex is more efficient and safer than neostigmine for reversing moderate and deep induced paralysis. </p> <p><b>Quality of evidence</b> </p> <p>We consider our overall findings on benefits and harms to provide evidence of moderate quality in favour of sugammadex. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012763-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012763-sec-0131"></div> <h3 class="title" id="CD012763-sec-0132">Implications for practice</h3> <section id="CD012763-sec-0132"> <p>In conclusion, results of this systematic review suggest that, in comparison with neostigmine, sugammadex can more rapidly reverse rocuronium‐induced neuromuscular block (NMB) regardless of the depth of the block. Sugammadex 2 mg/kg is 10.22 minutes (˜ 6.6 times) faster in reversing moderate NMB (second twitch (T2)) than neostigmine 0.05 mg/kg (1.96 vs 12.87 minutes), and sugammadex 4 mg/kg is 45.78 minutes (˜ 16.8 times) faster in reversing deep NMB (post‐tetanic count (PTC) 1 to 5) when compared with neostigmine 0.07 mg/kg (2.9 vs 48.8 minutes). With number needed to treat for an additional beneficial outcome (NNTB) of eight to avoid an adverse event, sugammadex appears to have a better safety profile than neostigmine when reversing NMB. Patients receiving sugammadex had 40% fewer adverse events than those given neostigmine (risk ratio (RR), specifically risk of bradycardia (RR 0.16, NNTB 14), postoperative nausea and vomiting (RR 0.52, NNTB 16), and overall signs of postoperative residual paralysis (RR 0.40, NNTB 13) were reduced. Both sugammadex and neostigmine were associated with serious adverse events in &lt; 1% of patients, and data show no difference in risk of serious adverse events between groups. </p> </section> <h3 class="title" id="CD012763-sec-0133">Implications for research</h3> <section id="CD012763-sec-0133"> <p>We suggest future trials should include large and adequate sample sizes and low risk of bias to confirm the findings mentioned above, specifically to evaluate the effect of sugammadex on risks of adverse events and serious adverse events, as well as on patient‐related outcomes, such as risk of residual NMB and other complications after NMB. More trials are needed to directly establish the efficacy and safety of sugammadex when used in situations such as "cannot intubate, cannot ventilate" and failed intubation during rapid sequence inducing with rocuronium. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012763-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012763-sec-0022"></div> <div class="table" id="CD012763-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients, ASA I to IV, who received non‐depolarizing NMBAs<br/> <b>Setting:</b> elective in‐patient or day‐case surgical procedures performed at centres across Europe and Asia<br/> <b>Intervention:</b> sugammadex 2.0 mg/kg<br/> <b>Comparison:</b> neostigmine 0.05 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Neostigmine 0.05 mg/kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Sugammadex 2.0 mg/kg </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery time<sup>a</sup> from second twitch (T2) to train‐of‐four ratio (TOFR) &gt; 0.9 (moderate block) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from T2 to TOFR &gt; 0.9 was <b>12.87 minutes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from T2 to TOFR &gt; 0.9 was <b>1.96 minutes</b> </p> <p>Mean recovery time from T2 to TOFR &gt; 0.9 in the sugammadex group was<b>10.22 minutes faster</b> (8.48 to 11.96 minutes faster) than neostigmine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>c</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA alfa‐boundary adjusted MD is ‐10.22 (95% CI ‐12.11 to ‐8.33; diversity (D<sup>2</sup>) = 87%, I<sup>2</sup> = 84%, random‐effects model, 80% power, alpha 0.05). Cumulative Z‐curve crosses the monitoring boundary (<a href="./full#CD012763-fig-0001">Figure 1</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from post‐tetanic count (PTC) 1 to 5 to train‐of‐four ratio (TOFR) &gt; 0.9 (deep block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risks of adverse events and serious adverse events<sup>b</sup>, bradycardia, PONV, and signs of residual neuromuscular blockade </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not analysed for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Recovery time was measured in minutes from administration of study drug to TOFR &gt; 0.9 by TOF‐watch assessor using acceleromyography at the same monitoring site in all studies (ulnar nerve and adductor pollicis muscle) </p> <p><sup>b</sup>Adverse events and serious adverse events were defined by study authors and were observed and assessed by safety outcome assessors in the operating theatre, in post‐anaesthetic care unit, or up to seven days after surgery, depending on each study. Furthermore, overall clinical signs of postoperative residual paralysis reported by trials were regarded as adverse events in this review. Risk of adverse events was measured as number of adverse events per all participants and/or number of participants experiencing one or more adverse events per all participants, depending on the study. Only adverse events that were possibly, probably, or definitely related to study drug were included in risk assessments </p> <p><sup>c</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD012763-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="TSA of all trials comparing sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg; recovery time from T2 to TOFR &gt; 0.9 minutes. With a required information size of 106, firm evidence in place favours sugammadex in a random‐effects model, with an alfa‐boundary adjusted MD of ‐10.22 (95% CI ‐12.11 to ‐8.33; diversity (D2) = 87%, I2 = 84%, random‐effects model). The cumulative Z‐curve crosses the monitoring boundary constructed for the required information size with 80% power and alpha of 0.05. However, none of the included trials had low risk of bias, and because TSA is ideally designed for trials with low risk of bias and cannot be adjusted for risk of bias, the precision of our findings has to be downgraded. Furthermore, the degree of diversity and heterogeneity is high, which once again raises questions about the reliability of the calculated required information size." data-id="CD012763-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>TSA of all trials comparing sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg; recovery time from T2 to TOFR &gt; 0.9 minutes.</b> With a required information size of 106, firm evidence in place favours sugammadex in a random‐effects model, with an alfa‐boundary adjusted MD of ‐10.22 (95% CI ‐12.11 to ‐8.33; diversity (D<sup>2</sup>) = 87%, I<sup>2</sup> = 84%, random‐effects model). The cumulative Z‐curve crosses the monitoring boundary constructed for the required information size with 80% power and alpha of 0.05. However, none of the included trials had low risk of bias, and because TSA is ideally designed for trials with low risk of bias and cannot be adjusted for risk of bias, the precision of our findings has to be downgraded. Furthermore, the degree of diversity and heterogeneity is high, which once again raises questions about the reliability of the calculated required information size. </p> </div> </div> </div> <div class="figure" id="CD012763-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012763-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="table" id="CD012763-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients, ASA I to IV, who received non‐depolarizing NMBAs<br/> <b>Setting:</b> elective in‐patient or day‐case surgical procedures performed in Italy and USA<br/> <b>Intervention:</b> sugammadex 4.0 mg/kg<br/> <b>Comparison:</b> neostigmine 0.07 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Neostigmine 0.07 mg/kg </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Sugammadex 4.0 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from second twitch (T2) to train‐of‐four ratio (TOFR) &gt; 0.9 (moderate block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery time<sup>a</sup> from post‐tetanic count (PTC 1 to 5) to train‐of‐four ratio (TOFR) &gt; 0.9 (deep block) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from PTC 1 to 5 to TOFR &gt; 0.9 was <b>48.8 minutes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from PTC 1 to 5 to TOFR &gt; 0.9 was <b>2.9 minutes</b> </p> <p>Mean recovery time from PTC 1 to 5 to TOFR &gt; 0.9 in the sugammadex group was <b>45.78 minutes faster</b> (52.15 to 39.41 minutes faster) than in the neostigmine group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of adverse events and serious adverse events<sup>b</sup>, bradycardia, PONV, and signs of residual neuromuscular blockade </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not analysed for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Recovery time was measured in minutes from administration of study drug to TOFR &gt; 0.9 by TOF‐watch assessor using acceleromyography at the same monitoring site in all studies (ulnar nerve and adductor pollicis muscle) </p> <p><sup>b</sup>Adverse events and serious adverse events were defined by study authors and were observed and assessed by safety outcome assessors in the operating theatre, in the post‐anaesthetic care unit, or up to seven days after surgery, depending on each study. Furthermore, overall clinical signs of postoperative residual paralysis reported by trials were regarded as adverse events in this review. Risk of adverse events was measured as number of adverse events per all participants and/or number of participants experiencing one or more adverse events per all participants, depending on the study. Only adverse events that were possibly, probably, or definitely related to study drug were included in risk assessments </p> <p><sup>c</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) and by one level owing to imprecision (small number of participants, n = 114) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012763-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sugammadex (any dose) vs neostigmine (any dose)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sugammadex (any dose) compared to Neostigmine (any dose)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs</b> <br/> <b>Setting: Elective in‐patient or day‐case surgical procedures performed in centres across Europe, USA and Asia</b> <br/> <b>Intervention:</b> Sugammadex (any dose)<br/> <b>Comparison:</b> Neostigmine (any dose) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with neostigmine (any dose)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sugammadex (any dose)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from second twitch (T2) to train‐of‐four ratio (TOFR) &gt; 0.9 (moderate block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from post‐tetanic count (PTC) 1 to 5 to train‐of‐four ratio (TOFR) &gt; 0.9 (deep block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of composite adverse events<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b> <br/> (137 to 204) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60<br/> (0.49 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2298<br/> (28 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>c</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA with continuity adjustment for zero event trials (0.001 in each arm); alfa‐boundary adjusted RR 0.62 (95% CI 0.51 to 0.74; diversity (D<sup>2</sup>) = 34%, I<sup>2</sup> = 14%, random‐effects model; 80% power, 0.05 alpha; <a href="./full#CD012763-fig-0003">Figure 3</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bradycardia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (6 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.16</b> <br/> (0.07 to 0.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1218<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>d</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PONV</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (33 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b> <br/> (0.28 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>e</sup> </p> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall signs of postoperative residual paralysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> <br/> (37 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.40</b> <br/> (0.28 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1474<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>f</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA with continuity adjustment for zero event trials (0.001 in each arm): alfa‐boundary adjusted RR 0.4 (95% CI 0.27 to 0.59; diversity (D<sup>2</sup>) = 0%, I<sup>2</sup> = 0%, random‐effects model, 80% power, 0.05 alpha, <a href="./full#CD012763-fig-0004">Figure 4</a>). Cumulative Z‐curve crosses the monitoring boundary constructed for a required information size of 424 participants indicating firm evidence in favour of sugammadex </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of serious adverse events<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>6 per 1000</b> <br/> (1 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.54</b> <br/> (0.13 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>959<br/> (10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<sup>g</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TSA with continuity adjustment for zero event trials (0.001 in each arm): alfa‐boundary adjusted RR 0.35 (95% CI 0.00 to 3190; diversity (D<sup>2</sup>) = 0%, I<sup>2</sup> = 0%, random‐effects model, 80% power, alpha 0.05), Cumulative Z‐curve does not cross the monitoring boundary constructed for a required information size of 8189 participants with 11.71% of the required information size included </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Recovery time was measured in minutes from administration of study drug to TOFR &gt; 0.9 by TOF‐watch assessor using acceleromyography at the same monitoring site in all studies (ulnar nerve and adductor pollicis muscle) </p> <p><sup>b</sup>Adverse events and serious adverse events were defined by study authors and were observed and assessed by safety outcome assessors in the operating theatre, in the post‐anaesthetic care unit or up to seven days after surgery, depending on each study. Furthermore, overall clinical signs of postoperative residual paralysis reported by trials were regarded as adverse events in this review. Risk of adverse events was measured as number of adverse events per all participants and/or number of participants experiencing one or more adverse events per all participants, depending on the study. Only adverse events that were possibly, probably, or definitely related to study drug were included in risk assessments </p> <p><sup>c</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> <p><sup>d</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> <p><sup>e</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) and by one level owing to imprecision (small number of participants‐ n = 389 ‐ and wide confidence interval (CI) ‐ 0.28 to 0.97) </p> <p><sup>f</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> <p><sup>g</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) and by one level owing to imprecision (small number of events ‐ 10/1000 in the neostigmine group vs 6/1000 in the sugammadex group ‐ and wide confidence interval (CI) ‐ 0.13 to 2.25) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD012763-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="TSA of dichotomous data on drug‐related risk of adverse events; sugammadex (any dose) vs neostigmine (any dose). This analyses includes continuity adjustment for zero event trials (0.001 in each arm) resulting in an alfa‐boundary adjusted RR of 0.62 (95% CI 0.51 to 0.74; diversity (D2) = 34%, I2 = 14%, random‐effects model), with a control event proportion of 27.97%. With the required information size of 502, analyses indicated firm evidence favouring sugammadex with 2298 participants included corresponding to a relative risk reduction (RRR) of 38% with 80% power and alpha of 0.05. Despite the fact that the cumulative Z‐curve does not cross the monitoring boundary directly, it is hard to imagine future trials radically changing the overall picture of this analysis. However, none of the included trials were at low risk of bias, and this does downgrade the reliability of our finding." data-id="CD012763-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>TSA of dichotomous data on drug‐related risk of adverse events; sugammadex (any dose) vs neostigmine (any dose)</b>. This analyses includes continuity adjustment for zero event trials (0.001 in each arm) resulting in an alfa‐boundary adjusted RR of 0.62 (95% CI 0.51 to 0.74; diversity (D<sup>2</sup>) = 34%, I<sup>2</sup> = 14%, random‐effects model), with a control event proportion of 27.97%. With the required information size of 502, analyses indicated firm evidence favouring sugammadex with 2298 participants included corresponding to a relative risk reduction (RRR) of 38% with 80% power and alpha of 0.05. Despite the fact that the cumulative Z‐curve does not cross the monitoring boundary directly, it is hard to imagine future trials radically changing the overall picture of this analysis. However, none of the included trials were at low risk of bias, and this does downgrade the reliability of our finding. </p> </div> </div> </div> <div class="figure" id="CD012763-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="TSA of dichotomous data on risk of signs of residual neuromuscular blockade; sugammadex (any dose) vs neostigmine (any dose). With continuity adjustment for zero event trials (0.001 in each arm), TSA resulted in an alfa‐boundary adjusted RR of 0.4 (95% CI 0.27 to 0.59; diversity (D2) = 0%, I2 = 0%, random‐effects model, with 80% power and alpha of 0.05), with a control event proportion of 13.08%. Cumulative Z‐curve crosses the monitoring boundary constructed for a required information size of 424 participants, indicating firm evidence in favour of sugammadex. However, none of the included trials had low risk of bias, and this equally diminishes the reliability and precision of our estimates." data-id="CD012763-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>TSA of dichotomous data on risk of signs of residual neuromuscular blockade; sugammadex (any dose) vs neostigmine (any dose)</b>. With continuity adjustment for zero event trials (0.001 in each arm), TSA resulted in an alfa‐boundary adjusted RR of 0.4 (95% CI 0.27 to 0.59; diversity (D<sup>2</sup>) = 0%, I<sup>2</sup> = 0%, random‐effects model, with 80% power and alpha of 0.05), with a control event proportion of 13.08%. Cumulative Z‐curve crosses the monitoring boundary constructed for a required information size of 424 participants, indicating firm evidence in favour of sugammadex. However, none of the included trials had low risk of bias, and this equally diminishes the reliability and precision of our estimates. </p> </div> </div> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012763-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012763-sec-0023"></div> <p>After several discussions with the editorial team, a decision was reached to split the original review (<a href="./references#CD012763-bbs2-0161" title="AbrishamiA , HoJ , WongJ , YinL , ChungF . Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007362.pub2] ">Abrishami 2009</a>) into two reviews based on the very extensive number of publications (&gt; 70) identified by the updated search along with various comparators, interventions, and outcome measures. </p> <section id="CD012763-sec-0024"> <h3 class="title" id="CD012763-sec-0024">Description of the condition</h3> <section id="CD012763-sec-0025"> <h4 class="title">Neuromuscular blockade</h4> <p>Neuromuscular blocking agents (NMBAs) are drugs that induce skeletal muscle relaxation primarily by causing a decreased response to the neurotransmitter acetylcholine (ACh) at the neuromuscular junction of skeletal muscle. At that site, ACh normally produces electrical depolarization of the postjunctional membrane of the motor end‐plate, which leads to conduction of muscle action potential and subsequently induces skeletal muscle contraction. Neuromuscular agents are classified as depolarizing or nondepolarizing (<a href="./references#CD012763-bbs2-0140" title="National Center for Biotechnology Information. Rocuronium. PubChem Compound Database2016. [https://pubchem.ncbi.nlm.nih.gov/compound/441290] ">PubChem 2016</a>). Non‐depolarizing NMBAs may be further subdivided into aminosteroidal and curariform types of agents. </p> <p>Use of NMBAs during surgery facilitates tracheal intubation, protects patients from vocal cord injury, and improves surgical conditions by suppressing voluntary or reflex skeletal muscle movements (<a href="./references#CD012763-bbs2-0095" title="BowmanWC . Neuromuscular block. British Journal of Pharmacology2006;147(Suppl 1):S277‐86. [PUBMED: 16402115] ">Bowman 2006</a>; <a href="./references#CD012763-bbs2-0121" title="KeatingGM . Sugammadex: a review of neuromuscular blockade reversal. Drugs2016;76(10):1041‐52. [PUBMED: 27324403] ">Keating 2016</a>). Following surgery, relaxation is no longer needed, it is important that effects of the NMBA can be quickly and effectively terminated. Postoperative residual neuromuscular blockade and resulting muscle weakness caused by non‐depolarizing NMBAs have been shown to be associated with increased mortality and morbidity (<a href="./references#CD012763-bbs2-0136" title="PedersenT . Complications and death following anaesthesia. A prospective study with special reference to the influence of patient‐, anaesthesia‐, and surgery‐related risk factors. Danish Medical Bulletin1994;41(3):319‐31. [PUBMED: 7924461] ">Pedersen 1994</a>; <a href="./references#CD012763-bbs2-0145" title="ShortenGD . Postoperative residual curarization: incidence, aetiology and associated morbidity. Anaesthesia and Intensive Care1993;21(6):782‐9. [PUBMED: 8122734 ] ">Shorten 1993</a>). Residual neuromuscular blockade may result in pulmonary complications, for example, laboured breathing, low oxygen levels in the blood, lung infection, and entry of gastric contents into the lungs (<a href="./references#CD012763-bbs2-0092" title="BergH , RoedJ , Viby‐MogensenJ , MortensenCR , EngbaekJ , SkovgaardLT , et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiologica Scandinavica1997;41(9):1095‐103. [PUBMED: 9366929 ] ">Berg 1997</a>; <a href="./references#CD012763-bbs2-0094" title="BevanDR , KahwajiR , AnserminoJM , ReimerE , SmithMF , O'ConnarGA , et al. Residual block after mivacurium with or without edrophonium reversal in adults and children. Anesthesiology1996;84(2):362‐7. [PUBMED: 8602667 ] ">Bevan 1996</a>; <a href="./references#CD012763-bbs2-0108" title="ErikssonLI , SatoM , SeveringhausJW . Effect of vecuronium‐induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology1993;78(4):693‐9. [PUBMED: 8096684 ] ">Eriksson 1993</a>; <a href="./references#CD012763-bbs2-0109" title="ErikssonLI , SundmanE , OlssonR , NilssonL , WittH , EkbergO , et al. Functional assessment of the pharynx at rest and during swallowing in partially paralysed humans. Simultaneous video manometry and mechanomyography of awake human volunteers. Anesthesiology1997;87(5):1035‐43. [PUBMED: 9366453 ] ">Eriksson 1997</a>; <a href="./references#CD012763-bbs2-0128" title="MurphyGS . Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiologica2006;72(3):97‐109. [PUBMED: 16493386] ">Murphy 2006</a>; <a href="./references#CD012763-bbs2-0129" title="MurphyGS , SzokolJW , MarymontJH , GreenbergSB , AvramMJ , VenderJS . Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesthesia and Analgesia2008;107(1):130‐7. [PUBMED: 18635478] ">Murphy 2008</a>; <a href="./references#CD012763-bbs2-0149" title="SundmanE , WittH , OlssonR , EkbergO , KuylenstiernaR , ErikssonLI . The incidence and mechanisms of pharyngeal and upper oesophageal dysfunction in partially paralysed humans. Pharyngeal video radiography and simultaneous manometry after atracurium. Anesthesiology2000;92(4):977‐84. [PUBMED: 10754616 ] ">Sundman 2000</a>). It can also lead to a postoperative decrease in muscle strength with associated complications, such as visual difficulties and delayed recovery and discharge time (<a href="./references#CD012763-bbs2-0131" title="MurphyGS , SzokolJW , AvramMJ , GreenbergSB , MarymontJH , VenderJS , et al. Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology2011;115(5):946‐54. [PUBMED: 21946094] ">Murphy 2011</a>). Postoperative residual blockade frequently occurs after routine anaesthesia (<a href="./references#CD012763-bbs2-0153" title="Viby‐MogensenJ , JørgensenBC , OrdingH . Residual curarization in the recovery room. Anesthesiology1979;50(6):539‐41. [PUBMED: 156513] ">Viby‐Mogensen 1979</a>). Its incidence varies among trials depending on the type of NMBA used. Some studies have demonstrated a lower incidence of residual block following short‐acting or intermediate‐acting NMBAs in comparison with long‐acting agents (<a href="./references#CD012763-bbs2-0093" title="BevanDR , SmithCE , DonatiF . Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium and pancuronium. Anesthesiology1988;69(2):272‐6. [PUBMED: 2900612 ] ">Bevan 1988</a>; <a href="./references#CD012763-bbs2-0098" title="BrullSJ , EhrenwerthJ , ConnellyNR , SilvermanDG . Assessment of residual curarization using low‐current stimulation. Canadian Journal of Anaesthesia1991;38(2):164‐8. [PUBMED: 1673643 ] ">Brull 1991</a>). However, postoperative residual neuromuscular blockade may still occur in the short‐acting or intermediate‐acting NMBA group, with incidence ranging from 16% to 60% (<a href="./references#CD012763-bbs2-0089" title="AppelbaumR , MulderR , SaddlerJ , KopmanAF , McShaneAJ . Atracurium associated with postoperative residual curarization (multiple letters). British Journal of Anaesthesia2003;90(4):523‐4. ">Appelbaum 2003</a>; <a href="./references#CD012763-bbs2-0091" title="BaillardC , Clec'hC , CatineauJ , SalhiF , GehanG , CupaM , et al. Postoperative residual neuromuscular block: a survey of management. British Journal of Anaesthesia2005;95(5):622‐6. [PUBMED: 16183681 ] ">Baillard 2005</a>; <a href="./references#CD012763-bbs2-0094" title="BevanDR , KahwajiR , AnserminoJM , ReimerE , SmithMF , O'ConnarGA , et al. Residual block after mivacurium with or without edrophonium reversal in adults and children. Anesthesiology1996;84(2):362‐7. [PUBMED: 8602667 ] ">Bevan 1996</a>; <a href="./references#CD012763-bbs2-0103" title="DebaeneB , PlaudB , DillyMP , DonatiF . Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology2003;98:1042‐8. [PUBMED: 12717123] ">Debaene 2003</a>; <a href="./references#CD012763-bbs2-0110" title="FawcettWJ , DashA , FrancisGA , LibanJB , CashmanJN . Recovery from neuromuscular blockade: residual curarization following atracurium or vecuronium by bolus dosing or infusions. Acta Anaesthesiologica Scandinavica1995;39(3):288‐93. [PUBMED: 7793202] ">Fawcett 1995</a>; <a href="./references#CD012763-bbs2-0115" title="HayesAH , MirakyrRK , BrestinDS , ReidJE , McCourtKC . Postoperative residual block after intermediate acting neuromuscular blocking drugs. Anaesthesia2001;56(4):312‐8. [PUBMED: 11284816 ] ">Hayes 2001</a>; <a href="./references#CD012763-bbs2-0122" title="KimKS , LewSH , ChoHY , CheongMA . Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine. Anesthesia and Analgesia2002;95(6):1656‐60. [PUBMED: 12456433 ] ">Kim 2002</a>; <a href="./references#CD012763-bbs2-0125" title="MaybauerDM , GeldnerG , BlobnerM , PuhringerF , HofmockelR , RexC , et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia2007;62(1):12‐7. [PUBMED: 17156221] ">Maybauer 2007</a>; <a href="./references#CD012763-bbs2-0126" title="McCaulC , TobinE , BoylanJF , McShaneAJ . Atracurium is associated with postoperative residual curarization. British Journal of Anaesthesia2002;89(5):766‐9. [PUBMED: 12393778] ">McCaul 2002</a>). </p> </section> <section id="CD012763-sec-0026"> <h4 class="title">Monitoring of neuromuscular blockade</h4> <p>The degree of neuromuscular blockade is monitored by assessment of various patterns of electrical stimulation. The train‐of‐four (TOF) twitch stimulation was developed as a clinical tool that could be used to assess neuromuscular block in the anaesthetized patient (<a href="./references#CD012763-bbs2-0086" title="AliHH , UttingJE , GrayC . Stimulus frequency in the detection of neuromuscular block in humans. British Journal of Anaesthesia1970;42(11):967‐78. [PUBMED: 5488360] ">Ali 1970</a>). This strategy involves stimulating the ulnar nerve with four supramaximal 200 microsecond stimuli separated by 0.5 seconds. This approach is repeated every 10 seconds. Twitches on a TOF pattern fade as relaxation increases. This enables the observer to compare T1 (first twitch of the TOF) versus T0 (control), as well as T4 (fourth twitch of the TOF) versus T1. This T1/T4 ratio is known as the TOF ratio (TOFR). Satisfactory recovery from neuromuscular block and clinical absence of residual curarization have not occurred until the TOFR is &gt; 0.9 (<a href="./references#CD012763-bbs2-0156" title="Viby‐MogensenJ . Postoperative residual curarization and evidence‐based anaesthesia. British Journal of Anaesthesia2000;84(3):301‐3. [PUBMED: 10793585] ">Viby‐Mogensen 2000</a>), contrary to TOFR &gt; 0.7, as previously suggested (<a href="./references#CD012763-bbs2-0087" title="AliHH , UttingJE , GrayTC . Quantitative assessment of residual antidepolarizing block II. British Journal of Anaesthesia1971;43(5):478‐85. [PUBMED: 4254032] ">Ali 1971</a>). During profound non‐depolarizing neuromuscular block, no response to TOF twitch stimulation may occur. In such circumstances, a post‐tetanic count (PTC) may be useful (<a href="./references#CD012763-bbs2-0154" title="Viby‐MogensenJ , Howardy‐HansenP , Chraemmer‐JørgensenB , OrdingH , EngbaekJ , NielsenA . Posttetanic count (PTC): a new method of evaluating an intense nondepolarizing neuromuscular blockade. Anesthesiology1981;55(4):458‐61. [PUBMED: 7294384] ">Viby‐Mogensen 1981</a>). If a 5 second tetanic stimulus at 50 Hz is administered, after no twitch response has been elicited, followed 3 seconds later by additional single twitches at 1 Hz, response to single twitch stimulation may occur. Although this pattern will not be seen during very profound block, a response will be seen in the early stages of recovery, before the TOF reappears. The number of post‐tetanic twitches is an indication of when the first twitch of the TOF will reappear. </p> <p>The muscle response to peripheral nerve stimulation can be assessed by visual and tactile methods and by electromyography, acceleromyography, and mechanomyography. Visual observation and palpation of the contracting muscle group are the easiest but least accurate methods of assessing neuromuscular block. Acceleromyography was introduced for clinical use in 1988 (<a href="./references#CD012763-bbs2-0120" title="JensenE , Viby‐MogensenJ , BangU . The Accelograph: a new neuromuscular transmission monitor. Acta Anaesthesiologica Scandinavica1988;32(1):49‐52. [PUBMED: 2830761] ">Jensen 1988</a>; <a href="./references#CD012763-bbs2-0155" title="Viby‐MogensenJ , JensenE , WernerM , NielsenHK . Measurement of acceleration: a new method of monitoring neuromuscular function. Acta Anaesthesiologica Scandinavica1988;32(1):45‐8. [PUBMED: 2830760] ">Viby‐Mogensen 1988</a>). This technique measures acceleration of a distal digit, which is directly proportionate to the force of muscle contraction and therefore is inversely proportionate to the degree of neuromuscular block. </p> <p>The monitor consists of an acceleration transducer (i.e. a piezo‐electric ceramic wafer with an electrode on each side) and a stimulation and computing unit. The transducer can be fastened to the thumb, and when the finger is moved in response to nerve stimulation, a voltage difference develops between the two electrodes. The voltage then is measured and is registered in the computing unit. </p> </section> </section> <section id="CD012763-sec-0027"> <h3 class="title" id="CD012763-sec-0027">Description of the intervention</h3> <section id="CD012763-sec-0028"> <h4 class="title">Reversal of neuromuscular blockade</h4> <p>The most commonly used NMBA reversal agents are neostigmine and edrophonium, both of which are cholinesterase inhibitors. They antagonize both aminosteroidal and curariform types of non‐depolarizing NMBAs by inhibiting the breakdown of ACh in the neuromuscular junction (NMJ), causing, ACh to bind the receptor and depolarize the muscle fibre and allowing greater transmission of nerve impulses. These medications, however, require that a muscarinic antagonist (e.g. glycopyrrolate, atropine) be used to compensate for their cholinergic side effects such as bradycardia, hypotension, bronchoconstriction, and postoperative nausea and vomiting (<a href="./references#CD012763-bbs2-0152" title="TramerMR , Fuchs‐BuderT . Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. British Journal of Anaesthesia1999;82(3):379‐86. [PUBMED: 10434820] ">Tramer 1999</a>). Adverse effects associated with the use of muscarinic antagonists include tachycardia, dry mouth, and urinary retention (<a href="./references#CD012763-bbs2-0127" title="MirakhurRK . Antagonism of the muscarinic effects of edrophonium with atropine or glycopyrrolate. A comparative study. British Journal of Anaesthesia1985;57(12):1213‐6. [PUBMED: 4084429 ] ">Mirakhur 1985</a>). </p> <p>In contrast to cholinesterase inhibitors, the NMBA reversal agent sugammadex does not interfere with acetylcholinesterase receptor systems; therefore, it does not produce the muscarinic side effects associated with other reversal medications for NMBAs. Sugammadex is a synthetically modified ɣ‐cyclodextrin, a chemical structure with a hydrophilic exterior and a hydrophobic core. It was specifically designed to reverse rocuronium‐induced paralysis by encapsulating rocuronium; however, its inner cavity is large enough to encapsulate other aminosteroidal NMBAs such as vecuronium and, to a much lesser degree, pancuronium (<a href="./references#CD012763-bbs2-0113" title="GolembiewskiJ . Sugammadex. Journal of PeriAnesthesia Nursing2016;31(4):354‐7. [PUBMED: 27444769] ">Golembiewski 2016</a>; <a href="./references#CD012763-bbs2-0133" title="NaguibM , BrullSJ . Sugammadex: a novel selective relaxant binding agent. Expert Review of Clinical Pharmacology2009;2(1):37‐53. [PUBMED: 24422770] ">Naguib 2009</a>). Sugammadex does not bind nor does it reverse the neuromuscular blocking effects of curariform NMBAs. Upon binding, it creates a complex formation between the molecule and the aminosteroidal NMBA, which results in more rapid reversal of the neuromuscular blockade than is achieved by anticholinesterase drugs (<a href="./references#CD012763-bbs2-0134" title="ParkJY . Benefits and risks of sugammadex. Korean Journal of Anesthesiology2015;68(1):1‐2. [PUBMED: 25664147] ">Park 2015</a>). Sugammadex does not bind to plasma proteins and is not metabolized. It is excreted unchanged in the urine by the kidneys. Renal clearance of sugammadex is rapid ‐ most of the dose (70%) is excreted within six hours (<a href="./references#CD012763-bbs2-0113" title="GolembiewskiJ . Sugammadex. Journal of PeriAnesthesia Nursing2016;31(4):354‐7. [PUBMED: 27444769] ">Golembiewski 2016</a>). </p> </section> </section> <section id="CD012763-sec-0029"> <h3 class="title" id="CD012763-sec-0029">How the intervention might work</h3> <p>The positively charged quaternary nitrogen of the aminosteroidal NMBA forms electrostatic bonds with negatively charged interior groups of sugammadex to encapsulate rocuronium and vecuronium (<a href="./references#CD012763-bbs2-0113" title="GolembiewskiJ . Sugammadex. Journal of PeriAnesthesia Nursing2016;31(4):354‐7. [PUBMED: 27444769] ">Golembiewski 2016</a>). Sugammadex forms a stable, inactive 1:1 complex with rocuronium or vecuronium; this reduces the amount of free NMBA that is available to bind to nicotinic acetylcholine receptors at the neuromuscular junction, resulting in reversal of neuromuscular blockade (<a href="./references#CD012763-bbs2-0121" title="KeatingGM . Sugammadex: a review of neuromuscular blockade reversal. Drugs2016;76(10):1041‐52. [PUBMED: 27324403] ">Keating 2016</a>). Once the NMBA is removed from its site of action and is rendered inactive (by encapsulation within the sugammadex molecule in the plasma), neuromuscular transmission and muscle function are restored. By reversing aminosteroid‐induced neuromuscular blockade, one can avoid the associated risks caused by residual block, can shorten time in the operating room, and can improve the patient's quality of recovery and discharge time (<a href="./references#CD012763-bbs2-0090" title="ArbousMS , MeursingAE , vanKleefJW , deLangeJJ , SpoormansHH , TouwP , et al. Impact of anaesthesia management characteristics on severe morbidity and mortality. Anesthesiology2005;102(2):257‐68. [PUBMED: 15681938] ">Arbous 2005</a>). </p> </section> <section id="CD012763-sec-0030"> <h3 class="title" id="CD012763-sec-0030">Why it is important to do this review</h3> <p>Residual neuromuscular block is a common complication in the post‐anaesthesia care unit, with approximately 40% of patients exhibiting a TOFR &lt; 0.9 (<a href="./references#CD012763-bbs2-0130" title="MurphyGS , BrullSJ . Residual neuromuscular block: lessons unlearned. Part I. Definitions, Incidence, and adverse physiologic effects of residual neuromuscular block. Anesthesia and Analgesia2010;111(1):120‐8. [PUBMED: 20442260] ">Murphy 2010</a>). The clinical safety and efficacy of sugammadex in reversing rocuronium‐induced neuromuscular blockade have been studied in several randomized controlled trials (RCTs) that compared this medication versus placebo or conventional reversal agents (<a href="./references#CD012763-bbs2-0101" title="deBoerHD , DriessenJJ , MarcusMA , KerkkampH , HeeringaM , KlimekM . Reversal of rocuronium‐induced (1.2mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose‐finding and safety study. Anesthesiology2007;107(2):239‐44. [PUBMED: 17667567] ">de Boer 2007</a>; <a href="./references#CD012763-bbs2-0112" title="GijsenbergF , RamaelS , HouwingN , vanLerselT . First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology2007;103(4):695‐703. [PUBMED: 16192761] ">Gijsenbergh 2005</a>; <a href="./references#CD012763-bbs2-0057" title="SacanO , WhitePF , TufanogullariB , KleinK . Sugammadex reversal of rocuronium‐induced neuromuscular blockade: a comparison with neostigmine‐glycopyrrolate and edrophonium‐atropine. Anesthesia and Analgesia2007;104(3):569‐74. [PUBMED: 17312210 ] ">Sacan 2007</a>; <a href="./references#CD012763-bbs2-0146" title="SorgenfreiIF , NorrildK , LarsenPB , StensballeJ , OstergaardD , PrinsME , et al. Reversal of rocuronium‐induced neuromuscular block by the selective relaxant binding agent sugammadex, a dose‐finding and safety study. Anesthesiology2006;104(4):667‐74. [PUBMED: 16571960] ">Sorgenfrei 2006</a>; <a href="./references#CD012763-bbs2-0147" title="SparrHJ , VermeyenKM , BeaufortAM , RietbergenH , ProostJH , SaldienV , et al. Early reversal of profound rocuronium‐induced neuromuscular blockade by sugammadex in a randomised multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology2007;106(5):935‐43. [PUBMED: 17457124 ] ">Sparr 2007</a>). The aim of our review was to update the best available evidence on this topic and to assess the efficacy and safety of sugammadex and neostigmine in reversal of neuromuscular blockade. We aimed to systematically review RCTs conducted to examine sugammadex and neostigmine administration. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012763-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012763-sec-0031"></div> <p>The main objective of this review was to compare the efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade caused by non‐depolarizing neuromuscular agents in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012763-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012763-sec-0032"></div> <section id="CD012763-sec-0033"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012763-sec-0034"> <h4 class="title">Types of studies</h4> <p>We included RCTs irrespective of publication status, date of publication, blinding status, outcomes published, or language. We contacted trial investigators and study authors to ask for relevant data. We included unpublished trials only if trial data and methodological descriptions were provided in written form or could be retrieved from the trial authors. We excluded observational studies. We did not include studies using a non‐standard design, such as cross‐over trials and cluster‐randomized trials. </p> </section> <section id="CD012763-sec-0035"> <h4 class="title">Types of participants</h4> <p>We included adults (&gt; 18 years of age) classified as American Society of Anesthesiologists (ASA) I to IV who had received non‐depolarizing NMBAs for an elective in‐patient or day‐case surgical procedure, and who consented to be included in the study. We did not include paediatric participants, healthy volunteers, or participants not undergoing surgical procedures. </p> </section> <section id="CD012763-sec-0036"> <h4 class="title">Types of interventions</h4> <p>We included all trials comparing sugammadex versus neostigmine in adults receiving non‐depolarizing NMBAs. We included any dose of sugammadex and neostigmine and any time point of administration of study drug. </p> <p>We excluded trials that compared sugammadex and neostigmine versus only placebo or no intervention. </p> </section> <section id="CD012763-sec-0037"> <h4 class="title">Types of outcome measures</h4> <section id="CD012763-sec-0038"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012763-list-0001"> <li> <p>Recovery time from second twitch (T2) to TOFR &gt; 0.9</p> </li> <li> <p>Recovery time from post‐tetanic count (PTC) 1 to 5 to TOFR &gt; 0.9</p> </li> </ol> </p> <p>For our first primary outcome "Recovery time from T2 to TOFR &gt; 0.9", we compared sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg. For our second primary outcome "Recovery time from PTC 1 to 5 to TOFR &gt; 0.9", we compared sugammadex 4 mg/kg versus neostigmine 0.07 mg/kg. In all studies, the TOF‐watch assessor used acceleromyography to measure recovery time in minutes from administration of the study drug to TOFR &gt; 0.9 at the same monitoring site (ulnar nerve and adductor pollicis muscle). </p> </section> <section id="CD012763-sec-0039"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012763-list-0002"> <li> <p>Risk of adverse events</p> </li> <li> <p>Risk of serious adverse events</p> </li> </ol> </p> <p>Study authors defined and safety outcome assessors observed and assessed adverse events and serious adverse events in the operating theatre, in the post‐anaesthetic care unit, or up to seven days after surgery, depending on each study. Furthermore, this review regarded as adverse events overall clinical signs of postoperative residual paralysis reported by trial authors. We measured risk of adverse events as the number of adverse events per all participants and/or the number of participants experiencing one or more adverse events per all participants. We included in risk assessments only adverse events that were possibly, probably, or definitely related to study drug. We included in the analysis adverse events and serious adverse events observed following any administered dose of sugammadex and neostigmine and at any time point of study drug administration. Additionally, for the purposes of this review, we presented adverse events as specific adverse events as well as composite adverse events, defined as the combination of all adverse events. </p> </section> </section> </section> <section id="CD012763-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012763-sec-0041"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 4); MEDLINE (WebSPIRS Ovid SP, 1950 to 2 May 2016); and Embase (WebSPIRS Ovid SP, 1980 to 2 May 2016). We applied no language restrictions. We did a top‐up search in May 2017. For specific information regarding our search strategies and results, please see <a href="./appendices#CD012763-sec-0137">Appendix 1</a>, <a href="./appendices#CD012763-sec-0138">Appendix 2</a>, and <a href="./appendices#CD012763-sec-0139">Appendix 3</a>. </p> </section> <section id="CD012763-sec-0042"> <h4 class="title">Searching other resources</h4> <p>We searched for ongoing clinical trials and unpublished trials at the following Internet sites. </p> <p> <ol id="CD012763-list-0003"> <li> <p><a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a> </p> </li> <li> <p><a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> </p> </li> <li> <p><a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a> </p> </li> </ol> </p> <p>We handsearched the reference lists of reviews, randomized and non‐randomized trials, and editorials for additional trials. We contacted the main authors of trials in this field to ask about missed, unreported, and ongoing trials. We applied no language restrictions to eligible reports. </p> <p>We conducted the latest search on 2 May 2016, along with a top‐up search in May 2017.</p> </section> </section> <section id="CD012763-sec-0043"> <h3 class="title" id="CD012763-sec-0043">Data collection and analysis</h3> <p>Two review authors (AMH, PD) independently screened and classified all citations as potential primary studies, review articles, or other; independently examined all potentially eligible primary trials and decided on their inclusion in the review; and furthermore independently extracted data from each trial and evaluated data on methods and outcomes in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>). We (AMH, PD) resolved disagreements by discussion and by consultation with the last review author (AA). </p> <section id="CD012763-sec-0044"> <h4 class="title">Selection of studies</h4> <p>We assessed articles identified via the described searches and excluded obviously irrelevant reports. Two review authors (AMH, PD) independently examined articles and screened titles and abstracts to identify eligible trials. We completed this process without blinding to study authors, institutions, journals of publication, or results. We resolved disagreements by reaching consensus among two review authors (AMH, PD) and by consultation with the last review author (AA). We listed all excluded trials along with reasons for their exclusion in the <a href="./references#CD012763-sec-0158" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD012763-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>We independently extracted and collected data from each trial without blinding to study authors, source institutions, or publication sources of trials. We resolved disagreements by discussion and approached all first authors of included trials for additional information on risks of bias. For more detailed information, please see <a href="#CD012763-sec-0151">Contributions of authors</a>. </p> </section> <section id="CD012763-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We evaluated the validity and design characteristics of each trial.</p> <p>We evaluated trials for major potential sources of bias (random sequence generation, allocation concealment, blinding of participants, blinding of personnel, blinding of primary outcome assessor, blinding of secondary outcome assessor, incomplete outcome data, selective reporting, funding bias and other bias; see <a href="./appendices#CD012763-sec-0140">Appendix 4</a>). We assessed each trial quality factor separately and defined trials as having low risk of bias only if they adequately fulfilled all of the criteria described below. </p> </section> <section id="CD012763-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>For our primary outcome (recovery time to TOFR &gt; 0.9), we used mean differences (MDs) with 95% confidence intervals (CIs) because data were continuous and were measured in the same way by all trials. For our secondary outcomes (risks of adverse events and serious adverse events), we calculated risk ratios (RRs) with 95% CIs for dichotomous data (binary outcomes), which were measured in the same way between trials. We also presented data for primary and secondary outcomes as relative differences. (See <a href="#CD012763-sec-0043">Data collection and analysis</a> section.) </p> </section> <section id="CD012763-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <section id="CD012763-sec-0049"> <h5 class="title">Trials with multiple intervention groups</h5> <p>In accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>), we combined data for secondary outcomes extracted from trials with two or more groups receiving different doses of sugammadex or neostigmine. We excluded trials that compared only different doses of sugammadex or different doses of neostigmine, as well as trials without a control group. </p> </section> <section id="CD012763-sec-0050"> <h5 class="title">Cross‐over trials</h5> <p>We planned to exclude cross‐over trials from our meta‐analyses because of potential risk for “carry‐over” of treatment effect. However, we identified no cross‐over trials through our search. </p> </section> </section> <section id="CD012763-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of trials with missing data to retrieve relevant information. For all included trials, we noted levels of attrition and any exclusions. In cases of missing data, we chose 'complete‐case analysis’ for our primary outcomes, which excludes from the analysis all participants for whom the outcome is missing. </p> <p>Selective outcome reporting, which occurs when non‐significant results are selectively withheld from publication (<a href="./references#CD012763-bbs2-0100" title="ChanAW , HróbjartssonA , HaahrMT , GøtzschePC , AltmanDG . Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA2004;291(20):2457‐65. [PUBMED: 15161896] ">Chan 2004</a>), is defined as selection, on the basis of trial results, of a subset of the original variables recorded for inclusion in publication of trials (<a href="./references#CD012763-bbs2-0118" title="HuttonJL , WilliamsonPR . Bias in meta‐analysis due to outcome variable selection within studies. Journal of the Royal Statistical Society Series C2000;49:359‐70. [DOI: 10.1111/1467‐9876.00197] ">Hutton 2000</a>). The most important types of selective outcome reporting include selective omission of outcomes from reports; selective choice of data for an outcome; selective reporting of different analyses using the same data; selective reporting of subsets of the data; and selective underreporting of data (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD012763-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We explored heterogeneity using the I<sup>2</sup> statistic and the Chi<sup>2</sup> test. An I<sup>2</sup> statistic above 50% represents substantial heterogeneity (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>). In cases of substantial heterogeneity, we tried to determine the cause of heterogeneity by performing relevant subgroup and sensitivity analyses (excluding potential outliers to see visual impact of the overall value of the I<sup>2</sup> statistic on forest plots). We used the Chi² test to provide an indication of heterogeneity between trials, with a P value ≤ 0.1 considered significant. However, in cases of presumed substantial clinical heterogeneity within an analysis, we planned to use the random‐effects model independent of I<sup>2</sup> value. </p> </section> <section id="CD012763-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>We included both published and unpublished studies during the selection process. We attempted to source published protocols for each of our included studies by using clinical trials registers. We compared published protocols versus published study results to assess the risk of selective reporting bias. Two review authors (AMH and PD) resolved disagreements by discussion and by consultation with the last review author (AA). As we included a sufficient number of studies (greater than 10), we assessed reporting biases (such as publication bias) by using funnel plots. We used the asymmetry of the funnel plot to assess risk of publication and other reporting bias (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>). An asymmetrical funnel plot may indicate publication of only positive results (<a href="./references#CD012763-bbs2-0106" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>). </p> </section> <section id="CD012763-sec-0054"> <h4 class="title">Data synthesis</h4> <section id="CD012763-sec-0055"> <h5 class="title">Data analysis</h5> <p>We used Review Manager software (<a href="./references#CD012763-bbs2-0143" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. ">RevMan 5.3.5</a>) and calculated MDs with 95% CIs for continuous outcomes, and RRs with 95% CIs for dichotomous variables. We used the Chi<sup>2</sup> test to obtain an indication of heterogeneity between trials, with P ≤ 0.1 considered significant. We quantified the degree of heterogeneity observed in the results by using the I² statistic, which can be interpreted as the proportion of total variation observed between trials that is attributable to differences between trials rather than to sampling error (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>). I² &gt; 75% is considered as very heterogeneous. However, we chose a random‐effects model for all of our analyses because clinical heterogeneity was a considerable issue beside the inter‐study heterogeneity expressed by the I² statistic. Thus, we saw little rationale to carry out comparative analyses examining the impact of the choice between using a fixed‐effect versus a random‐effects model. </p> </section> <section id="CD012763-sec-0056"> <h5 class="title">Trial sequential analysis</h5> <p>Risk of type 1 errors in meta‐analyses due to sparse data and repeated significance testing following updates with new trials remains a serious concern (<a href="./references#CD012763-bbs2-0097" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. Journal of Clinical Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD012763-bbs2-0150" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD012763-bbs2-0157" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD012763-bbs2-0158" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). As a result, spurious P values due to systematic errors from trials with high risk of bias, outcome reporting bias, publication bias, early stopping for benefit, and small trial bias may result in false conclusions. In a single trial, interim analysis increases the risk of type 1 errors. To avoid type 1 errors, group sequential monitoring boundaries (<a href="./references#CD012763-bbs2-0123" title="LanKKG , DeMetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70(3):659‐63. [DOI: 10.1093/biomet/70.3.659] ">Lan 1983</a>) are used to decide whether a trial could be terminated early because of a sufficiently small P value, with the cumulative Z‐curve crossing the monitoring boundary. </p> <p>Sequential monitoring boundaries can be applied equally to meta‐analyses and are labelled 'trial sequential monitoring boundaries’. In 'trial sequential analysis’ (TSA), the addition of each new trial to a cumulative meta‐analysis is viewed as an interim meta‐analysis, which provides useful information on the need for additional trials (<a href="./references#CD012763-bbs2-0157" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>It is appropriate and wise to adjust new meta‐analyses for multiple testing on accumulating data to control overall type 1 error risk in cumulative meta‐analysis (<a href="./references#CD012763-bbs2-0138" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD012763-bbs2-0139" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):45‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD012763-bbs2-0150" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD012763-bbs2-0158" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). </p> <p>When TSA is performed, the cumulative Z‐curve crossing the boundary indicates that a sufficient level of evidence has been reached; as a consequence, one may conclude that no additional trials may be needed. However, evidence is insufficient to allow a conclusion if the Z‐curve does not cross the boundary or does not surpass the required information size. </p> <p>To construct trial sequential monitoring boundaries (TSMBs), one needs a required information size, which is calculated as the least number of participants required in a well‐powered single trial with low risk of bias (<a href="./references#CD012763-bbs2-0097" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. Journal of Clinical Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD012763-bbs2-0139" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):45‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD012763-bbs2-0157" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>In this updated review, we adjusted the required information size for heterogeneity by using the diversity adjustment factor (<a href="./references#CD012763-bbs2-0158" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). We applied TSA, as it prevents an increase in the risk of type 1 errors (20%). If the actual accrued information size was too small, we provided the required information size in the light of actual diversity (<a href="./references#CD012763-bbs2-0158" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). </p> </section> </section> <section id="CD012763-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted the following subgroup analyses.</p> <p> <ol id="CD012763-list-0004"> <li> <p>Sugammadex 2.0 mg/kg versus neostigmine 0.05 mg/kg: recovery time from T2 to TOFR &gt; 0.9 </p> <ol id="CD012763-list-0005"> <li> <p>Total intravenous anaesthesia (TIVA) versus volatile anaesthetics</p> </li> </ol> </li> <li> <p>Sugammadex, any dose, versus neostigmine, any dose: adverse events</p> <ol id="CD012763-list-0006"> <li> <p>Composite adverse events: different dosages of sugammadex versus neostigmine</p> </li> <li> <p>Composite adverse events: TIVA versus volatile anaesthetics</p> </li> <li> <p>Bradycardia: atropine versus glycopyrrolate</p> </li> <li> <p>Postoperative nausea and vomiting (PONV): TIVA versus volatile anaesthetics</p> </li> </ol> </li> </ol> </p> <p>If analyses of various subgroups were significant, we planned to perform a test of interaction (<a href="./references#CD012763-bbs2-0088" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [PUBMED: 12543843] ">Altman 2003</a>). We considered P values &lt; 0.05 as indicating significant interaction between treatments and subgroup categories. However, because subgroup analyses showed no significant differences, we performed no tests of interaction. </p> </section> <section id="CD012763-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted the following sensitivity analyses.</p> <p> <ol id="CD012763-list-0007"> <li> <p>Sugammadex 2.0 mg/kg versus neostigmine 0.05 mg/kg, recovery time from T2 to TOFR &gt; 0.9, excluding meeting abstracts </p> </li> <li> <p>Sugammadex, any dose, versus neostigmine, any dose, composite adverse events, excluding meeting abstracts </p> </li> </ol> </p> <section id="CD012763-sec-0059"> <h5 class="title">Summary of findings table and GRADE</h5> <p>We used the principles of the GRADE approach to perform an overall assessment of evidence related to all of our outcomes. We constructed a 'Summary of findings' table using <a href="./references#CD012763-bbs2-0114" title="gradepro.org . GRADEpro GDT. Version Accessed December 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GradePro software</a>. As outcomes of clinical interest, we chose to present recovery time from T2 to TOFR &gt; 0.9 (moderate block); recovery time from PTC 1 to 5 to TOFR &gt; 0.9 (deep block); risks of adverse events, serious adverse events, bradycardia, and PONV; and signs of residual neuromuscular blockade (see <a href="./full#CD012763-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012763-tbl-0002">summary of findings Table 2</a>; and <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012763-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012763-sec-0060"></div> <section id="CD012763-sec-0061"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>; <a href="./references#CD012763-sec-0158" title="">Characteristics of excluded studies</a>; <a href="./references#CD012763-sec-0159" title="">Characteristics of studies awaiting classification</a>; and <a href="./references#CD012763-sec-0160" title="">Characteristics of ongoing studies</a>. </p> <section id="CD012763-sec-0062"> <h4 class="title">Results of the search</h4> <p>In May 2016, through electronic searches and searches of the references of potentially relevant articles, we identified 2502 publications. We excluded 2431 publications, as they were duplicates (n = 675), measured clearly irrelevant outcomes, or were not RCTs. We retrieved a total of 72 relevant publications for further assessment. Of these, 14 were ongoing trials, one trial was awaiting classification, and 16 were excluded with reasons. We reran the search in May 2017 and identified 513 citations (503 by searching databases and 10 by searching clinical trials). Upon reading titles/excluding duplicates, we found 11 studies of interest; of these, two are awaiting classification, six are ongoing, and three were excluded with explanation. In total, 41 RCTs (N = 4206) met our inclusion criteria. Of these, 31 trials (N = 2559) were eligible for meta‐analyses, 20 are ongoing, and three are awaiting classification. We have provided search results in a flow chart in <a href="#CD012763-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD012763-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012763-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012763-sec-0063"> <h4 class="title">Included studies</h4> <p>We included 41 trials (4206 participants) in our review.</p> <section id="CD012763-sec-0064"> <h5 class="title">Publication type</h5> <p>Of the 41 included trials, 29 (71%) were published as full‐text papers (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>). Twelve (29%) of the 41 trials were available only as meeting abstracts (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>). All of the included trials were published in English, with the exception of one article that was published in Turkish (<a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>). We contacted all 41 trial authors for missing information; 12 (29%) replied and provided supplementary data. </p> </section> <section id="CD012763-sec-0065"> <h5 class="title">Participants and settings</h5> <p>We reported full details of participants and settings in the <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a> section. </p> <p>Of the 41 included studies, 30 were single‐centre studies conducted in 15 countries: Turkey (seven studies: <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>, <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>, <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>, <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>, <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>, <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>, <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), Croatia (five studies: <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>, <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>, <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>, <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>, <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>), Greece (three studies: <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>, <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>, <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>), Germany (two studies: <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>, <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>), Israel (two studies: <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>, <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>), Italy (two studies: <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>, <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>) and one study each in Egypt (<a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>), Hungary (<a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>), Netherlands (<a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>), Czech Republic (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>), Portugal (<a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>), Poland (<a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>), Romania (<a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>), Korea (<a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>), and USA (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>). Eleven were multiple‐centre studies: 22 European centres in <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>, 13 European centres in <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a> and <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>, 10 European centres in <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>, nine US centres in <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a> and <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>, eight European centres in <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>, seven Korean centres in <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>, six Chinese plus four European centres in <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>, two Finnish centres in <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>, and an unspecified number of US centres in <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>. </p> <p>The sample size of included trials ranged from 22 to 1198 adults (aged &gt; 18 years) with ASA status I to IV. Among studies reporting ASA status, the distribution of participants across groups was as follows: ASA I: 1003 participants (32%); ASA II: 1772 participants (56%); ASA III: 331 participants (11%); and ASA IV: 31 participants (1%). </p> <p>Five trials included only morbidly obese (MOB) participants (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>), and one trial focused on super‐obese (SO) patients (<a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>). One trial included participants classified as New York Heart Association (NYHA) II to III (<a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>), and one trial investigated participants with myasthenia gravis (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>). </p> <p>Participants underwent diverse elective surgical procedures under general anaesthesia: extreme lateral interbody fusion (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>); trans‐sternal thymectomy (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>); laparoscopic or open abdominal surgery (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>); laparoscopic removal of adjustable gastric banding (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>); laparoscopic bariatric surgery (<a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>); laparoscopic sleeve gastrectomy (<a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>); elective bariatric surgery (<a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>); laparoscopic cholecystectomy or appendectomy (<a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>); laparoscopic cholecystectomy (<a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>); open bariatric surgery (<a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>); arthroscopic surgery (<a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>); non‐cardiac surgery (<a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>); interventional bronchoscopy (<a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>); extremity surgery (<a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>); thyroidectomy (<a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>); thyroidectomy or breast cancer surgery (<a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>); laparoscopic prostatectomy or nephrectomy (<a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>); endoscopic sinus surgery with or without septoplasty (<a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>); hip or knee joint replacement or hip fracture surgery (<a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>); open abdominal and urogenital surgery (<a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>); and septoplasty (<a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>). </p> <p>Four studies combined participants who underwent diverse elective surgical procedures (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>). Twelve studies provided no data on the type of elective surgical procedure performed (<a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>). </p> <p>Investigators maintained anaesthesia with opioid most often in combination with volatile anaesthetics, specifically with sevoflurane in 15 trials (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>); desflurane in six trials (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>); isoflurane in one trial (<a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>); and sevoflurane or desflurane in one trial (<a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>)<i>.</i> Twelve trials used propofol for maintenance (<a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>); and two trials used any anaesthetic, according to usual practice (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>)<i>.</i> Four trials provided no information on anaesthesia maintenance (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>). </p> <p>Most trials used rocuronium as a non‐depolarizing neuromuscular blocking‐agent (NMBA). However, <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a> used vecuronium; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a> used rocuronium or vecuronium, according to usual practice at the site; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a> compared sugammadex following rocuronium versus neostigmine following cisatracurium; and <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> compared atracurium for induction and mivacurium for maintenance versus rocuronium for both induction and maintenance. Two studies provided no information on the NMBA agent used (<a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>). </p> </section> <section id="CD012763-sec-0066"> <h5 class="title">Interventions</h5> <p>We summarized the interventions reported in included studies under <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>. </p> <p>All studies compared sugammadex and neostigmine, but investigators administered these drugs in different doses: <a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a> and <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a> compared sugammadex 2 mg/kg versus neostigmine 0.04 mg/kg; and 15 trials compared sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>, <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>, <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>, <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>, <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>). Two trials compared sugammadex 2 mg/kg versus neostigmine 0.07 mg/kg (<a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>). </p> <p>Three studies compared sugammadex 2 mg/kg versus neostigmine 2.5 mg (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>). <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a> compared sugammadex 3 mg/kg versus neostigmine 0.03 mg/kg, <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a> compared sugammadex 4 mg/kg versus neostigmine 0.04 mg/kg. Four trials compared sugammadex 4 mg/kg versus neostigmine 0.05 mg/kg (<a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>). Three trials compared sugammadex 4 mg/kg versus neostigmine 0.07 mg/kg (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>). <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a> compared sugammadex 4 mg/kg versus usual care (neostigmine with glycopyrrolate or atropine, no dose specified, or placebo/spontaneous recovery). <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> compared sugammadex 4 mg/kg versus neostigmine 1 to 2 mg, and <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a> did not specify dose for sugammadex or neostigmine. Four trials compared several different doses of sugammadex versus several different doses of neostigmine (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>). <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a> compared sugammadex 2 mg/kg ideal body weight versus sugammadex 2 mg/kg corrected body weight versus neostigmine 50 µg/kg ideal body weight versus neostigmine 50 µg/kg corrected body weight, <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> compared sugammadex 4 mg/kg total body weight versus neostigmine 70 μg/kg lean body weight, and <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a> compared sugammadex 2 mg/kg corrected body weight versus neostigmine 50 µg/kg corrected body weight. </p> </section> <section id="CD012763-sec-0067"> <h5 class="title">Outcomes</h5> <p>Of the 41 RCTs that met our inclusion criteria, 12 trials (n = 949) were eligible for meta‐analysis of the primary outcome (recovery time &gt; TOFR 0.9) (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). </p> <p>Of the 41 trials, 28 (N = 2298) were eligible for meta‐analysis of secondary outcomes (adverse events and serious adverse events): <a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>). </p> <p>Ten RCTs (N = 1647) were ineligible for meta‐analysis (<a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>) for the reasons provided in <a href="#CD012763-tbl-0004">Table 1</a> (table of studies ineligible for meta‐analysis). </p> <div class="table" id="CD012763-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies ineligible for meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for ineligibility</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary endpoint: acute effects of sugammadex and neostigmine on renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 4 mg /kg at reappearance of PTC 1 to 2 or T2 vs neostigmine 40 µg/kg + atropine 10 µg/kg at reappearance of T2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We believe that the use of more specific and sensitive new‐generation markers such as Cystatin C to evaluate kidney function will provide better understanding and interpretation of our results. Sugammadex has more tolerable effects on kidney function than does neostigmine. However, when compared with preoperative values, negative alteration of postoperative values can be seen. Neostigmine and sugammadex do not cause renal failure but may affect kidney function </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOFR recovery data available only as mean, no data on standard deviation, study author has not replied </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 50 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of cough reflexes was faster and respiration more efficient in patients receiving sugammadex. Safe extubation was determined by age, TOFR recovery, and effects of other anaesthetics </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOFR recovery data available only as mean, no data on standard deviation, study author has not replied </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 50 µg/kg + atropine 25 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An increase in BIS Index registered after reversal of rocuronium effects was faster during the recovery period in patients who were given sugammadex as compared with neostigmine. Although rapid increase in BIS Indices was registered in sugammadex group, more sensitive measurements are needed to confirm clinical value of this observation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary endpoint: influence of depth of the NMB on SRS (surgical rating score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neostigmine 1 to 2 mg + atropine 0.5 to 1 mg (for reversal of moderate NMB) vs sugammadex 4 mg/kg (for reversal of deep NMB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Application of 5‐point SRS showed that deep NMB results in improved quality of surgical conditions compared with moderate block in retroperitoneal laparoscopy, without compromise to patients’ perioperative and postoperative cardiorespiratory conditions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison: sugammadex 4 mg/kg vs usual care (neostigmine with glycopyrrolate or atropine, or placebo/spontaneous recovery). Study author has not replied with separate data on neostigmine with glycopyrrolate or atropine or placebo/spontaneous recovery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 4 mg/kg vs usual care</p> <p>(neostigmine with glycopyrrolate or atropine, or placebo/spontaneous recovery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex produced limited, transient (&lt; 1 hour) increases in activated partial thromboplastin time and prothrombin time but was not associated with increased risk of bleeding vs usual care </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No useable data available for quantitative meta‐analysis on recovery time or risk of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 50 µg/kg + atropine 10 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex facilitates reversal of neuromuscular blockade after bariatric surgery, depending on the depth of neuromuscular blockade induced </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome: cognitive function assessed by change in Mini‐Mental State Evaluation test (MMSE), Clock Drawing Test, and Isaacs Set Test, performed preoperatively, 1 hour postoperatively, and at discharge (1 to 15 days postoperatively) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex vs neostigmine/atropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference was observed regarding cognitive function after neostigmine/atropine combination or sugammadex was received for reversal of rocuronium‐induced neuromuscular blockade for elective surgery </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome: postoperative complications, data not available in useful format</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 2.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of sugammadex (compared with neostigmine) as reversal<br/> agent following laparoscopic sleeve gastrectomy; surgery was associated with higher postoperative oxygen saturation despite lower TOF count before administration of reversal agent.<br/> Lack of differences in other measured variables may stem from the small size of patient groups studied </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome: gastric emptying evaluated by paracetamol absorption test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 40 µg/kg + atropine group 15 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Although study results show a tendency toward faster gastric emptying in sugammadex group, this difference is not significant in most, possibly owing to small sample size in this study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aim: to evaluate effects of sugammadex on postoperative nausea‐vomiting, pain, coagulation parameters, and quantity of postoperative bleeding. Data not available in useful format </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neostigmine 0.05 mg/kg + atropine 0.02 mg/kg vs sugammadex 2 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex was associated with greater postoperative bleeding than neostigmine in septoplasty patients. For surgical procedures with high risk of bleeding, the safety of sugammadex needs to be verified </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Acronyms:</p> <p>BIS ‐ Bispectral Index</p> <p>MMSE ‐ Mini‐Mental State Examination</p> <p>NMB ‐ neuromuscular blockade</p> <p>T2 ‐ second twitch in train‐of‐four stimulation</p> <p>TOFR ‐ train‐of‐four ratio</p> <p>PTC ‐ post‐tetanic count</p> <p>SRS ‐ surgical rating score</p> </div> </div> <p>See <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a> for further information on the included studies. </p> </section> </section> <section id="CD012763-sec-0068"> <h4 class="title">Excluded studies</h4> <p>Among 83 identified relevant trials, we excluded 19 publications (<a href="./references#CD012763-bbs2-0042" title="AhoAj , KamataK , Yli‐HankalaA , LyytikäinenL‐P , KulkasA , JänttiV . Elevated BIS and entropy values after sugammadex or neostigmine: an electroencephalographicor electromyographic phenomenon?. Acta Anaesthesiologica Scandinavica2012;56(4):465‐73. [PUBMED: 22289106] ">Aho 2012</a>; <a href="./references#CD012763-bbs2-0043" title="BaysalA , DogukanM , TomanH , SagirogluG , KocakT . The use of sugammadex for reversal of residual blockade after administration of neostigmine and atropine. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2013; Vol. 30:142. ">Baysal 2013</a>; <a href="./references#CD012763-bbs2-0044" title="DahabaAA , BornemannH , HopfgartnerE , OhranM , KocherK , LiebmannM , et al. Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia. British Journal of Anaesthesia2012;108(4):602‐6. [PUBMED: 22315331] ">Dahaba 2012</a>; <a href="./references#CD012763-bbs2-0045" title="GaonaD , CarcelesMD , VeigaG , TedescoM , MottaP . Efficacy and safety of the reversal with sugammadex in deep neuromuscular blockade induced by rocuronium in pediatrics. 15th WFSA World Congress of Anaesthesiologists Predio Ferial de Buenos Aires Argentina. Oxford University Press, 2012; Vol. 108:308‐9. ">Gaona 2012</a>; <a href="./references#CD012763-bbs2-0046" title="GhoneimAA , ElBeltagyMA . Comparative study between sugammadex and neostigmine in neurosurgical anesthesia in pediatric patients. Saudi Journal of Anaesthesia2015;9(3):247‐52. [PUBMED: 26240540] ">Ghoneim 2015</a>; <a href="./references#CD012763-bbs2-0047" title="HarazimH , StouracP , SeidlovaD , AdamusM , KrikavaI , PavlikT . Use of rocuronium and active reversal of neuromuscular blockade with sugammadex in anaesthesia for caesarean section led to reduction of myalgia incidence in early postoperative period: prospective randomised interventional multicentric trial. European Journal of Anaesthesiology. 2014; Vol. 31:194‐5. ">Harazim 2014</a>; <a href="./references#CD012763-bbs2-0048" title="KakinumaA , NagataniH , YasudaA , YoshimuraT , SawaiJ , NakataY . Combined use of sugammadex and neostigmine for the reversal of rocuronium‐induced profound neuromuscular blockade. Anesthesia and Clinical Research Journal2013;4(7):337. [DOI: 10.4172/2155‐6148.1000337] ">Kakinuma 2013</a>; <a href="./references#CD012763-bbs2-0049" title="KaraT , OzbagriacikO , TurkHS , IsilCT , GokucO , UnsalO , et al. Sugammadex versus neostigmine in pediatric patients: a prospective randomized study. Revista Brasileira de Anestesiologia2014;64(6):400‐5. [PUBMED: 25437696] ">Kara 2014</a>; <a href="./references#CD012763-bbs2-0050" title="KzlayD , DalD , SaraçoğluT , EtiZ , GöğüşY . The effects of sugammadex and neostigmine‐atropine administration on hemodynamic parameters in cardiac patients undergoing non‐cardiac surgery. European Journal of Anaesthesiology. 2013; Vol. 30:75. ">Kzlay 2013</a>; <a href="./references#CD012763-bbs2-0052" title="NagyHIA , ElkadiHW . Can sugammadex improve the reversal profile of atracurium under sevoflurane anesthesia?. Egyptian Journal of Anaesthesia2014;30(1):95‐9. [DOI: 10.1016/j.egja.2013.09.007] ">Nagy 2014</a>; <a href="./references#CD012763-bbs2-0055" title="OzgünC , CakanT , BaltacıB , BaşarH . Comparison of reversal and adverse effects of sugammadex and combination of anticholinergic‐anticholinesterase agents in pediatric patients. Journal of Research in Medical Sciences2014;19(8):762‐8. [PUBMED: 25422663] ">Ozgun 2014</a>; <a href="./references#CD012763-bbs2-0056" title="PecekB , HollanJ , PrimanT , Tokic CrnicN , StankovicV , PolhD . New way of dosing sugammadex for termination of vecuronium induced neuromuscular block. Zdravniski Vestnik2015;84:439–46. ">Pecek 2013</a>; <a href="./references#CD012763-bbs2-0057" title="SacanO , WhitePF , TufanogullariB , KleinK . Sugammadex reversal of rocuronium‐induced neuromuscular blockade: a comparison with neostigmine‐glycopyrrolate and edrophonium‐atropine. Anesthesia and Analgesia2007;104(3):569‐74. [PUBMED: 17312210 ] ">Sacan 2007</a>; <a href="./references#CD012763-bbs2-0058" title="SchepensT , CammuG , SaldienV , DeNeveN , JorensPG , FoubertL , et al. Electromyographic activity of the diaphragm during neostigmine or sugammadex‐enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers. European Journal of Anaesthesiology2015;32(1):49‐57. [PUBMED: 25111539] ">Schepens 2015</a>; <a href="./references#CD012763-bbs2-0059" title="StouracP , AdamusM , SeidlovaD , PavlikT , JankuP , KrikavaI , et al. Low‐dose or high‐dose rocuronium reversed with neostigmine or sugammadex for cesarean delivery anesthesia: a randomized controlled noninferiority trial of time to tracheal intubation and extubation. Anesthesia and Analgesia2016;122(5):1536‐45. [DOI: 10.1213/ANE.0000000000001197; PUBMED: 26974018] ">Stourac 2016</a>; <a href="./references#CD012763-bbs2-0060" title="Veiga RuizG , Carceles BaronMD , Dominguez SerranoN , Lopez FuentesL , Orozco MontesJ , Alvarez‐GomezJA . Sugammadex reversal efficacy and security vs neostigmine in the rocuronium‐induced neuromuscular blockade in paediatric patients. European Journal of Anaesthesiology. Abstracts and Programme: EUROANAESTHESIA 2011: The European Anaesthesiology Congress: Paediatric Anaesthesia and Intensive Care, 2011; Vol. 28:153. ">Veiga Ruiz 2011</a>; <a href="./references#CD012763-bbs2-0051" title="NagashimaS , TakasusukiT , YamaguchiS , HamaguchiS . Effects of neostigmine and sugammadex on QT interval and QT dispersion. Dokkyo Journal of Medical Sciences2016;43:15‐22. ">Nagashima 2016</a>; <a href="./references#CD012763-bbs2-0054" title="NemesR , FülesdiB , PongráczA , AsztalosL , Szabó‐MaákZ , LengyelS , et al. Impact of reversal strategies on the incidence of postoperative residual paralysis after rocuronium relaxation without neuromuscular monitoring: a partially randomised placebo controlled trial. European Journal of Anaesthesiology2016;1:1. [PUBMED: 28030444] ">Nemes 2016</a>; <a href="./references#CD012763-bbs2-0053" title="NCT03111121 . Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy. https://clinicaltrials.gov/show/NCT03111121, March 23, 2017. ">NCT03111121</a>). </p> <p>We have explained reasons for exclusion of each trial in the <a href="./references#CD012763-sec-0158" title="">Characteristics of excluded studies</a> table. </p> <section id="CD012763-sec-0069"> <h5 class="title">Ongoing studies</h5> <p>We identified 20 ongoing and unpublished trials by searching <a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>, <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>, and <a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a>. The following five trials have been completed but to the best of our knowledge, no data from these trials have yet been published: <a href="./references#CD012763-bbs2-0064" title="NCT01539044 . Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal (ProjectO5Rs). https://clinicaltrials.gov/show/NCT01539044, February 15, 2012. ">NCT01539044</a>; <a href="./references#CD012763-bbs2-0065" title="NCT01748643 . CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity (CURES). https://clinicaltrials.gov/show/NCT01748643, December 6, 2012. ">NCT01748643</a>; <a href="./references#CD012763-bbs2-0066" title="NCT02160223 . Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea. https://clinicaltrials.gov/show/NCT02160223, June 8, 2014. ">NCT02160223</a>; <a href="./references#CD012763-bbs2-0068" title="NCT02330172 . Sugammadex Provide Better Surgical Condition Compared With Neostigmine in Laryngeal Microsurgery. https://clinicaltrials.gov/show/NCT02330172, December 9, 2014. ">NCT02330172</a>; <a href="./references#CD012763-bbs2-0070" title="NCT02414880 . Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection. https://clinicaltrials.gov/show/NCT02414880, April 5, 2015. ">NCT02414880</a>). Six trials are currently recruiting participants (<a href="./references#CD012763-bbs2-0067" title="NCT02256280 . A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia (DATA). https://clinicaltrials.gov/show/NCT02256280, September 24, 2014. ">NCT02256280</a>; <a href="./references#CD012763-bbs2-0069" title="NCT02361060 . Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery. https://clinicaltrials.gov/show/NCT02361060, December 23, 2014. ">NCT02361060</a>; <a href="./references#CD012763-bbs2-0071" title="NCT02454504 . Quality of Awakening and Impact on Cognitive Function After Administration of Sugammadex in Robotic Radical Cystectomy. https://clinicaltrials.gov/show/NCT02454504, May 6, 2015. ">NCT02454504</a>; <a href="./references#CD012763-bbs2-0073" title="NCT02666014 . Sugammadex Versus Neostigmine for Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery. https://clinicaltrials.gov/show/NCT02666014, February 2, 2015. ">NCT02666014</a>; <a href="./references#CD012763-bbs2-0075" title="NCT02698969 . Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography. https://clinicaltrials.gov/show/NCT02698969, February 15, 2016. ">NCT02698969</a>; <a href="./references#CD012763-bbs2-0077" title="NCT02860507 . Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency. https://clinicaltrials.gov/show/NCT02860507, August 2, 2016. ">NCT02860507</a>). Six trials are classified as ongoing (<a href="./references#CD012763-bbs2-0079" title="NCT02909439 . Quality of Recovery After Reversal With Neostigmine or Sugammadex. https://clinicaltrials.gov/show/NCT02909439, August 31, 2016. ">NCT02909439</a>; <a href="./references#CD012763-bbs2-0074" title="NCT02697929 . Sugammadex/Neostigmine and Liver Transplantation. https://clinicaltrials.gov/show/NCT02697929, February 13, 2016. ">NCT02697929</a>; <a href="./references#CD012763-bbs2-0081" title="NCT03108989 . Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia ‐ Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT03108989, April 6, 2017. ">NCT03108989</a>; <a href="./references#CD012763-bbs2-0082" title="NCT03116997 . Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant. https://clinicaltrials.gov/show/NCT03116997, April 12, 2017. ">NCT03116997</a>; <a href="./references#CD012763-bbs2-0080" title="NCT02939430 . Sugammadex Reversal of Neuromuscular Blockade and Postoperative Bleeding (Suga_bleeding). https://clinicaltrials.gov/show/NCT02939430, October 17, 2016. ">NCT02939430</a>; <a href="./references#CD012763-bbs2-0083" title="NCT03144453 . Recovery From Anesthesia After Robotic Assisted Radical Cystectomy. https://clinicaltrials.gov/show/NCT03144453, May 3, 2017. ">NCT03144453</a>) and three trials are not yet open for recruiting participants (<a href="./references#CD012763-bbs2-0072" title="NCT02648503 . Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patients Undergoing Elective Laparoscopic Cholecystectomy. https://clinicaltrials.gov/show/NCT02648503, December 7, 2015. ">NCT02648503</a>; <a href="./references#CD012763-bbs2-0076" title="NCT02845375 . Effect of Neuromuscular Blockade and Reversal on Breathing (BREATH). https://clinicaltrials.gov/show/NCT02845375, July 14, 2016. ">NCT02845375</a>; <a href="./references#CD012763-bbs2-0078" title="NCT02861131 . The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications. https://clinicaltrials.gov/show/NCT02861131, July 14, 2016. ">NCT02861131</a>). </p> <p>See <a href="./references#CD012763-sec-0160" title="">Characteristics of ongoing studies</a> for details. </p> </section> <section id="CD012763-sec-0070"> <h5 class="title">Studies awaiting classification</h5> <p>We reran the search in May 2017 and found three trials (<a href="./references#CD012763-bbs2-0062" title="NCT02243943 . Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile (Neuropa). https://clinicaltrials.gov/show/NCT02243943, September 12, 2014. ">NCT02243943</a>; <a href="./references#CD012763-bbs2-0061" title="KimK , OhY , KimT , OhS , SinY . Relationship between first‐twitch depression and train‐of‐four ratio during sugammadex reversal of rocuronium‐induced neuromuscular blockade. Korean Journal of Anesthesiology2016;1:1. [PUBMED: 27274368] ">Kim 2016</a>; <a href="./references#CD012763-bbs2-0063" title="SenA , ErdivanliB , TomakY , PergelA . Reversal of neuromuscular blockade with sugammadex or neostigmine/atropine: effect on postoperative gastrointestinal motility. Journal of Clinical Anesthesia2016;1:1. [PUBMED: 27290978] ">Sen 2016</a>) that published data after we had completed our main search in May 2016; we will include these trials in the next updated version of this review. </p> </section> </section> </section> <section id="CD012763-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of included studies using the 'Risk of bias' tool developed by Cochrane. The first review author (AMH) and the second review author (PD) independently assessed risk of bias for each study and resolved disagreements by discussion or by consultation with the last review author (AA). We have presented the various bias domains in <a href="./full#CD012763-fig-0002">Figure 2</a> ‐ Risk of bias graph ‐ and <a href="#CD012763-fig-0006">Figure 6</a> ‐ Risk of bias summary </p> <div class="figure" id="CD012763-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012763-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012763-sec-0072"> <h4 class="title">Allocation</h4> <section id="CD012763-sec-0073"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>Twenty‐seven trials (66%) reported adequate generation of random sequence that was computer‐based (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>); or was performed by using a central randomization system (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). </p> <p>Furthermore, one trial (2%) reported randomization by lots (<a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>). Thirteen trials (32%) did not report sufficient information for assessment of risk of bias(<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>)<i>.</i> </p> </section> <section id="CD012763-sec-0074"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>Eighteen trials (44%) reported adequate allocation concealment performed by using sequentially numbered opaque sealed envelopes (SNORES) (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>); or secondary to a central randomization system (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>)<i>.</i> </p> <p>One trial (2%) reported using no allocation concealment (<a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>). Twenty‐two trials (54%) did not describe their method of allocation concealment (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>)<i>.</i> </p> </section> </section> <section id="CD012763-sec-0075"> <h4 class="title">Blinding</h4> <section id="CD012763-sec-0076"> <h5 class="title">Blinding of participants (performance bias)</h5> <p>Fourteen trials (34%) adequately blinded participants and therefore had low risk of performance bias (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>)<i>.</i> </p> <p>Eight trials (20%) did not adequately blind participants and therefore had high risk of performance bias; two of these specifically reported that participants were not blinded (<a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), and six were marked as “open‐label” trials (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>). </p> <p>The remaining 19 trials (46%) did not provide sufficient data on participant blinding and we assigned risk of performance bias as unclear(<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>). </p> </section> <section id="CD012763-sec-0077"> <h5 class="title">Blinding of personnel (performance bias)</h5> <p>Seven trials (17%) reported adequate blinding of the anaesthesiologist and therefore had low risk of performance bias (<a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>)<i>.</i> </p> <p>Seventeen trials (41%) did not report adequate blinding of anaesthesiologists and therefore had high risk of performance bias; 11 of these specifically reported that the anaesthesiologist was not blinded: (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), and six trials were marked as “open‐label” trials (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>)<i>.</i> </p> <p>The remaining 17 trials (41%) did not provide sufficient data on anaesthesiologist blinding and therefore had unclear risk of performance bias (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>). </p> </section> <section id="CD012763-sec-0078"> <h5 class="title">Blinding of TOF‐watch assessment (detection bias)</h5> <p>Two trials (5%) specifically reported that the anaesthesiologist was also the TOF‐watch assessor: (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>)<i>.</i> Four trials (10%) reported adequate blinding of the TOF‐watch assessor and therefore had low risk of performance bias (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>). </p> <p>Twelve trials (29%) did not provide adequate blinding of the TOF‐watch assessor and therefore had high risk of detection bias; six of these trials specifically reported that the anaesthesiologist was not blinded (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), and six trials were marked as “open‐label” trials (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>)<i>.</i> </p> <p>For two trials (5%), risk of bias assessment was of no relevance, as trial authors presented no TOF‐watch data (<a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>)<i>.</i> </p> <p>The remaining 23 trials (56%) did not provide sufficient data on TOF‐watch assessor blinding and had unclear risk of detection bias (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>). </p> </section> <section id="CD012763-sec-0079"> <h5 class="title">Blinding of safety assessment (detection bias)</h5> <p>Twenty trials (49%) reported adequate blinding of the safety assessor and therefore had low risk of detection bias (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>)<i>.</i> </p> <p>Two trials (5%) did not adequately blind the safety assessor and therefore had high risk of detection bias; one of these specifically reported that the safety assessor was not blinded (<a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>), and the other trial was marked as an “open‐label” study (<a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>)<i>.</i> </p> <p>The remaining 19 trials (46%) did not provide sufficient data on safety assessor blinding and had unclear risk of detection bias (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>)<i>.</i> </p> </section> </section> <section id="CD012763-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>The following 28 trials (68%) had low risk of attrition bias as either all participants were accounted for, or missing outcome data were properly balanced among groups: <a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>. </p> <p>For three trials (7%), missing outcome data were not balanced across intervention groups (<a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>); these studies therefore had high risk of attrition bias. </p> <p>The remaining 10 trials (24%) did not provide sufficient data on incomplete outcomes and had unclear risk of attrition bias (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>)<i>.</i> </p> </section> <section id="CD012763-sec-0081"> <h4 class="title">Selective reporting</h4> <p>Twenty trials (49%) had low risk of reporting bias, as they were registered online: 16 on clinicaltrials.gov (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a> – NCT00451217; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a> – NCT01479764; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a> ‐ NTC00451100; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a> – NCT00724932; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a> ‐ NCT01629394; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a> ‐ NCT00473694; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a> – NCT00451217; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a> – NCT00473694; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> – NCT 01631149; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a> – NCT01422304; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a> – NCT01631396; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a> – NCT02419352; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a> – NCT00895609; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a> – NCT01050543; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a> – NCT00825812; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a> – NCT02215382); one on SYNABA – The Polish Clinical Trials authorization (<a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a> – 252922); one on ANZCTR ‐ Australian New Zealand Clinical Trials Registry (<a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a> ‐ ACTRN12614000651684); and finally two on Eudra‐CT (<a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a> ‐ 2009‐013537‐22; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a> ‐ 2011‐001683‐22). </p> <p>The remaining 20 trials (49%) were not registered online, but it is clear that the published article or meeting abstract includes all expected outcomes (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>). Therefore, these trials had low risk of reporting bias. </p> <p>One trial (2%) did not provide sufficient information for assessment of risk of bias and had unclear risk of reporting bias (<a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>). </p> </section> <section id="CD012763-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <section id="CD012763-sec-0083"> <h5 class="title">Funding bias</h5> <p>Merck, Sharp and Dohme or Schering‐Plough provided financial support for 11 trials (27%), indicating high risk of funding bias (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>)<i>.</i> Authors of the following trials were former employees, current employees, or members of advisory boards of Merck, Sharp and Dohme/Schering‐Plough, or had received honoraria for lectures, consultancy, or advisory board membership, or travel grants from Merck, Sharp and Dohme/Schering‐Plough: <a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a><i>,</i><a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). These studies had high risk of funding bias. </p> <p>We could not assess funding risk of bias for the following 14 trials (34%) owing to insufficient information: <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; these studies had unclear risk of funding bias. </p> <p>Eight trials (20%) had low risk of funding bias, as they were funded by departmental sources (<a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>). Trial authors funded two trials (5%) (<a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), and in two cases (5%), study authors received research grants (<a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; Polish Government grant; and <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; Inje University research grant). </p> </section> <section id="CD012763-sec-0084"> <h5 class="title">Other bias</h5> <p>Twenty‐one trials (51%) had low risk of other bias, as they reported specific information on sample size calculation (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>)<i>.</i> </p> <p>Of these 21 trials, 12 (29%) were powered to address this review’s primary outcome (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>), and seven trials (17%) were powered to address this review’s secondary outcome (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>)<i>.</i> Twenty trials (49%) did not provide information on sample size calculation (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a>; <a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>; <a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a>; <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>). </p> <p>Treatment groups were generally comparable with respect to baseline characteristics, except <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>, which described significant differences in body weight between groups that might have influenced the dosage of administered drugs; and <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>, which reported a higher proportion of women, higher mean age, and a higher percentage of ASA II to III participants in the sugammadex group. Furthemore, <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a> discontinued one intervention group owing to a marked difference in efficacy between groups after interim analysis. Therefore, these trials had high risk of other bias. </p> <p>All trials used the same method (acceleromyography) and at the same monitor site (ulnar nerve, adductor pollicis muscle). We analysed quality variables of neuromuscular recording methods among full‐text trials have provided a summary in <a href="#CD012763-tbl-0005">Table 2</a> ‐ Quality variables of neuromuscular monitoring methods among included trials. </p> <div class="table" id="CD012763-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality variables of neuromuscular monitoring methods among included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Method of recording</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Monitor site</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm fixation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Supramaximal stimulation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Temperature maintained and recorded</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Initial signal stabilization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Twich height calibration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preload used</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No *</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Studies with only abstracts were not included in this table because they did not document information regarding neuromuscular monitoring </p> <p>List of abbreviations:</p> <p>N. ulnaris ‐ ulnar nerve</p> <p>M. adductor pollicis ‐ adductor pollicis muscle</p> </div> </div> </section> </section> </section> <section id="CD012763-sec-0085"> <h3 class="title" id="CD012763-sec-0085">Effects of interventions</h3> <p>See: <a href="./full#CD012763-tbl-0001"><b>Summary of findings for the main comparison</b> Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</a>; <a href="./full#CD012763-tbl-0002"><b>Summary of findings 2</b> Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</a>; <a href="./full#CD012763-tbl-0003"><b>Summary of findings 3</b> Sugammadex (any dose) vs neostigmine (any dose)</a> </p> <p>See <a href="./full#CD012763-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012763-tbl-0002">summary of findings Table 2</a>; and <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD012763-sec-0086"> <h4 class="title">Comparison 1. Sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg for rocuronium reversal</h4> <section id="CD012763-sec-0087"> <h5 class="title">1.1 Primary outcome 1: recovery time from T2 to TOFR &gt; 0.9</h5> <p>Ten trials were included in this category (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). </p> <p>All trials used rocuronium for intubation and maintenance. The intubating dose of rocuronium was 0.6 mg/kg in five trials (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>), 0.6 to 1 mg/kg in <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>, and 1 mg/kg in <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a><i>.</i> The maintenance dose of rocuronium was 0.1 to 0.2 mg/kg in four trials (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>), 0.06 mg/kg corrected body weight (CBW) with maximum two additional doses in <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>, and 5 to 10 mg in two trials (<a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>)<i>.</i> No information on rocuronium dosage was available for three trials (<a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>). </p> <p>Meta‐analysis of results showed that sugammadex 2 mg/kg reversed neuromuscular blockade from T2 to TOFR &gt; 0.9 in 1.96 minutes, and neostigmine 0.05 mg/kg reversed neuromuscular blockade from T2 to TOFR &gt; 0.9 in 12.87 minutes. Therefore, sugammadex 2 mg/kg was on average 10.22 minutes (6.6 times) faster than neostigmine 0.05 mg/kg in reversing neuromuscular blockade at T2 reappearance (MD 10.22 minutes, 95% CI 8.48 to 11.96; I<sup>2</sup> = 84%; 10 studies; n = 835; random‐effects model; <a href="./references#CD012763-fig-0007" title="">Analysis 1.1</a>; GRADE quality of evidence: moderate; <a href="./full#CD012763-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the GRADE quality of evidence by one owing to high risk of bias. </p> <p>The following trials used NMBAs other than rocuronium and therefore were not included in the meta‐analysis. </p> <p><a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a> compared rocuronium‐sugammadex 2 mg/kg versus cisatracurium‐neostigmine 0.05 mg/kg and found that reversal with sugammadex was 4.7 times faster than with neostigmine (geometric mean recovery time of 1.9 vs 9.0; P &lt; 0.0001). </p> <p><a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a> investigated the effect of sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg in reversing vecuronium‐induced neuromuscular blockade (induction 0.1 mg/kg, maintenance 0.03 to 0.03 mg/kg) and described that the geometric mean time of recovery to TOFR &gt; 0.9 was significantly faster with sugammadex than with neostigmine (2.7 minutes, 95% CI 2.2 to 3‐3 vs 17.9, 95% CI 13.1 to 24.3, respectively; P &lt; 0.0001; n = 93). </p> <p>Other trials did not provide enough information or compared doses of sugammadex and neostigmine other than those previously mentioned and as such could not be included in the meta‐analysis: <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a> compared sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg and reported T2 to TOFR &gt; 0.9 recovery time of 2.5 minutes versus 8.5 minutes, respectively (P = 0.045, n = 38), but these data could not be included in the meta‐analysis, as standard deviation (SD) data were not reported in the paper and could not be obtained. <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a> examined recovery time from T2 to TOFR &gt; 0.9 comparing sugammadex 4 mg/kg (n = 20) versus neostigmine 0.05 mg/kg plus atropine 0.02 mg/kg (n = 20) and reported that mean reversal time (SD) was 2.47 (0.51) versus 24.21 (4.7) minutes, respectively. </p> <section id="CD012763-sec-0088"> <h6 class="title">Subgroup analysis</h6> <section id="CD012763-sec-0089"> <p><b>1.2 TIVA versus volatile anaesthetics</b></p> <p>Seven trials maintained anaesthesia with volatile anaesthetic (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>), and three trials used TIVA for maintenance (<a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). Subgroup analysis of results showed no significant subgroup differences in recovery time to TOFR &gt; 0.9 (<a href="./references#CD012763-fig-0008" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD012763-sec-0090"> <h6 class="title">Sensitivity analysis</h6> <section id="CD012763-sec-0091"> <p><b>1.3. Excluding meeting abstracts</b></p> <p>Sensitivity analysis that excluded data from meeting abstracts (MD 9.27 minutes, 95% CI 7.40 to 11.14; I<sup>2</sup> = 82%; n = 767; random‐effects model; <a href="./references#CD012763-fig-0009" title="">Analysis 1.3</a>) did not change overall results regarding significance. </p> </section> </section> </section> <section id="CD012763-sec-0092"> <h5 class="title">Primary outcome 2: recovery time from PTC 1 to 5 to TOFR &gt; 0.9</h5> <p>This outcome is not clinically relevant as dosages of sugammadex 2 mg/kg and neostigmine 0.05 mg/kg are too low to reverse the deep rocuronium‐induced neuromuscular blockade seen at PTC 1 to 5. </p> </section> <section id="CD012763-sec-0093"> <h5 class="title">Secondary outcomes: risk of adverse events and risk of serious adverse events</h5> <p>We have described these outcomes in detail under Comparison 3 (<a href="./references#CD012763-fig-0012" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD012763-sec-0094"> <h4 class="title">Comparison 2. Sugammadex 4 mg/kg versus neostigmine 0.07 mg/kg for rocuronium reversal</h4> <section id="CD012763-sec-0095"> <h5 class="title">Primary outcome 1. Recovery time from T2 to TOFR &gt; 0.9</h5> <p>This outcome is not clinically relevant as dosages of sugammadex 4 mg/kg and neostigmine 0.07 mg/kg are too high to reverse the moderate rocuronium‐induced neuromuscular blockade seen at T2. </p> </section> <section id="CD012763-sec-0096"> <h5 class="title">2.1 Primary outcome 2: recovery time from PTC 1 to 5 to TOFR &gt; 0.9</h5> <p>We combined two trials in this category (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>). Both trials used rocuronium 0.6 mg/kg as a single intubating dose and rocuronium 0.15 mg/kg for maintenance. <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> combined neostigmine with atropine 0.01 mg/kg, and <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a> combined neostigmine with glycopyrrolate 0.014 mg/kg. <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> administered sugammadex or neostigmine at reappearance of PTC 1 to 5, and <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a> at reappearance of PTC 1 to 2. <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> included morbidly obese female participants. <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> maintained anaesthesia with desflurane, and <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a> with sevoflurane. </p> <p>Meta‐analysis of trial results showed that sugammadex 4 mg/kg reversed neuromuscular blockade from PTC 1 to 5 to TOFR &gt; 0.9 in 2.9 minutes, and neostigmine 0.07 mg/kg reversed neuromuscular blockade from PTC 1 to 5 to TOFR &gt; 0.9 in 48.8 minutes. Sugammadex 4 mg/kg was therefore on average 45.78 minutes (16.8 times) faster than neostigmine 0.07 mg/kg in reversing neuromuscular blockade at reappearance of PTC 1 to 5 (MD 45.78 minutes, 95% CI 39.41 to 52.15; I<sup>2</sup> = 0%; two studies; n = 114; random‐effects model; <a href="./references#CD012763-fig-0010" title="">Analysis 2.1</a>; GRADE quality of evidence: low; <a href="./full#CD012763-tbl-0002">summary of findings Table 2</a>). We downgraded GRADE quality of evidence two levels owing to high risk of bias and imprecision. </p> <p>The following trials used NMBAs other than rocuronium, gave a dose of neostigmine different from the one described above, or had missing SD values and were not included in the meta‐analysis. <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a> investigated the effect of sugammadex 4 mg/kg versus neostigmine 0.07 mg/kg in reversing vecuronium‐induced neuromuscular blockade (induction 0.1 mg/kg, maintenance 0.015 mg/kg) and described that the geometric mean time of recovery to TOFR &gt; 0.9 was 15‐fold faster with sugammadex than with neostigmine (4.5 vs 66.2 minutes, respectively; P &lt; 0.0001; n = 83). <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a> reported that participants receiving sugammadex 4 mg/kg administered at PTC 1 to 2 recovered 3.4 times faster than those given neostigmine 0.05 mg/kg plus atropine 0.01 mg/kg (geometric mean recovery time of 2.4 (2.1 to 2.7) vs 8.4 (7.2 to 9.8) minutes, respectively; P &lt; 0.0001). <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>, reported that median recovery time from PTC 1 to 2 to TOFR &gt; 0.9 after sugammadex 2 mg/kg was 1.1 minutes versus 10.13 minutes for neostigmine 0.07 mg/kg (P &lt; 0.001; n = 31; no SD value reported). </p> </section> <section id="CD012763-sec-0097"> <h5 class="title">Secondary outcomes: risk of adverse events and risk of serious adverse events</h5> <p>We have described these outcomes in detail under Comparison 3 (<a href="./references#CD012763-fig-0012" title="">Analysis 3.2</a>). </p> </section> <section id="CD012763-sec-0098"> <h5 class="title">Other recovery times</h5> <p>Some trials measured recovery times other than those described in the comparisons above. Only single trials measured these data; therefore, we could not include them in the meta‐analysis, but we can describe the qualitative data as follows. </p> <p><a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a> reported mean recovery time from TOFR of 50% to &gt; 90% as 9.7 minutes after administration of neostigmine 2.5 mg and 2.8 minutes after administration of sugammadex 4 mg/kg (P &lt; 0.05; n = 40). <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a> compared sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg administered at T4/T1 20% and found that extubation time (defined as time to TOFR &gt; 0.9) was seven minutes in the neostigmine group and two minutes in the sugammadex group (P &gt; 0.05; n = 36). <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> compared moderate NMB (T1 to 2) induced by atracurium/mivacurium reversed by neostigmine 1 to 2 mg plus atropine 0.5 to 1 mg (n = 12) versus deep NMB (PTC 1 to 2) induced by high‐dose rocuronium and reversed by sugammadex 4 mg/kg (n = 12). Recovery times to TOFR &gt; 0.9 expressed as mean (SD) were, respectively, 10.9 (4.9) versus 5.1 (2.4) (P &lt; 0.01). <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a> investigated adequate doses for reversal of reappearance of four twitches of TOF and discovered that sugammadex 1 mg/kg, unlike neostigmine, rapidly and effectively reverses rocuronium‐induced block that has recovered spontaneously to threshold TOF count four. Furthermore, sugammadex 0.5 mg/kg reverses a similar block within eight minutes. <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a> compared sugammadex 4.0 mg/kg versus neostigmine 0.05 mg/kg plus glycopyrrolate 0.01 mg/kg administered when the TOF‐blinded anaesthesiologist considered the patient ready for reversal of NMB. The anaesthesiologist could ask the TOF‐watch operator whether the patient had recovered to at least 1 to 2 PTC before administering the reversal agent. This trial demonstrated significantly faster recovery to TOFR &gt; 0.9 ratio within two minutes (95% CI 1.8 to 2.5) in the sugammadex group versus eight minutes (95% CI 3.8 to 16.5 minutes) in the neostigmine group. <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a> investigated the efficacy of sugammadex (0.0625, 0.125, 0.25, 0.5, or 1.0 mg/kg), neostigmine (5, 8, 15, 25, or 40 µg/kg), and saline, and by using a bi‐exponential model and regression analysis concluded that sugammadex 0.22 mg/kg and neostigmine 34 µg/kg effectively and comparably reverse a rocuronium‐induced shallow residual neuromuscular block at TOFR = 0.5 (n = 99). <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a> investigated several different doses of sugammadex or neostigmine as well as placebo administered at TOFR ≥ 0.2 and found that residual neuromuscular block of TOFR = 0.2 cannot be reversed reliably with neostigmine within 10 minutes. However, substantially lower doses of sugammadex than the approved dose of 2.0 mg/kg may be sufficient to reverse residual rocuronium‐induced neuromuscular block at recovery of TOFR ≥ 0.2. <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a> looked at the effects of sugammadex 2 mg/kg (n = 50) versus neostigmine 70 µg/kg + atropine 0.4 mg per 1 mg neostigmine administered when four twitches of TOF were visible with fade and found that sugammadex speeds recovery of neuromuscular strength but only slightly (P &gt; 0.01; n = 100). </p> </section> </section> <section id="CD012763-sec-0099"> <h4 class="title">Comparison 3. Sugammadex (any dose) versus neostigmine (any dose)</h4> <section id="CD012763-sec-0100"> <h5 class="title">Primary outcome 1: recovery time from T2 to TOFR &gt; 0.9</h5> <p>This outcome was not clinically relevant as doses for sugammadex and neostigmine used are specific to the depth of the neuromuscular blockade. </p> </section> <section id="CD012763-sec-0101"> <h5 class="title">Primary outcome 2: recovery time from PTC 1 to 5 to TOFR &gt; 0.9</h5> <p>This outcome was not clinically relevant as doses for sugammadex and neostigmine used are specific to the depth of the neuromuscular blockade. </p> </section> <section id="CD012763-sec-0102"> <h5 class="title">3.1. Secondary outcomes: risks of adverse events and serious adverse events</h5> <p>The following 28 trials investigated adverse events possibly, probably, or definitely related to study drug: <a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a><i>.</i> </p> <p>Meta‐analysis of trial results showed significantly fewer adverse events in the sugammadex group than in the neostigmine group (RR 0.60, 95% CI 0.49 to 0.74; I<sup>2</sup> = 40%; 28 studies, n = 2298; random‐effects model; <a href="./references#CD012763-fig-0011" title="">Analysis 3.1</a>; GRADE quality of data: moderate; <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>; quality of evidence downgraded one level owing to high risk of bias). Specifically, the risk of composite adverse events was 283/1000 in the neostigmine group and 159/1000 in the sugammadex group. With number needed to treat for an additional beneficial outcome (NNTB) of eight to avoid an adverse event, sugammadex appears to have a stronger safety profile than neostigmine. Furthermore, data show significantly fewer participants with one or more adverse events (RR 0.62, 95% CI 0.48 to 0.81; I<sup>2</sup> = 0%; n = 1766; random‐effects model; <a href="./references#CD012763-fig-0015" title="">Analysis 3.5</a>; GRADE quality of data: moderate; <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>) in the sugammadex group than in the neostigmine group. </p> <p>Data on specific adverse events show significantly less risk of the following adverse events in the sugammadex group than in the neostigmine group: bradycardia (RR 0.16, 95% CI 0.07 to 0.34; I<sup>2</sup> = 0%; n = 1218; random‐effects model; <a href="./references#CD012763-fig-0016" title="">Analysis 3.6</a>; NNTB 14; GRADE quality of data: moderate; <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>; downgraded one level owing to high risk of bias), PONV (RR 0.52, 95% CI 0.28 to 0.97; I<sup>2</sup> = 0%; n = 389; random‐effects model; <a href="./references#CD012763-fig-0017" title="">Analysis 3.7</a>; NNTB 16; GRADE quality of data: low; <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>; downgraded two levels owing to high risk of bias and imprecision), desaturation (RR 0.23, 95% CI 0.06 to 0.83; I<sup>2</sup> = 0%; n = 134; random‐effects model; <a href="./references#CD012763-fig-0018" title="">Analysis 3.8</a>), need for transitory oxygen supplementation (RR 0.24, 95% CI 0.09 to 0.66; I<sup>2</sup> = 0%; n = 76; random‐effects model; <a href="./references#CD012763-fig-0020" title="">Analysis 3.10</a>), and procedural complications (RR 0.12, 95% CI 0.02 to 0.97; n = 168; I<sup>2</sup> = 0%; random‐effects model; <a href="./references#CD012763-fig-0019" title="">Analysis 3.9</a>). Also, significantly fewer participants were unable to perform 5 seconds of sustained head‐lift at extubation (RR 0.34, 95% CI 0.15 to 0.78; I<sup>2</sup> = 0%; n = 395; random‐effects model; <a href="./references#CD012763-fig-0021" title="">Analysis 3.11</a>) in the sugammadex group than in the neostigmine group. </p> <p>Data show no significant differences between sugammadex and neostigmine with regard to nausea (RR 0.83, 95% CI 0.44 to 1.56; I<sup>2</sup> = 0%; n = 719; <a href="./references#CD012763-fig-0023" title="">Analysis 3.13</a>), vomiting (RR 2.05, 95% CI 0.50 to 8.48; I<sup>2</sup> = 0%; n = 297; <a href="./references#CD012763-fig-0024" title="">Analysis 3.14</a>), postprocedural nausea (RR 1.39, 95% CI 0.27 to 7.12; I<sup>2</sup> = 0%; n = 168; <a href="./references#CD012763-fig-0025" title="">Analysis 3.15</a>), headache (RR 1.02, 95% CI 0.48 to 2.18; I<sup>2</sup> = 0%; n = 388; <a href="./references#CD012763-fig-0026" title="">Analysis 3.16</a>), hypertension (RR 1.45, 95% CI 0.23 to 9.05; I<sup>2</sup> = 0%; n = 287; <a href="./references#CD012763-fig-0027" title="">Analysis 3.17</a>), hypotension (RR 1.23, 95% CI 0.38 to 3.96; I<sup>2</sup> = 0%; n = 465; <a href="./references#CD012763-fig-0028" title="">Analysis 3.18</a>), cough (RR 1.42, 95% CI 0.42 to 4.81; I<sup>2</sup> = 65%; n = 200; <a href="./references#CD012763-fig-0029" title="">Analysis 3.19</a>), dry mouth (RR 0.44, 95% CI 0.10 to 1.87; I<sup>2</sup> = 17%; n = 289; <a href="./references#CD012763-fig-0030" title="">Analysis 3.20</a>), dizziness (RR 0.98, 95% CI 0.10 to 9.23; I<sup>2</sup> = 0%; n = 168; <a href="./references#CD012763-fig-0031" title="">Analysis 3.21</a>), tachycardia (RR 0.44, 95% CI 0.09 to 2.22; I<sup>2</sup> = 0%; n = 338; <a href="./references#CD012763-fig-0032" title="">Analysis 3.22</a>), pruritus (RR 1.62, 95% CI 0.20 to 12.88; I<sup>2</sup> = 0%; n = 175; <a href="./references#CD012763-fig-0033" title="">Analysis 3.23</a>), pyrexia (RR 1.43, 95% CI 0.23 to 8.91; I<sup>2</sup> = 0%; n = 264; <a href="./references#CD012763-fig-0034" title="">Analysis 3.24</a>), shivering (RR 0.75, 95% CI 0.40 to 1.43; I<sup>2</sup> = 0%; n = 190; <a href="./references#CD012763-fig-0035" title="">Analysis 3.25</a>), chills (RR 4.04, 95% CI 0.46 to 35.85; I<sup>2</sup> = 0%; n = 166; <a href="./references#CD012763-fig-0036" title="">Analysis 3.26</a>), rash (RR 0.83, 95% CI 0.17 to 3.96; I<sup>2</sup> = 0%; n = 701; <a href="./references#CD012763-fig-0037" title="">Analysis 3.27</a>), supraventricular extrasystoles (RR 0.32, 95% CI 0.03 to 3.05; I<sup>2</sup> = 0%; n = 189; <a href="./references#CD012763-fig-0038" title="">Analysis 3.28</a>), laryngospasm (RR 0.34, 95% CI 0.07 to 1.65; I<sup>2</sup> = 0%; n = 100; <a href="./references#CD012763-fig-0039" title="">Analysis 3.29</a>), increased upper airway secretion (RR 0.37, 95% CI 0.09 to 1.59; I<sup>2</sup> = 0%; n = 442; <a href="./references#CD012763-fig-0040" title="">Analysis 3.30</a>), procedural complications (RR 0.12, 95% CI 0.02 to 0.97; I<sup>2</sup> = 0%; n = 168; <a href="./references#CD012763-fig-0019" title="">Analysis 3.9</a>), procedural hypertension (RR 1.65, 95% CI 0.33 to 8.21; I<sup>2</sup> = 0%; n = 267; <a href="./references#CD012763-fig-0041" title="">Analysis 3.31</a>), procedural hypotension (RR 0.49, 95% CI 0.02 to 14.15; I<sup>2</sup> = 60%; n = 391; <a href="./references#CD012763-fig-0042" title="">Analysis 3.32</a>), abdominal pain (RR 0.98, 95% CI 0.10 to 9.27; I<sup>2</sup> = 0%; n = 196; <a href="./references#CD012763-fig-0043" title="">Analysis 3.33</a>). Furthermore, data show no significant differences in reported clinical signs of residual NMB (RR 1.0; n = 646; <a href="./references#CD012763-fig-0044" title="">Analysis 3.34</a>), inadequate reversal of NMB (RR 0.11, 95% CI 0.01 to 2.02; n = 368; <a href="./references#CD012763-fig-0045" title="">Analysis 3.35</a>), and recurrence of NMB (RR 0.74, 95% CI 0.05 to 10.74; I<sup>2</sup> = 33; n = 1289; <a href="./references#CD012763-fig-0046" title="">Analysis 3.36</a>). Clinical tests revealed no significant differences in the number of participants reporting general muscle weakness at extubation (RR 0.61, 95% CI 0.31 to 1.18; I<sup>2</sup> = 0%; n = 288; <a href="./references#CD012763-fig-0022" title="">Analysis 3.12</a>), at PACU discharge (RR 0.49, 95% CI 0.12 to1.90; I<sup>2</sup> = 0%; n = 410; <a href="./references#CD012763-fig-0047" title="">Analysis 3.37</a>), or in the number of participants unable to perform five seconds of sustained head‐lift at PACU discharge (RR 1.0; n = 399; <a href="./references#CD012763-fig-0048" title="">Analysis 3.38</a>). </p> <p>A single trial observed some drug‐related adverse events; therefore, we could not include them in a meta‐analysis of specific adverse events, but we used the data to calculate overall risk of adverse events. The following isolated adverse events were observed in the sugammadex group: three cases of breath‐hold (10%) in <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a><i>,</i> two cases of strange taste in the mouth (6%) in <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a><i>,</i> two cases of increased beta‐N‐acetyl‐D‐glucosaminidase (6%) in <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>, two cases of bronchospasm (4%) in <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>, and one case of each of the following: severe abdominal pain (2%), pharyngolaryngeal pain (2%), diarrhoea (2%), and tinnitus (2%) in <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a><i>;</i> decreased hematocrit (1%) and procedural haemorrhage (1%) in <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; tremor (3%) and altered facial sensation (3%) in <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a><i>;</i> postprocedural hypertension (3%), paraesthesia (3%), and increased blood creatinine phosphokinase (3%) in <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a><i>;</i> retching (2%), airway complication to anaesthesia (2%), and hot flush (2%) in <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; procedural pain (2%) in <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; leukocytosis (2%) in <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a><i>;</i> mild hypoventilation (1%) in <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; and finally one case of intraoperative movement (2%) in <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a><i>.</i> </p> <p>In the neostigmine group, the following isolated drug‐related adverse events were reported: four cases of breath‐hold (13%) in <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a><i>;</i> two cases of albumin present in the urine (4%) in <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; two cases of leukocytosis (5%) in <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; and one case of each of the following: involuntary muscle contractions (2%), visual accommodation disorder (2%), increased urine beta‐2 microglobulin (2%), severe bradycardia (2%), and productive cough (2%) in <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a><i>;</i> respiratory distress (1%) and delayed recovery from anaesthesia (1%) in <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; hyperhidrosis (3%)<i>,</i> decreased blood protein (3%), restlessness (3%), chest discomfort (3%), incision site complication (3%), and postprocedural complication (3%) in <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a><i>;</i> ventricular extrasystoles (2%), sleep disorder (2%), and increased gamma‐glutamyltransferase (2%) in <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a><i>;</i> anxiety (3%), depression (3%), and fatigue (3%) in <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a><i>;</i> dyspepsia (2%) and somnolence (2%) in <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; severe muscle weakness (1%) in <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; and finally one case of intraoperative movement (2%) in <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>. </p> <p>We have described in <a href="#CD012763-tbl-0006">Table 3</a> each observed adverse event possibly, probably, or definitely related to sugammadex or neostigmine. This table also presents risk of adverse events in descending order, as well as the number of studies observing each adverse event. </p> <div class="table" id="CD012763-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table of adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sugammadex</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neostigmine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Specific adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of AEs, %</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of AEs, %</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.42‐4.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shivering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.40‐1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Desaturation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.06‐0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General muscle weakness after extubation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.31‐1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>288</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breath‐hold</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PONV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.28‐0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>389</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laryngospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.07‐1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not able to perform 5 second head‐lift after extubation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.15‐0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>395</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.07‐0.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1218</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12 (0.02‐0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postprocedural nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.47‐3.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.10‐1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>289</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.48‐2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased beta‐N‐acetyl‐D‐glucosaminidase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strange taste in mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.44‐1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>719</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albumin present in the urine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 (0.50‐8.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bronchospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chills</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.04 (0.46‐35.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General muscle weakness at PACU discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.12‐1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>410</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.33‐8.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altered facial sensation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postprocedural hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased blood PK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased upper airway secretions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.09‐1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperhidrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased blood protein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incision site complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.02‐14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postprocedural complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.09‐2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>338</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.20‐12.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intraoperative movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.38‐3.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>465</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supraventricular extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.03‐3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical signs of inadequate reversal of NMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.01‐2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased gamma‐glutamyl‐transferase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Airway complication to anaesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hot flush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Involontary muscle contractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visual accomodation disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased B<sub>2</sub>‐microglobulin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Productive cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.23‐8.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.23‐9.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased hematocrit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed recovery from anaesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory distress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.10‐9.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.10‐9.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.17‐3.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>701</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe muscle weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild hypoventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical signs of recurrence of residual NMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.05‐10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1289</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical signs of residual NMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>646</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not able to perform 5 second head‐lift at PACU discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>399</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Redness at injection site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Table of reported adverse events possibly, probably, or definitely related to sugammadex or neostigmine, listed in descending order according to risk of adverse events. Furthermore, the number of studies observing for each adverse event is presented </p> <p>List of abbreviations:</p> <p>NMB ‐ neuromuscular blockade</p> <p>PACU ‐ post‐anaesthesia care unit</p> </div> </div> <p>The largest trial in this review (<a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>) randomized 1198 participants and reported that 64 out of 596 participants (10.7%) in the sugammadex group and 72 out of 588 (12.2 %) in the usual care group had at least one drug‐related adverse event. Unfortunately, we could not include these data in our meta‐analysis, as the "usual care" group combined participants who received either neostigmine or placebo, and we were not able to obtain data from the neostigmine group. </p> <section id="CD012763-sec-0103"> <h6 class="title">Subgroup analysis of composite adverse events</h6> <section id="CD012763-sec-0104"> <p><b>3.2 Different dosages of sugammadex and neostigmine</b></p> <p>Different trials used different dosages of sugammadex and neostigmine.</p> <p><a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a> compared sugammadex 2 mg/kg versus neostigmine 0.04 mg/kg. Twelve trials compared sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>). Two trials compared sugammadex 2 mg/kg versus neostigmine 0.07 mg/kg (<a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>). <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a> compared sugammadex 2 mg/kg versus neostigmine 2.5 mg. <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a> compared sugammadex 3 mg/kg versus neostigmine 0.03 mg/kg. Four trials compared sugammadex 4 mg/kg versus neostigmine 0.05 mg/kg (<a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>). Three trials compared sugammadex 4 mg/kg versus neostigmine 0.07 mg/kg (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>). Four trials compared several different doses of sugammadex versus several different doses of neostigmine (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>). Subgroup analysis of data showed no significant subgroup differences in RR for composite adverse events (<a href="./references#CD012763-fig-0012" title="">Analysis 3.2</a>). </p> </section> <section id="CD012763-sec-0105"> <p><b>3.3. TIVA versus volatile anaesthetics</b></p> <p>Twenty trials maintained anaesthesia with volatile anaesthetic (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>). Seven trials used TIVA for maintenance (<a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0022" title="KoglerJ , ChalfeN , Karaman IlićM , HodobaN . Sugammadex reversal of rocuronium‐induced neuromuscular block in interventional bronchoscopy procedures: a comparison with neostigmine. European Journal of Anaesthesiology. 2012; Vol. 29:146. ">Kogler 2012</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). One trial provided insufficient information (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>). Subgroup analysis of trial results showed no significant subgroup differences in RR for composite adverse events (<a href="./references#CD012763-fig-0013" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD012763-sec-0106"> <h6 class="title">Sensitivity analysis of composite adverse events</h6> <section id="CD012763-sec-0107"> <p><b>3.4 Excluding meeting abstracts</b></p> <p>Sensitivity analysis excluding data from meeting abstracts (RR 0.60, 95% CI 0.49 to 0.74; I<sup>2</sup> = 35%; n = 2091; random‐effects model; <a href="./references#CD012763-fig-0014" title="">Analysis 3.4</a>) did not change overall results regarding significance. </p> </section> </section> <section id="CD012763-sec-0108"> <h6 class="title">Subgroup analysis of bradycardia</h6> <section id="CD012763-sec-0109"> <p><b>3.7 Atropine versus glycopyrrolate</b></p> <p>All trials reporting bradycardia combined neostigmine with an antimuscarinic drug. Six trials used atropine (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). Five trials used glycopyrrolate (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>). Subgroup analysis of trial results showed no significant subgroup differences in RR for bradycardia (<a href="./references#CD012763-fig-0016" title="">Analysis 3.6</a>). </p> </section> </section> <section id="CD012763-sec-0110"> <h6 class="title">Subgroup analysis of PONV</h6> <section id="CD012763-sec-0111"> <p><b>3.9 TIVA versus volatile anaesthetics</b></p> <p>Five trials maintained anaesthesia with volatile anaesthetic (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), One trial used TIVA for maintenance (<a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>). Subgroup analysis of trial results showed no significant subgroup differences in RR for PONV (<a href="./references#CD012763-fig-0017" title="">Analysis 3.7</a>). </p> </section> </section> <section id="CD012763-sec-0112"> <h6 class="title">Qualitative data</h6> <p>Investigators reported effects of sugammadex and neostigmine on the following parameters in data format that was ineligible for meta‐analysis. </p> <section id="CD012763-sec-0113"> <p><b>Intraocular pressure (IOP)</b></p> <p><a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a> described that post‐extubation intraocular pressures (IOPs) were similar between sugammadex and neostigmine groups (P &gt; 0.05; n = 60); <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a> reported lower end‐extubation IOPs when sugammadex 2 mg/kg was used in comparison with neostigmine 0.05 mg/kg ‐ atropine 0.02 mg/kg (P &lt; 0.05; n = 36), suggesting that sugammadex may be a better option for reversal of neuromuscular blockade in conditions for which an increase in IOP is not desired, such as glaucoma and penetrating eye injury. </p> </section> <section id="CD012763-sec-0114"> <p><b>Haemodynamic effects</b></p> <p><a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a> (n = 90) examined the haemodynamic effects of sugammadex and neostigmine in cardiac participants undergoing non‐cardiac surgery. Investigators found that the sugammadex group had lower systolic, diastolic, and mean blood pressures and heart rate when compared with the neostigmine group (P &lt; 0.05). They reported no significant differences between and within groups in terms of QTc interval values. Study authors suggest that sugammadex might be preferred to neostigmine‐atropine combination for reversal of rocuronium‐induced neuromuscular blockade in cardiac patients undergoing non‐cardiac surgery, </p> </section> <section id="CD012763-sec-0115"> <p><b>Bleeding events</b></p> <p>The largest trial in this review<b>(</b><a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>; n = 1198) included participants undergoing hip/knee surgery or hip fracture surgery and compared sugammadex 4 mg/kg versus usual care (neostigmine or spontaneous recovery). Investigators reported bleeding events within 24 hours in 17 (2.9%) sugammadex and 24 (4.1%) usual care participants (RR 0.70, 95% CI 0.38 to 1.29). Compared with usual care, increases of 5.5% in activated partial thromboplastin time (aPTT; P &lt; 0.001) and 3.0% in prothrombin time (P &lt; 0.001) from baseline occurred with sugammadex 10 minutes after administration and resolved within 60 minutes. Data show no significant differences between sugammadex and usual care for other blood loss measures (transfusion, 24‐hour drain volume, drop in haemoglobin, and anaemia) or for risk of venous thromboembolism, and trials reported no cases of anaphylaxis. Sugammadex induced limited (&lt; 8% at 10 minutes) and transient (&lt; 1 hour) increases in aPTT and prothrombin time but was not associated with increased risk of bleeding or increased severity of bleeding. A much smaller trial (<a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a>; n = 50) investigated effects of sugammadex and neostigmine on postoperative coagulation parameters and bleeding after seroplasty with sugammadex, increasing postoperative bleeding measured by nasal tip dressings (4.1 ± 2.7 mL in the sugammadex group vs 2.5 ± 2.7 mL in the neostigmine group; P = 0.013) without significantly affecting prothrombin time (PT) (P = 0.953), aPTT values (P = 0.734), or international normalized ratio (INR) values (P = 0.612). </p> <p><a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a> reported no differences in intraoperative blood loss between sugammadex 4 mg/kg (n = 20) and neostigmine 0.05 mg/kg plus atropine 0.02 mg/kg groups (104.6 ± 13.2 vs 111.2 ± 9.8 mL, respectively; P = 0.060) </p> </section> <section id="CD012763-sec-0116"> <p><b>Renal function</b></p> <p><a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a> (n = 50) investigated effects of neostigmine and sugammadex on kidney function and found that both drugs may affect kidney function but sugammadex has more tolerable effects than neostigmine. </p> </section> <section id="CD012763-sec-0117"> <p><b>Gastric emptying</b></p> <p><a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a> measured gastric emptying by using the paracetamol absorption test. Values of plasma paracetamol concentration (PPC) immediately after arrival of participants in the recovery room (T0) were significantly higher between the sugammadex 2 mg/kg group (1.2 ± 0.9) and the neostigmine 0.04 mg/kg/atropine 0.015 mg/kg group (0.4 ± 0.4) (P &lt; 0.01). Values of PPC at 15, 30, 60, 120, and 150 minutes were higher without reaching statistical difference: T15, 2.1 ± 1.5 vs 1.5 ± 1.4; T30, 3.7 ± 3.8 vs 2.9 ± 2.2; T60, 4.2 ± 2.8 vs 3.5 ± 2.7; T120, 5.0 ± 3.4 vs 4.6 ± 3.6; and T150, 5.9 ± 3.4 vs 4.9 ± 3.2. </p> <p>Values for PPC at 90 minutes were minimally higher in the neostigmine‐atropine group: time 90, 4.6 ± 3.4 vs 4.7 ± 3.4 (P = NS). Study authors concluded that although results show a tendency toward faster gastric emptying in the sugammadex group, this difference did not reach statistical difference, possibly owing to the small sample size of the study . </p> </section> <section id="CD012763-sec-0118"> <p><b>Thyroid function</b></p> <p><a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a> (n = 24) investigated effects on thyroid function and observed a significant increase in T4 levels compared with baseline one hour after anaesthesia (from 13.3 to 17.5 in the neostigmine group, and from 12.6 to 16.2 pmol/L in the sugammadex group; P &lt; 0.05) that returned to baseline after 24 hours in both groups. T3 decreased in both groups postoperatively (from 5.2 to 3.5 in the neostigmine group, and from 4.9 to 3.3 pmol/L in the sugammadex group), with no intergroup differences noted (P &gt; 0.05). Mean thyroid‐stimulating hormone (TSH) after 24 hours was not different between groups (1.32 in the neostigmine group vs 1.27 pmol/L in the sugammadex group; P = 0.49). In conclusion, sugammadex treatment did not change the levels of thyroid hormones and may be used safely in patients undergoing total thyroidectomy. </p> </section> <section id="CD012763-sec-0119"> <p><b>Cognitive function</b></p> <p><a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a> (n = 114) investigated cognitive function in patients receiving sugammadex or neostigmine and found no significant differences between groups when measuring cognitive function with the mini‐mental state evaluation test (P = 0.25), as described in <a href="./references#CD012763-bbs2-0151" title="TombaughTN , McIntyreNJ . The mini‐mental state examination: a comprehensive review. Journal of the American Geriatric Society1992;40(9):922‐35. [PUBMED: 1512391] ">Tombaugh 1992</a>, and the Clock Drawing test (P = 0.06), as described in <a href="./references#CD012763-bbs2-0085" title="AgrellB , DehlinO . The clock‐drawing test. Age and Aging1998;27:399‐403. [PUBMED: 23144287] ">Agrell 1998</a>. </p> </section> <section id="CD012763-sec-0120"> <p><b>Postoperative vomiting and nausea (PONV)</b></p> <p><a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> reported higher PONV scores in the neostigmine group than in the sugammadex group (3.2 ± 1.5 vs 1.9 ± 1.3; P = 0.015; n = 40) with no significant difference in antiemetic supplement (7 (35%) vs 3 (15%); P = 0.10). </p> <p><a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> compared sugammadex 2 mg/kg (n = 24) versus neostigmine 0.05 mg/kg plus atropine 0.02 mg/kg (n = 26) and reported no differences regarding nausea/vomiting between groups (P = 0.512). </p> <p><a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a> (n = 40) observed no differences between sugammadex 2 mg/kg and neostigmine 0.05 mg/kg in nausea/vomiting among morbidly obese participants undergoing bariatric surgery. </p> </section> <section id="CD012763-sec-0121"> <p><b>Pain</b></p> <p><a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> compared moderate NMB (T1 to T2) induced by atracurium/mivacurium reversed by neostigmine 1 to 2 mg plus atropine 0.5 to 1 mg (n = 12) versus deep NMB (PTC 1 to 2) induced by high‐dose rocuronium and reversed by sugammadex 4 mg/kg (n = 12) and found no significant differences in pain score as measured by a 10‐point scale (2.6 ± 1.6 vs 2.1 ± 2.2, respectively). </p> <p><a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> compared sugammadex 2 mg/kg (n = 24) versus neostigmine 0.05 mg/kg plus atropine 0.02 mg/kg (n = 26) and reported no differences regarding postoperative pain between groups (P = 0.280). </p> </section> </section> <section id="CD012763-sec-0122"> <h6 class="title">Overall signs of postoperative residual paralysis</h6> <p>We chose the following parameters as overall signs of postoperative residual paralysis: inability to perform 5 second head‐lift test and general muscle weakness after extubation and at PACU discharge, amblyopia, asthenia, desaturation &lt; 90%, transitory oxygen supplementation, respiratory distress, respiratory depression, postoperative respiratory complications (evaluated by PRSES – postoperative system evaluation score), moderate dyspnoea, pneumonia, acute lung failure, or symptoms of residual NMB or recurrence of NMB if specifically reported by study authors. The following 15 studies reported any of these adverse events: <a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>). </p> <p>Meta‐analysis of trial results showed significantly reduced risk of overall signs of postoperative residual paralysis (RR 0.40, 95% CI 0.28 to 0.57; I<sup>2</sup> = 0%; n = 1474; random‐effects model; NNTB 13; <a href="./references#CD012763-fig-0049" title="">Analysis 3.39</a>; GRADE quality of evidence: moderate; <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>) in the sugammadex group when compared with the neostigmine group. We downgraded GRADE quality of evidence one level owing to high risk of bias. </p> <p>Investigators reported the following data on overall events of postoperative residual paralysis, which were ineligible for meta‐analysis.<br/> <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> (n = 40) found higher peripheral oxygen saturation levels (SpO<sub>2</sub>) levels at recovery admission in the sugammadex group (97 ± 2.3% vs 94.4 ± 4%; P = 0.018), along with faster ability to swallow after extubation (7.1 ± 1.8 minutes vs 12.2 ± 6 minutes; P = 0.0027), and faster ability to get into bed independently (24 ± 9 minutes vs 33.4 ± 12 minutes; P = 0.022) when compared with the neostigmine group. </p> <p><a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a> (n = 34) reported that respiratory function was restored more quickly in morbidly obese (MOB) participants who received sugammadex when measured by postoperative forced vital capacity (1.6 ± 0.7 vs 2.41 ± 0.8 L; P &lt; 0.05), forced expiratory volume in one second (1.37 ± 0.7 vs 2.05 ± 0.6 L/s; P &lt; 0.05), and peak expiratory flow 30 minutes postoperatively (2.55 ± 1.7 vs 3.75 ± 1.4 L/s; P &lt; 0.05), but observed no significant differences in spirometry performed 15 minutes postoperatively. </p> <p><a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a> (n = 40) observed no differences between sugammadex 2 mg/kg and neostigmine 0.05 mg/kg in respiratory function among morbidly obese participants undergoing bariatric surgery. </p> <p><a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> compared moderate NMB (T1 to T2) induced by atracurium/mivacurium reversed by neostigmine 1 to 2 mg plus atropine 0.5 to 1 mg (n = 12) with deep NMB (PTC 1 to 2) induced by high‐dose rocuronium and reversed by sugammadex 4 mg/kg (n = 12), and found no significant difference in saturation in PACU (98.6 ± 1.8 vs 98.2 ± 1.4, respectively) or breathing rate in PACU (14.5 ± 2.2 vs 14.5 ± 2.2, respectively). </p> <p><a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a> found lower saturation levels (95.8 ± 0.014 vs 96.72 ± 0.01; P &lt; 0.02), lower minimal saturation (93% vs 94%), and no difference in respiratory complications when comparing neostigmine 2.5 mg (n = 25) versus sugammadex 2 mg/kg (n = 32). </p> <p><a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> compared sugammadex 2 mg/kg (n = 24) versus neostigmine 0.05 mg/kg plus atropine 0.02 mg/kg (n = 26) and reported no differences between groups regarding saturation levels after extubation (97.6 ± 0.2 vs 98.0 ± 0.2, respectively; P = 0.280). </p> <p>Furthermore, several trials conducted postoperative neuromuscular monitoring to quantify the risk of residual neuromuscular blockade, defined as TOFR &lt; 0.9: <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a> found that zero out of 74 (0%) sugammadex participants and 33 out of 76 (43.4%) neostigmine participants had TOFR &gt; 0.9 at PACU admission (odds ratio (OR) 0.0, 95% CI 0.0 to 0.6; P &lt; 0.0001). Of the 33 neostigmine participants, 2 also had clinical evidence of residual NMB. </p> <p><a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a> described that 2 out of 50 participants (4%) in the sugammadex group had residual NMB (TOFR &lt; 0.9) at the time of extubation compared with 26 out of 43 participants (60.5) in the neostigmine group, although data provided no clinical evidence (i.e. respiratory problems) of residual NMB in either group. </p> <p><a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a> described that TOF at PACU was 109.8% versus 85.5% (P &lt; 0.05; n = 70) in the sugammadex and neostigmine groups, respectively, and reached &gt; 90% in every case in the sugammadex group but not in the neostigmine group. </p> <p>No participants experienced recurrence of neuromuscular blockade based on neuromuscular monitoring in <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a> (n = 133). </p> </section> </section> </section> <section id="CD012763-sec-0123"> <h4 class="title">Sugammadex (any dose) versus neostigmine (any dose), drug‐related serious adverse events (SAEs) </h4> <p>Fourteen trials reported serious adverse events (SAEs) possibly, probably, or definitely related to study drug (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a>; <a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>; <a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a>)<i>.</i> Meta‐analysis of trial results showed no significant differences between sugammadex and neostigmine regarding participants with one or more serious adverse events or for composite adverse events (RR 0.54, 95% CI 0.13 to 2.25; I<sup>2</sup> = 0%; ten studies; n = 959; random‐effects model; <a href="./references#CD012763-fig-0050" title="">Analysis 3.40</a>; GRADE quality of evidence: low; <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>). We downgraded GRADE quality of evidence two levels owing to high risk of bias and imprecision. </p> <p>Clearly reported drug‐related serious adverse events included one case of acute myocardial infarction, pneumonia, and inadequate NMB reversal in the neostigmine group (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>), one case of acute lung failure in the neostigmine group (<a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>), one case of postoperative upper abdominal pain in the neostigmine group (<a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a><i>)<b>,</b> </i> one case of postprocedural haemorrhage in the sugammadex group (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>), and finally one case of respiratory depression in the sugammadex group (<a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>). </p> <section id="CD012763-sec-0124"> <h5 class="title">Trial sequential analysis (TSA)</h5> <p>We applied TSA to several outcome data as described in <a href="./full#CD012763-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD012763-tbl-0002">summary of findings Table 2</a>, and <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>. </p> <p>TSA of all trials comparing neostigmine 0.05 mg/kg versus sugammadex 2.0 mg/kg with regard to recovery time from T2 to TOFR &gt; 0.9 minutes indicates that with a required information size of 106, firm evidence sugammadex in a random‐effects model, with an alfa‐boundary adjusted MD of ‐10.22 (95% CI ‐12.11 to ‐8.33; diversity (D<sup>2</sup>) = 87%; I<sup>2</sup> = 84%; random‐effects model; <a href="./full#CD012763-fig-0001">Figure 1</a>). The cumulative Z‐curve crossed the monitoring boundary constructed for the required information size with 80% power and alpha of 0.05. However, none of the included trials had low risk of bias, and given that TSA is ideally designed for trials with low risk of bias and cannot be adjusted for risk of bias, the precision of our findings has to be downgraded. Furthermore, we found a high degree of diversity and heterogeneity, which once again raises questions about the reliability of the calculated required information size. </p> <p>TSA of dichotomous data on drug‐related risk of adverse events when neostigmine (any dose) was compared with sugammadex (any dose) with continuity adjustment for zero event trials (0.001 in each arm) resulted in an alfa‐boundary adjusted RR of 0.62 (95% CI 0.51 to 0.74; diversity (D<sup>2</sup>) = 34%; I<sup>2</sup> = 14%; random‐effects model; <a href="./full#CD012763-fig-0003">Figure 3</a>), with a control event proportion of 27.97%. With the required information size of 502, analyses provided firm evidence in favour of sugammadex, with 2298 participants included, corresponding to a relative risk reduction (RRR) of 38% with 80% power and alpha of 0.05. Despite the fact that the cumulative Z‐curve does not cross the monitoring boundary directly, it is hard to imagine future trials radically changing the overall picture of this analysis. Once again, none of the included trials had low risk of bias and this does downgrade the reliability of our finding. </p> <p>TSA of dichotomous data on risk of serious adverse events when neostigmine (any dose) was compared with sugammadex (any dose) with continuity adjustment for zero event trials (0.001 in each arm) resulted in an alfa‐boundary adjusted RR of 0.35 (95% CI 0.00 to 3190; diversity (D<sup>2</sup>) = 0%; I<sup>2</sup> = 0%; random‐effects model), with a control event proportion of 1.04%. The cumulative Z‐curve does not cross the monitoring boundary constructed for a required information size of 8189 participants, with 11.71% of the required information size included across included trials so far with 80% power and alpha of 0.05. Once again, none of the included trials had low risk of bias and this affects the reliability and precision of our estimates. </p> <p>TSA of dichotomous data on risk of signs of residual neuromuscular blockade when neostigmine (any dose) was compared with sugammadex (any dose) with continuity adjustment for zero event trials (0.001 in each arm) resulted in an alfa‐boundary adjusted RR of 0.4 (95% CI 0.27 to 0.59; diversity (D<sup>2</sup>) = 0%; I<sup>2</sup> = 0%; random‐effects model), with 80% power and alpha of 0.05 (<a href="./full#CD012763-fig-0004">Figure 4</a>), with a control event proportion of 13.08%. The cumulative Z‐curve crosses the monitoring boundary constructed for a required information size of 424 participants, indicating firm evidence in favour of sugammadex. However, as previously described, none of the included trials had low risk of bias and this equally diminishes the reliability and precision of our estimates. </p> <p>Finally, owing to overall high risks of bias, imprecision, and indirectness involved in assessment of GRADE for the above analysis, one could easily argue that the required power should be 90% ‐ not 80% ‐ by which the required information size would be increased; nevertheless we cannot rule out the direction of results in favour of sugammadex, despite the absence of large trials with low risk of bias. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012763-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012763-sec-0125"></div> <section id="CD012763-sec-0126"> <h3 class="title" id="CD012763-sec-0126">Summary of main results</h3> <p>In this systematic review of 41 randomized controlled trials (RCTs; 4206 participants) comparing the efficacy and safety of sugammadex versus neostigmine in reversing rocuronium‐induced neuromuscular blockade (NMB), we found a large and significant difference in reversal time favouring sugammadex. For meta‐analyses of primary outcomes, 12 studies (n = 949) were eligible. </p> <p>Meta‐analysis of trial results showed that sugammadex 2 mg/kg reversed NMB from second twitch (T2) to train‐of‐four ratio (TOFR) &gt; 0.9 in 1.96 minutes, and neostigmine 0.05 mg/kg reversed NMB from T2 to TOFR &gt; 0.9 in 12.87 minutes. Sugammadex 2 mg/kg was therefore on average 10.22 minutes (6.6 times) faster than neostigmine 0.05 mg/kg in reversing NMB at T2 reappearance (mean difference (MD) 10.22 minutes, 95% confidence interval (CI) 8.48 to 11.96; I<sup>2</sup> = 84%; ten studies; n = 835; random‐effects model; GRADE quality of evidence: moderate; <a href="./references#CD012763-fig-0007" title="">Analysis 1.1</a>). Reversal time from post‐tetanic count (PTC) 1 to 5 to TOFR &gt; 0.9 was not investigated; this was considered clinically irrelevant owing to the doses of sugammadex and neostigmine used for this comparison. </p> <p>Sugammadex 4 mg/kg reversed NMB from PTC 1 to 5 to TOFR &gt; 0.9 in 2.9 minutes, and neostigmine 0.07 mg/kg reversed NMB from PTC 1 to 5 to TOFR &gt; 0.9 in 48.8 minutes. Sugammadex 4 mg/kg was therefore on average 45.78 minutes (16.8 times) faster than neostigmine 0.07 mg/kg in reversing NMB at PTC 1 to 5 reappearance (MD 45.78 minutes, 95% CI 39.41 to 52.15; I<sup>2</sup> = 0%; n = 114; random‐effects model; GRADE quality of evidence: low; <a href="./references#CD012763-fig-0010" title="">Analysis 2.1</a>). Reversal time from T2 to TOFR &gt; 0.9 was not investigated since it was deemed clinically irrelevant owing to the doses of sugammadex and neostigmine used for this comparison. </p> <p>We found 28 trials (n = 2298) eligible for meta‐analysis of the secondary outcomes (risks of adverse events and serious adverse events). We found significantly fewer composite adverse events in the sugammadex group than in the neostigmine group (risk ratio (RR) 0.60, 95% CI 0.49 to 0.74; I<sup>2</sup> = 40%; 28 studies; n = 2298; random‐effects model; GRADE quality of data: moderate; <a href="./references#CD012763-fig-0011" title="">Analysis 3.1</a>). Specifically, the risk of composite adverse events was 283/1000 in the neostigmine group and 159/1000 in the sugammadex group. Analysis of number needed to treat for an additional beneficial outcome (NNTB) revealed that eight patients should be treated with sugammadex rather then neostigmine to avoid one patient experiencing a single random adverse event. Furthermore, significantly fewer participants had one or more adverse events (RR 0.62, 95% CI 0.48 to 0.81; I<sup>2</sup> = 0%; n = 1766; random‐effects model; GRADE quality of data: moderate; <a href="./references#CD012763-fig-0015" title="">Analysis 3.5</a>) in the sugammadex group than in the neostigmine group. Review of specific adverse events in the sugammadex group compared with the neostigmine group revealed significantly less risk of the following adverse events: bradycardia (<a href="./references#CD012763-fig-0016" title="">Analysis 3.6</a>), postoperative nausea and vomiting (PONV) (<a href="./references#CD012763-fig-0017" title="">Analysis 3.7</a>), desaturation (<a href="./references#CD012763-fig-0018" title="">Analysis 3.8</a>), and need for transitory oxygen supplementation (<a href="./references#CD012763-fig-0020" title="">Analysis 3.10</a>). Also, a significantly lower number of participants in the sugammadex group were not able to perform 5 second sustained head‐lift at extubation (<a href="./references#CD012763-fig-0021" title="">Analysis 3.11</a>). Data showed no significant differences between sugammadex and neostigmine regarding participants with one or more serious adverse events, nor in composite adverse events (RR 0.54, 95% CI 0.13 to 2.25; I<sup>2</sup> = 0%; ten studies; n = 959; random‐effects model; GRADE quality of evidence: low; <a href="./references#CD012763-fig-0050" title="">Analysis 3.40</a>). Reversal time from T2 and PTC 1 to 5 to TOFR &gt; 0.9 was not investigated, as it is clinically irrelevant owing to the doses of sugammadex and neostigmine used for this comparison. </p> </section> <section id="CD012763-sec-0127"> <h3 class="title" id="CD012763-sec-0127">Overall completeness and applicability of evidence</h3> <p>For our primary outcome, we performed a comparison of the effects of sugammadex and neostigmine at two depths of NMB: moderate block as indicated by reappearance of T2, and deep block as indicated by reappearance of PTC 1 to 5 on neuromuscular monitoring. However, administration of neostigmine is not recommended for reversal of deep block and absence of any signs of neuromuscular recovery due to the ceiling effect (<a href="./references#CD012763-bbs2-0099" title="CaldwellJE . Clinical limitations of acetylcholinesterase antagonists. Journal of Critical Care2009;24(1):21‐8. [PUBMED: 19272535] ">Caldwell 2009</a>; <a href="./references#CD012763-bbs2-0137" title="PlaudB , DebaeneB , DonatiF , MartyJ . Residual paralysis after emergence from anesthesia. Anesthesiology2010;112(4):1013‐22. [PUBMED: 20234315] ">Plaud 2010</a>), which is seen when maximal acetylcholine concentration is not sufficient to adequately compete with the muscle relaxant. According to the current prescribing information, this is an off‐label indication (<a href="./references#CD012763-bbs2-0159" title="Highligts of prescribing information: BLOXIVERZ™ (neostigmine methylsulfate). www.fda.gov. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204078s000lbl.pdf] ">www.fda.gov</a>). Nevertheless, our search identified two trials (<a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>, <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>) in which sugammadex and neostigmine were used to reverse rocuronium‐induced deep NMB, and one trial (<a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>) in which sugammadex and neostigmine were used to reverse vecuronium‐induced deep block. As this was not an exclusion criterion in the original protocol and the data were available, we chose to include these three studies in our review. However, for reasons explained above, the clinical importance of these comparatory findings aside from the obvious faster reversal due to sugammadex remains questionable. </p> <p>In this context, one could argue that a comparison between sugammadex and neostigmine for reversing a shallow NMB would be more relevant. However, this was not a predefined outcome in the original protocol. Furthermore, our search identified five trials in which some degree of shallow block was indicated (<a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a>; <a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), but none of these trials obtained comparable data on recovery time to TOFR &gt; 0.9. </p> <p>The overall quantity of data on which our conclusions can be based is large, and data were drawn from 41 randomized controlled trials with 4206 participants. According to GRADE, the quality of evidence for most of our meta‐analyses is moderate. Most trial participants were adults classified as American Society of Anesthesiologists (ASA) I to III who were undergoing elective surgery, and reported outcomes were relevant in a clinical setting. Primary and secondary outcomes, recovery time to TOFR &gt; 0.9, and adverse effects, were generally well reported. Therefore, on basis of the large number of identified studies and participants, available evidence seems to be applicable to adult patients of ASA classification I to III who are undergoing elective surgery. </p> <p>According to our meta‐analyses, sugammadex 2 mg/kg given at T2 reverses the NMB within 1.96 minutes and 6.6 times (10.22 minutes) faster than neostigmine 0.05 mg/kg (12.87 minutes). Furthermore, sugammadex 4 mg/kg, given to deep NMB at PTC 1 to 5 reappearance, reverses the block in 2.9 minutes and 16.8 times (45.78 minutes) faster than neostigmine 0.07 mg/kg (48.8 minutes). </p> <p>The time difference offers several potential advantages in that a patient who is paralysed with a neuromuscular blocking agent has to be out of the NMB with TOFR &gt; 0.9 before undergoing tracheal extubation, to avoid adverse effects due to residual paralysis (<a href="./references#CD012763-bbs2-0107" title="EikermannM , BlobnerM , GroebenH , RexC , GroteT , NeuhäuserM , et al. Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesthesia and Analgesia2006;102(3):937‐42. [PUBMED: 16492855] ">Eikermann 2006</a>; <a href="./references#CD012763-bbs2-0129" title="MurphyGS , SzokolJW , MarymontJH , GreenbergSB , AvramMJ , VenderJS . Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesthesia and Analgesia2008;107(1):130‐7. [PUBMED: 18635478] ">Murphy 2008</a>; <a href="./references#CD012763-bbs2-0132" title="MurphyGS , SzokolJW , AvramMJ , GreenbergSB , ShearT , VenderJS , et al. Postoperative residual neuromuscular blockade is associated with impaired clinical recovery. Anesthesia and Analgesia2013;117(1):133‐41. [PUBMED: 23337416] ">Murphy 2013</a>). </p> <p>Sugammadex rapidly reverses NMB. This appears favourable because it reduces required anaesthesia time for the patient. Additionally, unlike neostigmine, sugammadex can be administered at any stage during a surgical procedure and independent of the depth of blockade. A reduced duration of anaesthesia not only may improve recovery time for the patient but could potentially reduce costs by saving the time needed for a prolonged awakening and potentially enabling smoother flow of patients through the operating theatre. </p> <p>The cost‐effectiveness of sugammadex was not a predefined outcome of this review. To demonstrate cost‐effectiveness of sugammadex, two issues must be established: reduced patient recovery time perioperatively, and translation of any such reduction into resource utilization in terms of freeing up staff to work on productive alternative activities such as caring for other patients. This outcome is very difficult to assess owing to various confounders, such as the organizational structure of each hospital (<a href="./references#CD012763-bbs2-0104" title="DexterF , CoffinS , TinkerJH . Decreases in anesthesia‐controlled time cannot permit one additional surgical operation to be reliably scheduled during the workday. [Decreases in anesthesia‐controlled time cannot permit one additional surgical operation to be reliably scheduled during the workday]. Anesthesia &amp; Analgesia1995;81(6):1263‐8. [PUBMED: 7486114] ">Dexter 1995</a>), procedural flow, variability of NMB, monitoring and extubation practices, turnover times between procedures, frequency of emergency procedures, operating room overtime resource use, staff payments, productive alternative use of freed resources (<a href="./references#CD012763-bbs2-0111" title="Fuchs‐BuderT , MeistelmanC , SchreiberJU . Is sugammadex economically viable for routine use. Current Opinions in Anesthesiology2012;25(2):217‐20. [PUBMED: 22157200] ">Fuchs‐Buder 2012</a>; <a href="./references#CD012763-bbs2-0135" title="PatonF , PauldenM , ChambersD , HeirsM , DuffyS , HunterJM , et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. British Journal of Anaesthesia2010;105(5):558‐67. [PUBMED: 20935005] ">Paton 2010</a>), and finally the cost of available drugs in each country. Furthermore, it is difficult to calculate whether any reduction in adverse events associated with sugammadex, besides improved quality of care, can readily be translated into cost‐effectiveness. </p> <p>One systematic review (<a href="./references#CD012763-bbs2-0135" title="PatonF , PauldenM , ChambersD , HeirsM , DuffyS , HunterJM , et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. British Journal of Anaesthesia2010;105(5):558‐67. [PUBMED: 20935005] ">Paton 2010</a>) compared the cost‐effectiveness of sugammadex versus neostigmine/glycopyrrolate for routine reversal of moderate or profound muscle relaxation produced by rocuronium and vecuronium. Results from included trials (<a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>, <a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>, <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>, <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>) indicate that sugammadex 2 mg/kg (4 mg/kg) produces more rapid recovery from moderate NMB than is achieved with neostigmine/glycopyrrolate. Economic assessment indicated that if the reductions in recovery time associated with sugammadex in these trials were replicated in routine clinical practice, sugammadex would be cost‐effective if those reductions were achieved in the operating theatre, but not if they were achieved in the recovery room. Review authors went on to conclude that further research is required to evaluate the effects of sugammadex on patient safety, predictability of recovery from NMB, patient outcomes, and efficient use of resources. A recent Canadian study (<a href="./references#CD012763-bbs2-0119" title="InsingaRP , JoyalC , GoyetteA , GalarneauA . A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada. BMC Anesthesiology2016;16(1):114. [PUBMED: 7852231] ">Insinga 2016</a>) used a discrete model‐event simulation to investigate the potential impact of substituting sugammadex for neostigmine on operating room efficiency and incidence of residual NMB. Study authors concluded that the principal impact for patients managed by moderate NMB is likely to be seen as a reduction in the risk of residual NMB and associated complications. For patients maintained at a deep level of block until the procedure is completed, sugammadex was likely to both enhance operating room efficiency and reduce residual block complications. Last but not least, the cost per anaesthetic case might increase in case of unrestricted use of sugammadex, as shown in a retrospective observational audit (<a href="./references#CD012763-bbs2-0124" title="LedowskiT , HillyardS , KozmanA , JohnstonF , GilliesE , GreenawayM , et al. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anesthesia and Intensive Care Journal2012;40(2):340‐3. [PUBMED: 22417031] ">Ledowski 2012</a>). </p> <p>In conclusion, considerable uncertainties remain regarding the cost‐effectiveness of sugammadex, and further investigation is needed. Currently, the cost of sugammadex is relatively high as the result of proprietary rights. The price for the smallest vial (100 mg/mL, 2 mL) in Denmark is around 117 euros. In addition, drug patents are set to expire on 27 January 2021 (<a href="./references#CD012763-bbs2-0105" title="Generic Bridion availability. www.drugs.com. [www.drugs.com/availability/generic‐bridion.html] ">Drugs.com</a>). How this will affect the price and clinical usage of sugammadex remains to be established. </p> <p>Another important clinical consideration in the choice of reversing agent is the risk of adverse effects. </p> <p>The decision to use a drug is based on an overall assessment of its benefits and harms. Monitoring and reporting of adverse events during a clinical trial constitutes a cumbersome and complex task involving many assumptions and choices, such as adequate blinding of study participants and investigators, distinction between adverse and serious adverse events, causality of adverse events to study drugs, reporting by patients, and finally consistent and transparent monitoring, coding, and reporting by investigators. </p> <p>Trials included in this review defined, monitored, and reported adverse events in many different ways. Some trials (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>) coded all adverse events and serious adverse events described by the investigator in a systematic way using the Medical Dictionary for Regulatory Activities (MeDRA). Other trials reported symptoms related to study drug administration without necessarily defining them as adverse events (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a>) ‐ an issue most often seen in meeting abstracts (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>; <a href="./references#CD012763-bbs2-0025" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Sugammadex does not influence thyroid hormones in the patients undergoing thyroidectomy in propofol anesthesia. European Journal of Anaesthesiology. 2012; Vol. 29:141. ">Kvolik 2012b</a>) that is probably due to word count restriction. Furthermore, some included trials specifically addressed causality between adverse events and study drugs by presenting not only adverse events observed regardless of relation to study drug but also adverse events possibly, probably, or definitely related to study drug (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>), although others did not specifically address this issue (<a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a>; <a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>). Smaller trials with few observed adverse events usually presented all observed adverse events (<a href="./references#CD012763-bbs2-0002" title="BalakaC , PoulidaS , MiliatouM , RoussakisA , LavranouV , MoshakiM , et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. Journal of Cardiothoracic and Vascular Anesthesia. 2011; Vol. 25:S22‐3. [3275631; http://www.jcvaonline.com/article/S1053‐0770(11)00191‐1/pdf] ">Balaka 2011</a>; <a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a>; <a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a>; <a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a>), while bigger trials presented the most frequently occurring adverse events (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>). Additionally, some trials used blinded safety outcome assessors (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a>) in contrast to others (<a href="./references#CD012763-bbs2-0013" title="GrintescuI , MireaL , OlogoiuD , UngureanuR , MekauvarS , VasilescuM . Comparison of the cost effectiveness of sugammadex and neostigmine during general anaesthesia for laparoscopic cholecystectomy. British Journal of Anaesthesia. 2009; Vol. 103, issue 6:917. ">Grintescu 2009</a>; <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a>). Last but not least, very few of the included trials were designed and powered to address safety as a primary outcome (<a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>). </p> <p>As explained earlier in the <a href="#CD012763-sec-0032">Methods</a> and <a href="./full#CD012763-sec-0060">Results</a> sections, overall clinical signs of postoperative residual paralysis such as inability to perform 5 second head‐lift and general muscle weakness observed in some trials (<a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a>; <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a>; <a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a>; <a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a>; <a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>) were regarded as adverse events in this review. Furthermore, we decided to include reported symptoms related to drug administration as adverse events, even though they were not specifically defined as adverse events, to avoid potentially dismissing good quality data because of lack of correct phrasing. We have addressed and explained under the notes section in <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a> any discrepancy in adverse events presented in the original article and in this review due to definitions of adverse events or additional data about adverse events supplied through email correspondence with trial authors. Readers of medical journals and of this review need to be aware of these issues as they appraise this review and the literature critically. </p> <p>Included trials provided sparse data regarding which body weight dose calculations were based upon (i.e. ideal, correlated, or lean body weight), and we were unable to retrieve additional data that would shed light on this. As a consequence, we have regarded the weight data provided as total body weight. </p> <p>Our results show an overall significantly lower risk of adverse events in the sugammadex group than in the neostigmine group (<a href="./references#CD012763-fig-0011" title="">Analysis 3.1</a>; <a href="./references#CD012763-fig-0015" title="">Analysis 3.5</a>), along with an NNTB of eight for avoidance of an adverse event. </p> <p>Data show significantly less risk of the clinically important adverse effect PONV (<a href="./references#CD012763-fig-0017" title="">Analysis 3.7</a>) and less risk of overall signs of postoperative residual paralysis in the sugammadex group (<a href="./references#CD012763-fig-0049" title="">Analysis 3.39</a>), making this treatment preferable because residual blockade increases the risk of serious adverse effects such as acute respiratory failure (<a href="./references#CD012763-bbs2-0129" title="MurphyGS , SzokolJW , MarymontJH , GreenbergSB , AvramMJ , VenderJS . Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesthesia and Analgesia2008;107(1):130‐7. [PUBMED: 18635478] ">Murphy 2008</a>; <a href="./references#CD012763-bbs2-0144" title="SauerM , StahnA , SolteszS , Noeldge‐SchomburgG , MenckeT . The influence of residual neuromuscular block on the incidence of critical respiratory events. A randomised, prospective, placebo‐controlled trial. European Journal of Anaesthesiology2011;28(12):842‐8. [PUBMED: 21455074] ">Sauer 2011</a>). Data also show reduced risk of bradycardia (<a href="./references#CD012763-fig-0016" title="">Analysis 3.6</a>) in the sugammadex group. However, the two groups reported many adverse reactions similarly, as presented in the <a href="./full#CD012763-sec-0060">Results</a> section. Results show that no cases of anaphylaxis were reported. </p> <p>Our results may not be directly applicable to all groups of patients because sugammadex may have different outcomes for patients with higher ASA classes and for patients with special comorbidities or systemic dysfunction. </p> <p>These patients are not represented well in the trials included in our meta‐analyses, but lower risk of adverse effects as well as sufficient reversal from neuromuscular blockade may be even more beneficial for this group of patients, and inclusion of these more fragile patients in future trials could potentially reduce the NNTB for avoidance of adverse events. However, this might not be applicable to all patient groups (e.g.. severe renal impairment has been discussed as a possible contraindication to treatment. Sugammadex is excreted unchanged in the urine by the kidneys. Renal clearance of sugammadex is rapid, with most of the dose (70%) excreted within six hours (<a href="./references#CD012763-bbs2-0113" title="GolembiewskiJ . Sugammadex. Journal of PeriAnesthesia Nursing2016;31(4):354‐7. [PUBMED: 27444769] ">Golembiewski 2016</a>). None of the included trials enrolled participants with renal dysfunction. However, <a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a> (n = 50) investigated the effects of neostigmine and sugammadex on adults of ASA I to II with normal renal function and found that both drugs may impair renal function, but sugammadex was more tolerable than neostigmine. A pharmacokinetic study (<a href="./references#CD012763-bbs2-0148" title="StaalsLM , SnoeckMM , DriessenJJ , vanHamersveltHW , FlocktonEA , van denHeuvelMW , et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end‐stage renal failure: a pharmacokinetic study. British Journal of Anaesthesia2010;104(1):31‐9. [PUBMED: 20007792 ] ">Staals 2010</a>) investigated the pharmacokinetics of sugammadex 2 mg/kg and of rocuronium 0,6 mg/kg in 15 participants with renal failure and in 15 healthy controls. Investigators found that urinary excretion of sugammadex was reduced among participants with renal failure. The median quantity of sugammadex excreted in the urine within 72 hours among participants with renal failure was 29%, and 73% in controls. Nevertheless, one has to conclude on the basis of existing evidence that studies on the use of sugammadex for patients with renal impairment are needed to examine safety, preferably with longer follow‐up than 72 hours, because late renal impairment has to be addressed equally. </p> <p>Sugammadex has been suspected of increasing the risk of specific adverse effects such as QTc prolongation and bleeding events (<a href="./references#CD012763-bbs2-0096" title="http://www.ema.europa.eu/ . Summary of Product Characteristics of BRIDION. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000885/WC500052310.pdf. ">Bridion 2014</a>). However, we found limited data from few trials in our systematic review on these variables, and presented data were ineligible for meta‐analysis. </p> <p>The summary of product characteristics provided by Bridion states that the "administration of 4 and 16 mg/kg of Sugammadex in healthy volunteers resulted in maximum and mean prolongations of the aPTT by 17% and 22%, respectively, and PT by 11% and 22%, respectively. These mean aPTT and PT prolongations were limited and of short duration &lt; 30 min" (<a href="./references#CD012763-bbs2-0096" title="http://www.ema.europa.eu/ . Summary of Product Characteristics of BRIDION. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000885/WC500052310.pdf. ">Bridion 2014</a>). <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a> (n = 1198) included participants undergoing hip or knee surgery and compared sugammadex 4 mg/kg versus usual care (neostigmine or spontaneous recovery). Study findings indicate that sugammadex induced limited (&lt; 8% at 10 minutes) and transient (&lt; 1 hour) increases in activated partial thromboplastin time (aPTT) and prothrombin time (PT) but was not associated with increased risk or severity of bleeding. <a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> (n = 50) investigated the effects of sugammadex and neostigmine on postoperative coagulation parameters and bleeding after seroplasty and demonstrated that sugammadex increased postoperative bleeding without significantly affecting PT and aPTT values. An RCT of healthy adults reported that after administration of sugammadex at doses of 4 mg/kg and 16 mg/kg, a dose‐dependent, limited, temporary, and clinically irrelevant prolongation in PT and aPTT was observed (<a href="./references#CD012763-bbs2-0102" title="DeKamPJ , KruithofAC , vanLieropMJ , MoerlandM , DennieJ , TroyerMD , et al. Lack of a clinically relevant effect of sugammadex on anti‐Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low‐molecular‐weight heparin in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics2014;52(8):631‐41. [PUBMED: 24800921] ">De Kam 2014</a>). A one‐year retrospective study (n = 193) performed in participants with high risk of postoperative bleeding (laparotomy for cancer surgery requiring suction drains) did not find sugammadex at doses of 2 and 4 mg·kg<sup>–1</sup> to be associated with increased bleeding as measured by the amount of blood found in suction drains and dressings (<a href="./references#CD012763-bbs2-0141" title="RaftJ , Betala BelingaJF , JurkolowG , DesandesE , LongroisD , MeistelmanC . Clinical evaluation of post‐surgical bleeding after a sugammadex injection. Annales Françaises d'Anesthésie et de Réanimation2011;30(10):714‐7. [PUBMED: 21741200] ">Raft 2011</a>). </p> <p>However, upon review of the published literature, we are unable to refute or reject any safety concern with regard to sugammadex for patients at high risk of bleeding due to existing severe coagulopathy or due to the nature of procedures associated with high risk of transfusion because evidence is inadequate to support or withhold any use of sugammadex. </p> <p>We found limited evidence with regard to haemodynamic implications of sugammadex use, but <a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a> compared the haemodynamic effects of sugammadex and neostigmine in participants with cardiac disease undergoing non‐cardiac surgery. Haemodynamic parameters were more prominently increased among participants receiving neostigmine, and cardiac function was noted to be more stable among those given sugammadex. Data show no significant differences between and within groups in terms of QTc values. </p> <p>Morbidly obese patients make up a high‐risk group (<a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>), and because of their often compromised respiratory function, they are considered especially vulnerable to residual curarization in the postoperative period influencing respiratory function (<a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>). Three trials (n = 161) investigated the optimal sugammadex dose per kilogram body weight; total body weight (TBW) (<a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>), corrected body weight (CBW) (<a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>; <a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>), and ideal body weight (IBW) (<a href="./references#CD012763-bbs2-0012" title="GeorgiouP , ZotouA , SiampaliotiA , TagariP , TsiotsiP , FilosKS . Clinical and cost‐effectiveness of Sugammadex versus Neostigmine reversal of Rocuronium‐induced neuromuscular block in super obese patients undergoing open laparotomy for bariatric surgery. A randomized controlled trial. European Journal of Anaesthesiology. Barcelona: Euroanesthesia 2013, 2013; Vol. 30:141. ">Georgiou 2013</a>). All three studies found sugammadex 2 mg/kg to be significantly faster than neostigmine 0.04 to 0.05 mg/kg in reversing neuromuscular blockade at T2 reappearance, and in reducing the risk of postoperative residual curarization (<a href="./references#CD012763-bbs2-0009" title="FolettoM , CarronM , ZarantonelloF , PrevedelloL . Respiratory function after sugammadex and neostigmine administration for reversal of moderate rocuronium‐induced neuromuscular blockade in morbidly obese patients. 8 ed. Springer New York. Montreal, Canada: 19th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, IFSO 2014, 2014; Vol. 24:1139. ">Foletto 2014</a>; <a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a>). </p> <p>Researchers have speculated about the influence of volatile anaesthetics and recovery times when neuromuscular blocking agents (NMBAs) are used (<a href="./references#CD012763-bbs2-0142" title="ReidJE , BreslinDS , MirakhurRK , HayesAH . Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol. Canadian Journal of Anesthesia2001;48(4):351‐5. [PUBMED: 11339776] ">Reid 2001</a>). However, we found no significant differences in recovery time to TOFR &gt; 0.9 when anaesthesia maintained with volatile anaesthetic (eight trials; n = 490) was compared with total intravenous anaesthetic (TIVA) (four trials; n = 381) (<a href="./references#CD012763-fig-0008" title="">Analysis 1.2</a>). </p> <p>Sugammadex was specifically designed to reverse rocuronium as a non‐depolarizing NMBA, as is demonstrated by most of the trials included in this review. However, two of the included trials (<a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>) used sugammadex to revert vecuronium. Furthermore, <a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a> compared sugammadex following rocuronium versus neostigmine following cisatracurium, and <a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> compared atracurium for induction and mivacurium for maintenance versus rocuronium for both induction and maintenance. Two studies (<a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a>; <a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a>) provided no information on the NMBA used. </p> </section> <section id="CD012763-sec-0128"> <h3 class="title" id="CD012763-sec-0128">Quality of the evidence</h3> <p>This systematic review provides a robust assessment of the efficacy of sugammadex because it includes a large number of trials with large numbers of participants showing a consistent direction of results across all trials and additional confirmation through various exploratory analyses favouring the intervention for our primary outcome. </p> <p>However, this review also has several potential limitations, as our findings and interpretations are limited by the quality and quantity of available evidence from included RCTs. The RCT is considered the most rigorous method of determining whether a cause‐effect relationship exists between an intervention and an outcome. The strength of the RCT lies in the process of randomization, but several potential risks of bias in trial methods can affect results. </p> <p>The review authors have judged the risk of bias for each included study by using the recommended risk of bias assessment in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>). All of our studies had at least one "high or unclear risk of bias", and we considered the risk that trials may overestimate or underestimate the true intervention effect a serious limitation for all trials. In particular, judgements of performance risk of bias and funding risk of bias were overall high. We judged none of the included studies as having low risk of bias. </p> <p>Application of the GRADE approach enables us to incorporate risk of bias, directness of evidence, heterogeneity, precision of effect estimate, and risk of publication bias. </p> <p>The GRADE quality of our findings ranks as moderate for our primary outcome, and from low to moderate across different outcomes. The main limiting factors that accounted for decreased quality of evidence included high risk of bias and imprecision (<a href="./full#CD012763-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012763-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>). </p> <p>We mainly assessed the risk of bias of included trials using published data, which ultimately may not reflect the truth. We contacted all trial authors; 12 (33.3%) responded and provided further information. Lack of reporting of some of the data may have affected our judgement on risk of bias in either direction. </p> <p>We applied several statistical methods to explore and reduce the extent of bias, such as complete case analysis, trial sequential analysis (TSA), overall methodological bias assessment, and analyses of various relevant clinical and physiological outcomes. </p> <p>Application of TSA to our primary outcome indicates that at this stage, sugammadex appears superior to neostigmine. TSA provided firm evidence in favour of sugammadex for outcomes such as recovery time from T2 to TOFR &gt; 0.9 minutes, adverse events, and overall signs of postoperative residual paralysis. However, none of the included trials were at low risk of bias, and as TSA cannot be adjusted for risk of bias, we did not calculate the low risk of bias adjusted information size, which ultimately affects the reliability and precision of our findings. </p> <p>Evaluated outcomes consistently favoured sugammadex. However, we graded the quality of evidence as moderate because of the high proportion of trials at high risk of bias, large clinical and statistical heterogeneity, and small sample sizes, but we upgraded the level of evidence in favour of sugammadex as indicated by TSA analyses. </p> <p>On the basis of the criteria mentioned above, we deemed the overall GRADE quality of evidence in this review to be moderate. </p> <p>Sugammadex was specifically designed to reverse rocuronium as a non‐depolarizing NMBA, as most of the trials included in this review demonstrated this. However, two of the included trials (<a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a>; <a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a>) used sugammadex to revert vecuronium. </p> </section> <section id="CD012763-sec-0129"> <h3 class="title" id="CD012763-sec-0129">Potential biases in the review process</h3> <p>We have followed the recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> as this official guide describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions (<a href="./references#CD012763-bbs2-0116" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org. ">Higgins 2011</a>). We have adhered to this handbook in handling the included RCTs. </p> <p>Meta‐analyses are limited by the quality and quantity of available evidence. Even though our meta‐analyses are based on a large quantity of data, results and methods for some of the included studies were not thoroughly described. Furthermore, some of the included trials were not specifically designed to address the primary or secondary outcomes of this review, leading to possibly biased data. We have addressed this problem by labelling studies with high risk of "other bias", as is shown in <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>, <a href="./full#CD012763-fig-0002">Figure 2</a>, and <a href="#CD012763-fig-0006">Figure 6</a>, and by downgrading the GRADE quality of evidence (<a href="./full#CD012763-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD012763-tbl-0002">summary of findings Table 2</a>, and <a href="./full#CD012763-tbl-0003">summary of findings Table 3</a>). Additionally, we are aware that as we have performed many analyses of specific adverse events, the probability of achieving significant results by chance is high. </p> <p>We used the same search strategy as was used in the original version of this review (<a href="./references#CD012763-bbs2-0161" title="AbrishamiA , HoJ , WongJ , YinL , ChungF . Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007362.pub2] ">Abrishami 2009</a>), and we found 41 eligible studies for inclusion. We cannot exclude the possibility that we may have missed some of the published literature beyond the electronic databases searched for this review. However, the 41 trials with 4206 participants included in this review appear to provide sufficient data for meta‐analyses, and our TSAs indicate a better safety profile and clinical superiority of sugammadex compared with neostigmine for the population included in this trial. </p> <p>We found 20 relevant ongoing trials registered at <a href="https://clinicaltrials.gov" target="_blank">https://clinicaltrials.gov</a> and three trials awaiting classification, but none of these studies have published data within our main search update from 2008 to 2 May 2016. When published, these trials may change the results and conclusions of this review. However, the main strength of this update consists of the quantity of data comparing sugammadex versus neostigmine in reversing NMB. The new search added eight years of research and 38 new trials to the review that was originally published (<a href="./references#CD012763-bbs2-0161" title="AbrishamiA , HoJ , WongJ , YinL , ChungF . Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007362.pub2] ">Abrishami 2009</a>), which comprised three trials comparing sugammadex and neostigmine. Additionally, we have substantially updated and revised the methods of this review compared with methods of the previous one. </p> <p>As a consequence, this review diverges from intended adherence to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> by not following the original protocol (<a href="./references#CD012763-bbs2-0161" title="AbrishamiA , HoJ , WongJ , YinL , ChungF . Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007362.pub2] ">Abrishami 2009</a>) prepared for the first version of this review (<a href="./references#CD012763-bbs2-0161" title="AbrishamiA , HoJ , WongJ , YinL , ChungF . Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007362.pub2] ">Abrishami 2009</a>). After several discussions with the editorial team, we made the decision to split the original review in two based on the extensive number of publications using various comparators, interventions, and outcome measures. Therefore, it seemed more appropriate to take the original review in a different direction and place more emphasis on safety issues and efficacy. Although this may be perceived as introduction of post hoc analyses, review authors selected outcomes and subgroup and sensitivity analyses for this review before identifying included trials (search) and extracting data to minimize the risk of bias. </p> </section> <section id="CD012763-sec-0130"> <h3 class="title" id="CD012763-sec-0130">Agreements and disagreements with other studies or reviews</h3> <p>The original published review (<a href="./references#CD012763-bbs2-0161" title="AbrishamiA , HoJ , WongJ , YinL , ChungF . Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007362.pub2] ">Abrishami 2009</a>) found no difference with regard to adverse effects between sugammadex and neostigmine. This review found that sugammadex reduced the risk of adverse events when compared with neostigmine. We updated this review as of 2 May 2016 with regard to the search, adding eight years of research and 38 new trials; the original review (<a href="./references#CD012763-bbs2-0161" title="AbrishamiA , HoJ , WongJ , YinL , ChungF . Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007362.pub2] ">Abrishami 2009</a>) comprised three trials. We re‐ran the search on 10 May 2017. Currently three trials are awaiting classification and 20 studies are ongoing. </p> <p>Our results on the primary outcome, recovery time, are in accordance with the findings of all RCTs included in the meta‐analyses, as they reflect superiority for sugammadex as a reversing agent over neostigmine. With regard to our secondary outcomes ‐ risks of adverse and serious adverse events ‐ we found more diverging results among the included trials, although overall risk of adverse events was reduced in the sugammadex group (<a href="./references#CD012763-fig-0011" title="">Analysis 3.1</a>; <a href="./references#CD012763-fig-0015" title="">Analysis 3.5</a>). No previous publication has addressed this issue with the same rigour. </p> <p>A recent systematic review of sugammadex versus neostigmine for reversal of NMB (<a href="./references#CD012763-bbs2-0084" title="Abad‐GurumetaA , Ripollés‐MelchorJ , Casans‐FrancésR , EspinosaA , Martínez‐HurtadoE , Fernández‐PérezC , et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia2015;70(12):1441‐52. [PUBMED: 26558858] ">Abad‐Gurumeta 2015</a>) included 1553 participants across 17 RCTs (all are included in this review). </p> <p><a href="./references#CD012763-bbs2-0084" title="Abad‐GurumetaA , Ripollés‐MelchorJ , Casans‐FrancésR , EspinosaA , Martínez‐HurtadoE , Fernández‐PérezC , et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia2015;70(12):1441‐52. [PUBMED: 26558858] ">Abad‐Gurumeta 2015</a> focused mainly on postoperative residual paralysis and drug‐related adverse events (<a href="./references#CD012763-bbs2-0084" title="Abad‐GurumetaA , Ripollés‐MelchorJ , Casans‐FrancésR , EspinosaA , Martínez‐HurtadoE , Fernández‐PérezC , et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia2015;70(12):1441‐52. [PUBMED: 26558858] ">Abad‐Gurumeta 2015</a>). Review authors found that sugammadex reduced all signs of residual postoperative paralysis (RR 0.46, 95% CI 0.29 to 0.71; P = 0.0004) and risk of minor respiratory events (RR 0.51, 95% CI 0.32 to 0.80; P = 0.0034). However, they reported no differences in critical respiratory events (RR 0.13, 95% CI 0.02 to 1.06; P = 0.06). Sugammadex reduced drug‐related adverse effects (RR 0.72, 95% CI 0.54 to 0.95; P = 0.02) but data show no differences in the rate of postoperative nausea or the rate of postoperative vomiting, Findings of this review were generally in line with the results of our updated review with regard to adverse and serious adverse events. </p> <p>Another systematic review (<a href="./references#CD012763-bbs2-0135" title="PatonF , PauldenM , ChambersD , HeirsM , DuffyS , HunterJM , et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. British Journal of Anaesthesia2010;105(5):558‐67. [PUBMED: 20935005] ">Paton 2010</a>), which included four trials (n = 606), compared sugammadex versus neostigmine/glycopyrrolate for routine reversal of NMB with economics evaluation. Researchers found that sugammadex was beneficial in terms of enhanced patient safety and increased predictability of recovery from rocuronium‐induced NMB, with more efficient use of theatre time and staff. Conclusions of review authors on recovery time, adverse events, and cost‐benefit considerations are in line with those of our updated review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012763-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="TSA of all trials comparing sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg; recovery time from T2 to TOFR &gt; 0.9 minutes. With a required information size of 106, firm evidence in place favours sugammadex in a random‐effects model, with an alfa‐boundary adjusted MD of ‐10.22 (95% CI ‐12.11 to ‐8.33; diversity (D2) = 87%, I2 = 84%, random‐effects model). The cumulative Z‐curve crosses the monitoring boundary constructed for the required information size with 80% power and alpha of 0.05. However, none of the included trials had low risk of bias, and because TSA is ideally designed for trials with low risk of bias and cannot be adjusted for risk of bias, the precision of our findings has to be downgraded. Furthermore, the degree of diversity and heterogeneity is high, which once again raises questions about the reliability of the calculated required information size." data-id="CD012763-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p><b>TSA of all trials comparing sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg; recovery time from T2 to TOFR &gt; 0.9 minutes.</b> With a required information size of 106, firm evidence in place favours sugammadex in a random‐effects model, with an alfa‐boundary adjusted MD of ‐10.22 (95% CI ‐12.11 to ‐8.33; diversity (D<sup>2</sup>) = 87%, I<sup>2</sup> = 84%, random‐effects model). The cumulative Z‐curve crosses the monitoring boundary constructed for the required information size with 80% power and alpha of 0.05. However, none of the included trials had low risk of bias, and because TSA is ideally designed for trials with low risk of bias and cannot be adjusted for risk of bias, the precision of our findings has to be downgraded. Furthermore, the degree of diversity and heterogeneity is high, which once again raises questions about the reliability of the calculated required information size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012763-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="TSA of dichotomous data on drug‐related risk of adverse events; sugammadex (any dose) vs neostigmine (any dose). This analyses includes continuity adjustment for zero event trials (0.001 in each arm) resulting in an alfa‐boundary adjusted RR of 0.62 (95% CI 0.51 to 0.74; diversity (D2) = 34%, I2 = 14%, random‐effects model), with a control event proportion of 27.97%. With the required information size of 502, analyses indicated firm evidence favouring sugammadex with 2298 participants included corresponding to a relative risk reduction (RRR) of 38% with 80% power and alpha of 0.05. Despite the fact that the cumulative Z‐curve does not cross the monitoring boundary directly, it is hard to imagine future trials radically changing the overall picture of this analysis. However, none of the included trials were at low risk of bias, and this does downgrade the reliability of our finding." data-id="CD012763-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p><b>TSA of dichotomous data on drug‐related risk of adverse events; sugammadex (any dose) vs neostigmine (any dose)</b>. This analyses includes continuity adjustment for zero event trials (0.001 in each arm) resulting in an alfa‐boundary adjusted RR of 0.62 (95% CI 0.51 to 0.74; diversity (D<sup>2</sup>) = 34%, I<sup>2</sup> = 14%, random‐effects model), with a control event proportion of 27.97%. With the required information size of 502, analyses indicated firm evidence favouring sugammadex with 2298 participants included corresponding to a relative risk reduction (RRR) of 38% with 80% power and alpha of 0.05. Despite the fact that the cumulative Z‐curve does not cross the monitoring boundary directly, it is hard to imagine future trials radically changing the overall picture of this analysis. However, none of the included trials were at low risk of bias, and this does downgrade the reliability of our finding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="TSA of dichotomous data on risk of signs of residual neuromuscular blockade; sugammadex (any dose) vs neostigmine (any dose). With continuity adjustment for zero event trials (0.001 in each arm), TSA resulted in an alfa‐boundary adjusted RR of 0.4 (95% CI 0.27 to 0.59; diversity (D2) = 0%, I2 = 0%, random‐effects model, with 80% power and alpha of 0.05), with a control event proportion of 13.08%. Cumulative Z‐curve crosses the monitoring boundary constructed for a required information size of 424 participants, indicating firm evidence in favour of sugammadex. However, none of the included trials had low risk of bias, and this equally diminishes the reliability and precision of our estimates." data-id="CD012763-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><b>TSA of dichotomous data on risk of signs of residual neuromuscular blockade; sugammadex (any dose) vs neostigmine (any dose)</b>. With continuity adjustment for zero event trials (0.001 in each arm), TSA resulted in an alfa‐boundary adjusted RR of 0.4 (95% CI 0.27 to 0.59; diversity (D<sup>2</sup>) = 0%, I<sup>2</sup> = 0%, random‐effects model, with 80% power and alpha of 0.05), with a control event proportion of 13.08%. Cumulative Z‐curve crosses the monitoring boundary constructed for a required information size of 424 participants, indicating firm evidence in favour of sugammadex. However, none of the included trials had low risk of bias, and this equally diminishes the reliability and precision of our estimates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012763-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012763-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg, Outcome 1 Recovery time from T2 to TOFR &gt; 0.9." data-id="CD012763-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg, Outcome 1 Recovery time from T2 to TOFR &gt; 0.9. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg, Outcome 2 Subgroup analysis: TIVA vs volatile anaesthetics." data-id="CD012763-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg, Outcome 2 Subgroup analysis: TIVA vs volatile anaesthetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg, Outcome 3 Sensitivity analysis: meeting abstracts excluded." data-id="CD012763-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg, Outcome 3 Sensitivity analysis: meeting abstracts excluded. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg, Outcome 1 Recovery time from PTC 1 to 5 to TOFR &gt; 0.9." data-id="CD012763-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg, Outcome 1 Recovery time from PTC 1 to 5 to TOFR &gt; 0.9. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 1 Risk of composite adverse events." data-id="CD012763-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 1 Risk of composite adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 2 Composite adverse events: subgroup analysis for dosage." data-id="CD012763-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 2 Composite adverse events: subgroup analysis for dosage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 3 Composite adverse events: subgroup analysis ‐ TIVA vs volatile anaesthetics." data-id="CD012763-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 3 Composite adverse events: subgroup analysis ‐ TIVA vs volatile anaesthetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 4 Composite adverse events: sensitivity analysis ‐ excluding meeting abstracts." data-id="CD012763-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 4 Composite adverse events: sensitivity analysis ‐ excluding meeting abstracts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 5 Participants with ≥ adverse event." data-id="CD012763-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 5 Participants with ≥ adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 6 Bradycardia: subgroup analysis ‐ atropine vs glycopyrrolate." data-id="CD012763-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 6 Bradycardia: subgroup analysis ‐ atropine vs glycopyrrolate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 7 PONV: subgroup analysis ‐ TIVA vs volatile anaesthetics." data-id="CD012763-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 7 PONV: subgroup analysis ‐ TIVA vs volatile anaesthetics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 8 Desaturation." data-id="CD012763-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 8 Desaturation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 9 Procedural complications." data-id="CD012763-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 9 Procedural complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 10 Transitory oxygen supplementation." data-id="CD012763-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 10 Transitory oxygen supplementation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 11 Not able to perform 5 second head‐lift after extubation." data-id="CD012763-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 11 Not able to perform 5 second head‐lift after extubation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 12 General muscle weakness after extubation." data-id="CD012763-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 12 General muscle weakness after extubation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 13 Nausea." data-id="CD012763-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 13 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 14 Vomiting." data-id="CD012763-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 14 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 15 Postprocedural nausea." data-id="CD012763-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 15 Postprocedural nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 16 Headache." data-id="CD012763-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 16 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 17 Hypertension." data-id="CD012763-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 17 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 18 Hypotension." data-id="CD012763-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 18 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 19 Cough." data-id="CD012763-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 19 Cough.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 20 Dry mouth." data-id="CD012763-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 20 Dry mouth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 21 Dizziness." data-id="CD012763-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 21 Dizziness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 22 Tachycardia." data-id="CD012763-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 22 Tachycardia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 23 Pruritus." data-id="CD012763-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 23 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 24 Pyrexia." data-id="CD012763-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 24 Pyrexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 25 Shivering." data-id="CD012763-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 25 Shivering.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 26 Chills." data-id="CD012763-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 26 Chills.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 27 Rash." data-id="CD012763-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 27 Rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 28 Supraventricular extrasystoles." data-id="CD012763-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 28 Supraventricular extrasystoles. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 29 Laryngospasm." data-id="CD012763-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 29 Laryngospasm.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 30 Increased upper airway secretion." data-id="CD012763-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 30 Increased upper airway secretion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 31 Procedural hypertension." data-id="CD012763-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 31 Procedural hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 32 Procedural hypotension." data-id="CD012763-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.32</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 32 Procedural hypotension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 33 Abdominal pain." data-id="CD012763-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.33</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 33 Abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 34 Clinical signs of residual NMB." data-id="CD012763-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.34</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 34 Clinical signs of residual NMB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 35 Clinical signs of inadequate reversal of NMB." data-id="CD012763-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.35</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 35 Clinical signs of inadequate reversal of NMB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 36 Clinical signs of recurrence of residual NMB." data-id="CD012763-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.36</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 36 Clinical signs of recurrence of residual NMB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 37 General muscle weakness at PACU discharge." data-id="CD012763-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.37</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 37 General muscle weakness at PACU discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 38 Not able to perform 5 second head‐lift at PACU discharge." data-id="CD012763-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.38</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 38 Not able to perform 5 second head‐lift at PACU discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 39 Overall signs of postoperative residual paralysis." data-id="CD012763-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.39</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 39 Overall signs of postoperative residual paralysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 40 Risk of composite serious adverse events." data-id="CD012763-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.40</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 40 Risk of composite serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012763-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/urn:x-wiley:14651858:media:CD012763:CD012763-CMP-003-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_t/tCD012763-CMP-003-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 41 Participants with ≥ 1 serious adverse event." data-id="CD012763-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.41</div> <div class="figure-caption"> <p>Comparison 3 Sugammadex (any dose) vs neostigmine (any dose), Outcome 41 Participants with ≥ 1 serious adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012763/media/CDSR/CD012763/image_n/nCD012763-CMP-003-41.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012763-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients, ASA I to IV, who received non‐depolarizing NMBAs<br/> <b>Setting:</b> elective in‐patient or day‐case surgical procedures performed at centres across Europe and Asia<br/> <b>Intervention:</b> sugammadex 2.0 mg/kg<br/> <b>Comparison:</b> neostigmine 0.05 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Neostigmine 0.05 mg/kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Sugammadex 2.0 mg/kg </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery time<sup>a</sup> from second twitch (T2) to train‐of‐four ratio (TOFR) &gt; 0.9 (moderate block) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from T2 to TOFR &gt; 0.9 was <b>12.87 minutes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from T2 to TOFR &gt; 0.9 was <b>1.96 minutes</b> </p> <p>Mean recovery time from T2 to TOFR &gt; 0.9 in the sugammadex group was<b>10.22 minutes faster</b> (8.48 to 11.96 minutes faster) than neostigmine </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>c</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA alfa‐boundary adjusted MD is ‐10.22 (95% CI ‐12.11 to ‐8.33; diversity (D<sup>2</sup>) = 87%, I<sup>2</sup> = 84%, random‐effects model, 80% power, alpha 0.05). Cumulative Z‐curve crosses the monitoring boundary (<a href="./full#CD012763-fig-0001">Figure 1</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from post‐tetanic count (PTC) 1 to 5 to train‐of‐four ratio (TOFR) &gt; 0.9 (deep block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risks of adverse events and serious adverse events<sup>b</sup>, bradycardia, PONV, and signs of residual neuromuscular blockade </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not analysed for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Recovery time was measured in minutes from administration of study drug to TOFR &gt; 0.9 by TOF‐watch assessor using acceleromyography at the same monitoring site in all studies (ulnar nerve and adductor pollicis muscle) </p> <p><sup>b</sup>Adverse events and serious adverse events were defined by study authors and were observed and assessed by safety outcome assessors in the operating theatre, in post‐anaesthetic care unit, or up to seven days after surgery, depending on each study. Furthermore, overall clinical signs of postoperative residual paralysis reported by trials were regarded as adverse events in this review. Risk of adverse events was measured as number of adverse events per all participants and/or number of participants experiencing one or more adverse events per all participants, depending on the study. Only adverse events that were possibly, probably, or definitely related to study drug were included in risk assessments </p> <p><sup>c</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012763-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients, ASA I to IV, who received non‐depolarizing NMBAs<br/> <b>Setting:</b> elective in‐patient or day‐case surgical procedures performed in Italy and USA<br/> <b>Intervention:</b> sugammadex 4.0 mg/kg<br/> <b>Comparison:</b> neostigmine 0.07 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Neostigmine 0.07 mg/kg </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Sugammadex 4.0 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from second twitch (T2) to train‐of‐four ratio (TOFR) &gt; 0.9 (moderate block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery time<sup>a</sup> from post‐tetanic count (PTC 1 to 5) to train‐of‐four ratio (TOFR) &gt; 0.9 (deep block) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from PTC 1 to 5 to TOFR &gt; 0.9 was <b>48.8 minutes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean recovery time from PTC 1 to 5 to TOFR &gt; 0.9 was <b>2.9 minutes</b> </p> <p>Mean recovery time from PTC 1 to 5 to TOFR &gt; 0.9 in the sugammadex group was <b>45.78 minutes faster</b> (52.15 to 39.41 minutes faster) than in the neostigmine group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of adverse events and serious adverse events<sup>b</sup>, bradycardia, PONV, and signs of residual neuromuscular blockade </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not analysed for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Recovery time was measured in minutes from administration of study drug to TOFR &gt; 0.9 by TOF‐watch assessor using acceleromyography at the same monitoring site in all studies (ulnar nerve and adductor pollicis muscle) </p> <p><sup>b</sup>Adverse events and serious adverse events were defined by study authors and were observed and assessed by safety outcome assessors in the operating theatre, in the post‐anaesthetic care unit, or up to seven days after surgery, depending on each study. Furthermore, overall clinical signs of postoperative residual paralysis reported by trials were regarded as adverse events in this review. Risk of adverse events was measured as number of adverse events per all participants and/or number of participants experiencing one or more adverse events per all participants, depending on the study. Only adverse events that were possibly, probably, or definitely related to study drug were included in risk assessments </p> <p><sup>c</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) and by one level owing to imprecision (small number of participants, n = 114) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012763-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sugammadex (any dose) vs neostigmine (any dose)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sugammadex (any dose) compared to Neostigmine (any dose)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs</b> <br/> <b>Setting: Elective in‐patient or day‐case surgical procedures performed in centres across Europe, USA and Asia</b> <br/> <b>Intervention:</b> Sugammadex (any dose)<br/> <b>Comparison:</b> Neostigmine (any dose) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with neostigmine (any dose)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sugammadex (any dose)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from second twitch (T2) to train‐of‐four ratio (TOFR) &gt; 0.9 (moderate block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery time<sup>a</sup> from post‐tetanic count (PTC) 1 to 5 to train‐of‐four ratio (TOFR) &gt; 0.9 (deep block) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Outcome not clinically relevant for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of composite adverse events<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b> <br/> (137 to 204) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60<br/> (0.49 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2298<br/> (28 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>c</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA with continuity adjustment for zero event trials (0.001 in each arm); alfa‐boundary adjusted RR 0.62 (95% CI 0.51 to 0.74; diversity (D<sup>2</sup>) = 34%, I<sup>2</sup> = 14%, random‐effects model; 80% power, 0.05 alpha; <a href="./full#CD012763-fig-0003">Figure 3</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bradycardia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (6 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.16</b> <br/> (0.07 to 0.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1218<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>d</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PONV</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (33 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b> <br/> (0.28 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>e</sup> </p> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall signs of postoperative residual paralysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> <br/> (37 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.40</b> <br/> (0.28 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1474<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>f</sup> </p> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA with continuity adjustment for zero event trials (0.001 in each arm): alfa‐boundary adjusted RR 0.4 (95% CI 0.27 to 0.59; diversity (D<sup>2</sup>) = 0%, I<sup>2</sup> = 0%, random‐effects model, 80% power, 0.05 alpha, <a href="./full#CD012763-fig-0004">Figure 4</a>). Cumulative Z‐curve crosses the monitoring boundary constructed for a required information size of 424 participants indicating firm evidence in favour of sugammadex </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of serious adverse events<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>6 per 1000</b> <br/> (1 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.54</b> <br/> (0.13 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>959<br/> (10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<sup>g</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TSA with continuity adjustment for zero event trials (0.001 in each arm): alfa‐boundary adjusted RR 0.35 (95% CI 0.00 to 3190; diversity (D<sup>2</sup>) = 0%, I<sup>2</sup> = 0%, random‐effects model, 80% power, alpha 0.05), Cumulative Z‐curve does not cross the monitoring boundary constructed for a required information size of 8189 participants with 11.71% of the required information size included </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio; RR: risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Recovery time was measured in minutes from administration of study drug to TOFR &gt; 0.9 by TOF‐watch assessor using acceleromyography at the same monitoring site in all studies (ulnar nerve and adductor pollicis muscle) </p> <p><sup>b</sup>Adverse events and serious adverse events were defined by study authors and were observed and assessed by safety outcome assessors in the operating theatre, in the post‐anaesthetic care unit or up to seven days after surgery, depending on each study. Furthermore, overall clinical signs of postoperative residual paralysis reported by trials were regarded as adverse events in this review. Risk of adverse events was measured as number of adverse events per all participants and/or number of participants experiencing one or more adverse events per all participants, depending on the study. Only adverse events that were possibly, probably, or definitely related to study drug were included in risk assessments </p> <p><sup>c</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> <p><sup>d</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> <p><sup>e</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) and by one level owing to imprecision (small number of participants‐ n = 389 ‐ and wide confidence interval (CI) ‐ 0.28 to 0.97) </p> <p><sup>f</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) </p> <p><sup>g</sup>Downgraded one level owing to high risk of bias (evidence limited by inclusion of data from open‐label studies and studies with potential funding bias ‐ for details, see <a href="./full#CD012763-fig-0002">Figure 2</a> and <a href="./references#CD012763-sec-0157" title="">Characteristics of included studies</a>) and by one level owing to imprecision (small number of events ‐ 10/1000 in the neostigmine group vs 6/1000 in the sugammadex group ‐ and wide confidence interval (CI) ‐ 0.13 to 2.25) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sugammadex (any dose) vs neostigmine (any dose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012763-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies ineligible for meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for ineligibility</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary endpoint: acute effects of sugammadex and neostigmine on renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 4 mg /kg at reappearance of PTC 1 to 2 or T2 vs neostigmine 40 µg/kg + atropine 10 µg/kg at reappearance of T2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We believe that the use of more specific and sensitive new‐generation markers such as Cystatin C to evaluate kidney function will provide better understanding and interpretation of our results. Sugammadex has more tolerable effects on kidney function than does neostigmine. However, when compared with preoperative values, negative alteration of postoperative values can be seen. Neostigmine and sugammadex do not cause renal failure but may affect kidney function </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0024" title="KvolikS , MraovicB , KristekJ , StefanicM , MihaljevicI . Reversal with sugammadex hastens recovery of tracheal reflexes and extubation compared with neostigmine in patients undergoing thyroidectomy. European Journal of Anaesthesiology. 2012; Vol. 29:142. ">Kvolik 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOFR recovery data available only as mean, no data on standard deviation, study author has not replied </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 50 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recovery of cough reflexes was faster and respiration more efficient in patients receiving sugammadex. Safe extubation was determined by age, TOFR recovery, and effects of other anaesthetics </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0026" title="KvolikS , RakipovicA , MraovicB , KristekJ , IkicV , KristicM . Faster increase of BIS registered after the reversal of neuromuscular blockade with sugammadex vs. neostigmine. European Journal of Anaesthesiology. 2013; Vol. 30:40. ">Kvolik 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOFR recovery data available only as mean, no data on standard deviation, study author has not replied </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 50 µg/kg + atropine 25 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An increase in BIS Index registered after reversal of rocuronium effects was faster during the recovery period in patients who were given sugammadex as compared with neostigmine. Although rapid increase in BIS Indices was registered in sugammadex group, more sensitive measurements are needed to confirm clinical value of this observation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary endpoint: influence of depth of the NMB on SRS (surgical rating score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neostigmine 1 to 2 mg + atropine 0.5 to 1 mg (for reversal of moderate NMB) vs sugammadex 4 mg/kg (for reversal of deep NMB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Application of 5‐point SRS showed that deep NMB results in improved quality of surgical conditions compared with moderate block in retroperitoneal laparoscopy, without compromise to patients’ perioperative and postoperative cardiorespiratory conditions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0031" title="Rahe‐MeyerN , FennemaH , SchulmanS , KlimschaW , PrzemeckM , BlobnerM , et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology2014;121(5):969‐77. [PUBMED: 25208233] ">Rahe‐Meyer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison: sugammadex 4 mg/kg vs usual care (neostigmine with glycopyrrolate or atropine, or placebo/spontaneous recovery). Study author has not replied with separate data on neostigmine with glycopyrrolate or atropine or placebo/spontaneous recovery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 4 mg/kg vs usual care</p> <p>(neostigmine with glycopyrrolate or atropine, or placebo/spontaneous recovery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex produced limited, transient (&lt; 1 hour) increases in activated partial thromboplastin time and prothrombin time but was not associated with increased risk of bleeding vs usual care </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0032" title="RazielA , MessingerG , SakranN , SzoldA , GoiteinD . Comparison of two neuromuscular anesthetics reversal in obese patients undergoing bariatric surgery ‐ a prospective study. 21st International Congress of the European Association for Endoscopic Surgery, EAES. Vienna, Austria, 2013:31. ">Raziel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No useable data available for quantitative meta‐analysis on recovery time or risk of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 50 µg/kg + atropine 10 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex facilitates reversal of neuromuscular blockade after bariatric surgery, depending on the depth of neuromuscular blockade induced </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0033" title="RigaM , BatistakiC , MatsotaP , LyrakosG , ZafeiropoulouF , KostopanagiotouG . Effect of sugammadex versus neostigmine/atropine combination on cognitive function of adult patients after elective surgery: preliminary results. European Journal of Anaesthesiology. 2014; Vol. 31:157‐8. ">Riga 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome: cognitive function assessed by change in Mini‐Mental State Evaluation test (MMSE), Clock Drawing Test, and Isaacs Set Test, performed preoperatively, 1 hour postoperatively, and at discharge (1 to 15 days postoperatively) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex vs neostigmine/atropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference was observed regarding cognitive function after neostigmine/atropine combination or sugammadex was received for reversal of rocuronium‐induced neuromuscular blockade for elective surgery </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0036" title="ShermanA , AbelanskyY , EvronS , EzriT . The effect of sugammadex vs. neostigmine on the postoperative respiratory complications following laparoscopic sleeve gastrectomy. European Journal of Anaesthesiology. 2014; Vol. 31:152. ">Sherman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome: postoperative complications, data not available in useful format</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 2.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of sugammadex (compared with neostigmine) as reversal<br/> agent following laparoscopic sleeve gastrectomy; surgery was associated with higher postoperative oxygen saturation despite lower TOF count before administration of reversal agent.<br/> Lack of differences in other measured variables may stem from the small size of patient groups studied </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0037" title="SusticA , DijanaD . Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents. European Anaesthesiology Congress, EUROANAESTHESIA. Lippincott Williams and Wilkins, 2012; Vol. 29:140. ">Sustic 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome: gastric emptying evaluated by paracetamol absorption test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex 2 mg/kg vs neostigmine 40 µg/kg + atropine group 15 µg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Although study results show a tendency toward faster gastric emptying in sugammadex group, this difference is not significant in most, possibly owing to small sample size in this study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aim: to evaluate effects of sugammadex on postoperative nausea‐vomiting, pain, coagulation parameters, and quantity of postoperative bleeding. Data not available in useful format </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neostigmine 0.05 mg/kg + atropine 0.02 mg/kg vs sugammadex 2 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sugammadex was associated with greater postoperative bleeding than neostigmine in septoplasty patients. For surgical procedures with high risk of bleeding, the safety of sugammadex needs to be verified </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Acronyms:</p> <p>BIS ‐ Bispectral Index</p> <p>MMSE ‐ Mini‐Mental State Examination</p> <p>NMB ‐ neuromuscular blockade</p> <p>T2 ‐ second twitch in train‐of‐four stimulation</p> <p>TOFR ‐ train‐of‐four ratio</p> <p>PTC ‐ post‐tetanic count</p> <p>SRS ‐ surgical rating score</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies ineligible for meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012763-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality variables of neuromuscular monitoring methods among included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Method of recording</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Monitor site</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm fixation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Supramaximal stimulation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Temperature maintained and recorded</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Initial signal stabilization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Twich height calibration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preload used</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0001" title="AdamusM , HrabalekL , WanekT , GabrhelikT , ZapletalovaJ . Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. Journal of Anesthesia2011;25(5):716‐20. [PUBMED: 21842171] ">Adamus 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0003" title="BlobnerM , ErikssonLI , ScholzJ , MotschJ , Della RoccaG , PrinsME . Reversal of rocuronium‐induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. European Journal of Anaesthesiology2010;27:874‐81. [PUBMED: 20683334] ">Blobner 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0004" title="BrueckmannB , SasakiN , GrobaraP , LiMK , WooT , deBieJ , et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized,controlled study. British Journal of Anaesthesia2015;115(5):743‐51. [PUBMED: 25935840] ">Brueckmann 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0005" title="CarronM , VeroneseS , FolettoM , OriC . Sugammadex allows fast‐track bariatric surgery. Obesity Surgery2013;23(10):1558‐63. [PUBMED: 23519634] ">Carron 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0006" title="CastroDSJr , LeãoP , BorgesS , GomesL , PachecoM , FigueiredoP . Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surgical Laparoscopy Endoscopy &amp; Percutaneous Techniques2014;24(5):420‐3. [PUBMED: 24752165] ">Castro 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0007" title="CheongSH , KiS , LeeJ , LeeJH , KimMH , HurD , et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean Journal of Anesthesiology2015;68(6):547‐55. [PUBMED: 26634077] ">Cheong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0008" title="FlocktonEA , MastronardiP , HunterJM , GomarC , MirakhurRK , AguileraL , et al. Reversal of rocuronium‐induced neuromuscular block with sugammadex is faster than reversal of cisatracurium‐induced block with neostigmine. British Journal of Anaesthesia2008;100(5):622‐30. [PUBMED: 18385265] ">Flockton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0010" title="GaszynskiT , SzewczykT , GaszynskiW . Randomized comparison of sugammadex and neostigmine for reversal of rocuronium‐induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia2012;108(2):236‐9. [PUBMED: 22012861] ">Gaszynski 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0011" title="GeldnerG , NiskanenM , LaurilaP , MizikovV , HublerM , BeckG , et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia2012;67(9):991‐8. [PUBMED: 22698066] ">Geldner 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0014" title="HakimoğluS , TuzcuK , DavarcıI , KarcıoğluM , Ayhan TuzcuE , HancıV , et al. Comparison of sugammadex and neostigmine‐atropine on intraocular pressure and postoperative effects. Kaohsiung Journal of Medical Sciences2016;32(2):80‐5. [PUBMED: 26944326] ">Hakimoglu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0015" title="IllmanHL , LaurilaP , AntilaH , MeretojaOA , AlahuhtaS , OlkkolaKT . The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train‐of‐four monitoring. Anesthesia and Analgesia2011;112(1):63‐8. [PUBMED: 20978247] ">Illman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0016" title="IsikY , PalabiyikO , CeginBM , GoktasU , KatiI . Effects of sugammadex and neostigmine on renal biomarkers. Medical Science Monitor2016;22:803‐9. [PUBMED: 26963316] ">Isik 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0017" title="JonesRK , CaldwellJE , BrullSJ , SotoRG . Reversal of profound rocuronium‐induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology2008;109(5):816–24. [PUBMED: 18946293] ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0018" title="KaufholdN , SchallerSJ , Stäuble CG BaumüllerE , UlmK , BlobnerM , et al. Sugammadex and Neostigmine dose‐finding study for reversal of residual neuromuscular block at a train‐of‐four ratio of 0.2 (SUNDRO20). British Journal of Anaesthesia2016;116(2):233‐40. [PUBMED: 26787792] ">Kaufhold 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0019" title="Khuenl‐BradyKS , WattwilM , VanackerBF , Lora‐TamayoJI , RietbergenH , Alvarez‐GómezJA . Sugammadex provides faster reversal of vecuronium‐induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia2010;110(1):64‐73. [PUBMED: 19713265] ">Khuenl‐Brady 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0020" title="KizilayD , DalD , SaracogluKT , EtiZ , GogusFY . Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. Journal of Clinical Anesthesia2016;28:30‐5. [PUBMED: 26796612] ">Kizilay 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0021" title="KoçF , TuranG , SubaşıD , EkinciO . Comparison of sugammadex and neostigmine in short term surgery [Turkish: Kısa süreli cerrahide sugammadeks ile neostigminin karşılaştırılması]. Journal of Clinical and Analytical Medicine2015;6(1):41‐5. [3275673; http://www.jcam.com.tr/files/KATD‐1694.pdf] ">Koc 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0023" title="KoyuncuO , TurhanogluS , Ozbakis AkkurtC , KarcıogluM , OzkanM , OzerC , et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. Journal of Clinical Anesthesia2015;27(1):51‐6. [PUBMED: 25544263] ">Koyuncu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0027" title="LemmensHJ , El‐OrbanyMI , BerryJ , MorteJBJr , MartinG . Reversal of profound vecuronium‐induced neuromuscular block under sevofluraneanesthesia: sugammadex versus neostigmine. BMC Anesthesiology2010;10:15. [PUBMED: 20809967] ">Lemmens 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0028" title="MartiniCH , BoonM , BeversRF , AartsLP , DahanA . Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia2014;112(3):498‐505. [PUBMED: 24240315] ">Martini 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0029" title="MekawyN , EmanA , AliF . Improved recovery profiles in sinonasal surgery sugammadex: does it have a role?. Egyptian Journal of Anaesthesia2012;28(3):175‐8. [DOI: 10.1016/j.egja.2011.12.007] ">Mekawy 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0030" title="PongráczA , SzatmáriS , NemesR , FülesdiB , TassonyiE . Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train‐of‐four stimulation. Anesthesiology2013;119(1):36‐42. [PUBMED: 23665915] ">Pongracz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0034" title="SaboD , JonesRK , BerryJ , SloanT , ChenJY , GroudineS . Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium‐induced blockade in patients undergoing abdominal surgery. Anesthesia and Clinical Research Journals2011;2(6):Open assess journal, no pages. ">Sabo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0035" title="SchallerSJ , FinkH , UlmK , BlobnerM . Sugammadex and neostigmine dose‐finding study for reversal of shallow residual neuromuscular block. Anesthesiology2010;113(5):1054‐60. [DOI: 10.1097/ALN.0b013e3181f4182a; PUBMED: 20885293] ">Schaller 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0038" title="TaşN , KorkmazH , YağanÖ , KorkmazM . Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: a randomized prospective study. Medical Science Monitor2015;14:2382‐6. [PUBMED: 26271275] ">Tas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0039" title="WooT , KimKS , ShimYH , KimMK , YoonSM , LimYJ , et al. Sugammadex versus neostigmine reversal of moderate rocuronium‐induced neuromuscular blockade in Korean patients. Korean Journal of Anesthesiololgy2013;65(6):501‐7. [PUBMED: 24427455] ">Woo 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes *</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No *</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0040" title="WuX , OerdingH , LiuJ , VanackerB , YaoS , DahlV , et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology2014;14(53):eCollection. [DOI: 10.1186/1471‐2253‐14‐53; PUBMED: 25187755] ">Wu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012763-bbs2-0041" title="YaganO , KarakahyaRH , TasN , CanakciE , HanciV , YurtluBS . Intraocular pressure changes associated with tracheal extubation: comparison of sugammadex with conventional reversal of neuromuscular blockade. Journal of the Pakistan Medical Assosication2015;65(11):1219‐25. [PUBMED: 26564297] ">Yagan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceleromyography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. ulnaris,</p> <p>M. adductor pollicis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Studies with only abstracts were not included in this table because they did not document information regarding neuromuscular monitoring </p> <p>List of abbreviations:</p> <p>N. ulnaris ‐ ulnar nerve</p> <p>M. adductor pollicis ‐ adductor pollicis muscle</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality variables of neuromuscular monitoring methods among included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012763-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table of adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sugammadex</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neostigmine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Specific adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of AEs, %</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of AEs, %</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.42‐4.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shivering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.40‐1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Desaturation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.06‐0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General muscle weakness after extubation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.31‐1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>288</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breath‐hold</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PONV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.28‐0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>389</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laryngospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.07‐1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not able to perform 5 second head‐lift after extubation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.15‐0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>395</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.07‐0.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1218</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12 (0.02‐0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postprocedural nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.47‐3.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.10‐1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>289</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.48‐2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased beta‐N‐acetyl‐D‐glucosaminidase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strange taste in mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.44‐1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>719</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albumin present in the urine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 (0.50‐8.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bronchospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chills</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.04 (0.46‐35.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General muscle weakness at PACU discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.12‐1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>410</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.33‐8.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altered facial sensation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postprocedural hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased blood PK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased upper airway secretions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.09‐1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperhidrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased blood protein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incision site complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.02‐14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postprocedural complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.09‐2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>338</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (0.20‐12.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intraoperative movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.38‐3.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>465</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supraventricular extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.03‐3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical signs of inadequate reversal of NMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.01‐2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased gamma‐glutamyl‐transferase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Airway complication to anaesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hot flush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Involontary muscle contractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visual accomodation disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased B<sub>2</sub>‐microglobulin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Productive cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.23‐8.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.23‐9.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased hematocrit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Procedural haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed recovery from anaesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory distress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.10‐9.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.10‐9.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.17‐3.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>701</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe muscle weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild hypoventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical signs of recurrence of residual NMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.05‐10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1289</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical signs of residual NMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>646</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not able to perform 5 second head‐lift at PACU discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>399</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Redness at injection site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Table of reported adverse events possibly, probably, or definitely related to sugammadex or neostigmine, listed in descending order according to risk of adverse events. Furthermore, the number of studies observing for each adverse event is presented </p> <p>List of abbreviations:</p> <p>NMB ‐ neuromuscular blockade</p> <p>PACU ‐ post‐anaesthesia care unit</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table of adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/full#CD012763-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012763-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recovery time from T2 to TOFR &gt; 0.9 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.22 [‐11.96, ‐8.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subgroup analysis: TIVA vs volatile anaesthetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.83 [‐11.45, ‐8.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 TIVA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.50 [‐10.15, ‐6.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Volitile anaesthetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.57 [‐12.96, ‐8.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sensitivity analysis: meeting abstracts excluded <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.27 [‐11.14, ‐7.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012763-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recovery time from PTC 1 to 5 to TOFR &gt; 0.9 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐45.78 [‐52.15, ‐39.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012763-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sugammadex (any dose) vs neostigmine (any dose)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Risk of composite adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.49, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Composite adverse events: subgroup analysis for dosage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.49, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Sugammadex 2 mg/kg vs neostigmine 0.04 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.05, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sugammadex 2 mg/kg vs neostigmine 0.05 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.34, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sugammadex 2 mg/kg vs neostigmine 0.07 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.57, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Sugammadex 2 mg/kg vs neostigmine 2.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Sugammadex 3 mg/kg vs neostigmine 0.03 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Sugammadex 4 mg/kg vs neostigmine 0.05 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Sugammadex 4 mg/kg vs neostigmine 0.07 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.25, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Sugammadex, several doses vs neostigmine, several doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.40, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Composite adverse events: subgroup analysis ‐ TIVA vs volatile anaesthetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.49, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 TIVA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.20, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Volatile anaesthetic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.55, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Composite adverse events: sensitivity analysis ‐ excluding meeting abstracts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.49, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Participants with ≥ adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Bradycardia: subgroup analysis ‐ atropine vs glycopyrrolate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.07, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Atropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.05, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Glycopyrrolate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.06, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 PONV: subgroup analysis ‐ TIVA vs volatile anaesthetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.28, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 TIVA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [0.15, 84.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Volatile anaesthetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.25, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Desaturation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.06, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Procedural complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Transitory oxygen supplementation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.09, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Not able to perform 5 second head‐lift after extubation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.15, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 General muscle weakness after extubation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.31, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.44, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.50, 8.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Postprocedural nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.27, 7.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.48, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.23, 9.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.38, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.42, 4.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.10, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.10, 9.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Tachycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.09, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.20, 12.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Pyrexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.23, 8.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Shivering <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.40, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Chills <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.04 [0.46, 35.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.17, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Supraventricular extrasystoles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Laryngospasm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.07, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Increased upper airway secretion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.09, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Procedural hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.33, 8.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Procedural hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.02, 14.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.10, 9.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Clinical signs of residual NMB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Clinical signs of inadequate reversal of NMB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Clinical signs of recurrence of residual NMB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.05, 10.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 General muscle weakness at PACU discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.12, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Not able to perform 5 second head‐lift at PACU discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Overall signs of postoperative residual paralysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.28, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Risk of composite serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.13, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Participants with ≥ 1 serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.13, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sugammadex (any dose) vs neostigmine (any dose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012763/references#CD012763-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012763&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012763-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012763-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012763-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012763-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012763-note-0014">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012763\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012763"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012763\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012763\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012763"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012763\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012763"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012763\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012763\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012763"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012763&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012763';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012763/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012763/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012763%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717389282"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012763/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717389286"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012763/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db6b80d459365',t:'MTc0MDcxNzM4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 